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          Proper control of lipid metabolism in the endoplasmic reticulum, lipid bodies, 
peroxisomes and mitochondria is essential for longevity regulation. However, the 
molecular mechanisms linking longevity and lipid metabolism in these organelles have 
not been defined prior to studies described here. The establishment of such mechanisms 
operating in chronologically aging yeast was the objective of my thesis.  
          To develop a tool for quantitative monitoring of the age-related dynamics of 
changes in the cellular and organellar lipidomes of chronologically aging yeast, I was 
able to solve the inherent limitations of the currently used methods for lipidomic analysis 
(including the limitations characteristic of mass spectrometry-based techniques) by 
devising a survey-scan electrospray ionization mass spectrometry method for quantitative 
lipidomics. This novel method enables within a very limited period of time and using a 
very low number of cells to resolve, unequivocally identify and accurately quantitate all 
molecular forms of lipid species composing yeast lipidome and the majority of molecular 
forms of lipid species composing the lipidome of cultured human cells.   
          Using a combination of the functional genetic, cell biological, electron and 
fluorescence microscopical, proteomic, lipidomic, and metabolomic analyses, I 
established three molecular mechanisms linking longevity and lipid metabolism confined 
to the endoplasmic reticulum, lipid bodies, peroxisomes and mitochondria. One of these 
mechanisms underlies the ability of a caloric restriction diet to extend longevity of 
iv 
chronologically aging yeast by specifically remodeling the metabolism of neutral lipids in 
the endoplasmic reticulum, lipid bodies and peroxisomes. The other mechanism underlies 
the ability of lithocholic acid, a novel anti-aging compound that my research enabled to 
identify, to extend yeast chronological life span by targeting the longevity-defining 
aspects of lipid metabolism confined to the endoplasmic reticulum, lipid bodies and 
peroxisomes. The third mechanism underlies the ability of lithocholic acid to extend 
yeast chronological life span under caloric restriction conditions by remodeling lipid 
metabolism in the mitochondrial membrane, thereby altering the repertoire of membrane 
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1.1. A complexity of biological aging 
          Aging is a highly complex biological phenomenon, which at the organismal level 
manifests itself as the progressive decline in the ability of an organism to resist stress, 
damage and disease [1 - 4]. At the demographic level, aging can be defined as an 
exponential increase in the mortality rate with the age of the cohort [1, 4, 5]. Aging of 
multicellular eukaryotic organisms affects numerous processes within cells [2 - 4, 6 - 10]. 
Some of these processes damage cellular macromolecules and organelles, while the 
others prevent the collapse of cellular homeostasis by repairing the damage [1, 3 - 5]. A 
lifelong accumulation of unrepaired cellular damage increases a risk of disease and death 
[1, 4, 6, 11]. A challenge is to understand how the spatiotemporal organization of 
damage-producing and damage-repairing processes influences longevity and how cells 
integrate and control these processes. The most important unanswered question is 
whether aging is the final step of a developmental program governed by a certain 
signaling network [12 - 18] or merely a result of the lifelong accumulation of unrepaired 
cellular and molecular damage [1, 5, 19]. 
 
1.2. An evolutionarily conserved signaling network regulates longevity 
          Growing evidence supports the view that the fundamental mechanisms of aging are 
conserved across phyla [1, 3, 5, 20 - 23]. The identification of single-gene mutations that 
extend life span in yeast, worms, flies and mice revealed numerous proteins that regulate 
longevity. These proteins have been implicated in a wide array of cellular processes 
including cell cycle, cell growth, stress response, protein folding, apoptosis, autophagy, 
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proteasomal protein degradation, actin organization, signal transduction, nuclear DNA 
replication, chromatin assembly and maintenance, ribosome biogenesis and translation, 
lipid and carbohydrate metabolism, oxidative metabolism in mitochondria, NAD
+
 
homeostasis, amino acid biosynthesis and degradation, and ammonium and amino acid 
uptake [2-4, 7, 22 - 25]. The spatiotemporal organization of all these numerous cellular 
processes and their functional states are governed by a limited number of nutrient- and 
energy-sensing signaling pathways that are conserved across phyla and include the 
insulin/IGF-1, AMPK/TOR and cAMP/PKA pathways (Figure 1.1) [7, 26, 27]. 
          In response to an endocrine signal that monitors the nutritional status of the whole 
organism, the insulin/insulin-like growth factor 1 (IGF-1) pathway regulates longevity in 
worms, fruit flies and mice (Figure 1.1) [28]. If activated by an insulin-like ligand, this 
pathway operates through a phosphatidylinositol-3-kinase (PI3K) and a cascade of 
protein kinases to ultimately cause phosphorylation of a Forkhead box type O (FoxO) 
family transcription factor, thereby sequestering it in the cytosol [29, 30]. Reduced 
signaling through the insulin/IGF-1 pathway increases the life spans of worms, fruit flies 
and mice by inhibiting phosphorylation of their FoxO transcription factors (DAF-16, 
dFOXO and FoxO1, respectively), thus allowing their translocation into the nucleus [31]. 
Within the nucleus, FoxO orchestrates a pro-longevity transcriptional program by 
activating or repressing transcription of a number of genes involved in signaling, 
development, transcription, translation, metabolism, detoxification, stress response and 
apoptosis [32, 33]. 
          Unlike the insulin/IGF-1 signaling pathway regulating longevity in response to the 
nutritional status of the whole organism, the AMP-activated protein kinase/target of 
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rapamycin (AMPK/TOR) pathway functions as an intracellular sensor for the nutrient 
and energy status (Figure 1.1) [34, 35]. This pathway regulates longevity in yeast, worms, 
fruit flies and mammals [27, 36 - 38]. Activated under low nutrient or energy conditions, 
AMPK responds to the high AMP:ATP ratio by inhibiting TOR protein kinase that 
associates with several other proteins into the TOR complex 1 (TORC1) [34, 35]. The 
resulting inhibition of TORC1 slows down the energy-consuming processes of cellular 
growth, ribosome biogenesis and protein translation, orchestrates a pro-longevity 
translational program by causing a switch from cap-dependent to cap-independent 
translation, promotes nutrient- and energy-producing autophagy aimed at the removal of 
damaged macromolecules and organelles, activates mitochondrial translation of oxidative 
phosphorylation subunits, and alters mitochondrial gene expression [34, 39 - 41]. 
Noteworthy, under low levels of amino acids, the life-extending inhibition of TORC1 can 
be also achieved in an AMPK-independent manner [42 - 45]. Moreover, under low 
nutrient or energy conditions, the phosphorylation of AMPK by the LKB1 protein kinase 
increases the life span of worms in a TORC1-independent fashion by decelerating 
hydrolysis of the neutral lipids triacylglycerols (TAG) [46]. 
          The cAMP/protein kinase A (cAMP/PKA) pathway regulates longevity in yeast 
and mice. In yeast, glucose deprivation reduces cAMP/PKA signaling by attenuating 
several activators of adenylate cyclase Cyr1p, including the G protein-coupled receptor 
Gpr1p, Gα protein Gpa2p and two small GTP-binding proteins, Ras1p and Ras2p (Figure 
1.1) [47, 48]. Reduced signaling through the cAMP/PKA pathway inhibits 
phosphorylation of the protein kinase Rim15p and stress response transcription factors 
Msn2p and Msn4p by PKA in the cytosol, thereby restoring the kinase activity of 
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Rim15p and allowing the translocation of Msn2p and Msn4p into the nucleus [49 - 51]. 
Upon entering the nucleus, Msn2p and Msn4p orchestrate - in a Rim15p-dependent 
fashion - a pro-longevity transcriptional program by activating transcription of a number 
of genes involved in stress protection, reactive oxygen species (ROS) detoxification, 
proteolysis, the tricarboxylic acid cycle, carbohydrate metabolism, trehalose biosynthesis 
and cell growth regulation [52 - 55]. The resulting establishment of a pro-longevity 
transcriptional pattern increases yeast chronological life span (CLS), which is measured 
by the length of time a yeast cells remains viable in a nondividing state and reminiscent 
of the life span of a postmitotic cell in a multicellular organism [56]. One of the longevity 
genes whose transcription in the nucleus is activated by Msn2p and Msn4p encodes the 
nicotinamidase Pnc1p [49]. The Pnc1p-dependent degradation of nicotinamide, an 
inhibitor of the sirtuins Sir2p and Hst2p, enhances their ability to stabilize arrayed repeats 
of the ribosomal DNA (rDNA) locus in the nucleus [57]. The resulting attenuation of the 
formation of toxic extrachromosomal circular forms of rDNA increases yeast replicative 
life span (RLS), which is defined by the maximum number of daughter cells that a 
mother cell can produce before senescence and reminiscent of the life span of a 
mitotically active cell in a multicellular organism [8]. In mice, the cAMP/PKA signaling 
pathway regulates longevity in response to cAMP produced by the AC5 isoform of 
adenylate cyclase, which is highly abundant in the heart and brain [58]. Reduced 
cAMP/PKA signaling in mice lacking AC5 attenuates the inhibitory effect of PKA on the 
Raf/MEK/ERK protein kinase cascade [58]. The resulting activation of the protein kinase 
ERK enhances the susceptibility of mice to oxidative stress (perhaps, due to the observed 
increase in the abundance of the ROS scavenging enzyme manganese superoxide 
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dismutase) and apoptosis, ultimately extending longevity and delaying age-related 
degenerative processes in the heart and bone [58]. Of note, the Ste11p/Ste7p/Kss1p 
protein kinase cascade in yeast - which is homologous to the Raf/MEK/ERK cascade in 
mammals - may also regulate yeast chronological life span in response to cAMP/PKA 
signaling [58], thereby modulating yeast longevity synergistically with the other 
downstream effectors of PKA (i.e., Rim15p, Msn2p and Msn4p). A recently reported life 
span extension in mice lacking a regulatory subunit of PKA and the observed in these 
mice - and in mice lacking its catalytic subunit – significant attenuation of age-related 
pathologies [59 - 60] further support the essential role for cAMP/PKA in regulating 
longevity and modulating physiological processes underlying healthy aging. 
          By sharing a compendium of protein kinases and adaptor proteins, the insulin/IGF-
1, AMPK/TOR and cAMP/PKA pathways in yeast, worms, fruit flies and mammals 
converge into a complex network regulating longevity [7, 26, 27, 34, 35]. It is 
conceivable that this network may also include several protein components that currently 
are not viewed as being in any of these three pathways (Rtg2p in yeast; CLK-1, ISP-1, 
JNK, MST-1, PHA-4, Rictor/TORC2/SGK-1, SIR-2.1, SKN-1 and SMK-1 in worms; 
dSir2 and JNK in fruit flies; and MCLK, P66
Shc
, SIRT1, SIRT6, and SIRT7 in mammals) 
[7, 27, 61 - 63]. Moreover, this network responds to the age-related partial mitochondrial 
dysfunction and is modulated by mitochondrially produced ROS [27, 34, 62, 64]. By 
sensing the nutritional status of the whole organism as well as the intracellular nutrient 
and energy status, functional state of mitochondria, and concentration of ROS produced 
in mitochondria, the longevity network regulates life span across species by coordinating 
information flow along its convergent, divergent and multiply branched signaling 
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pathways. These pathways function as biochemical logic circuits that process information 
via positive and negative feedback and feed-forward regulatory loops, dual-control 
switches, and protein scaffolds.  
 
Figure 1.1. The spatiotemporal organization of numerous longevity-related cellular processes and their 
functional states are governed by a limited number of nutrient- and energy-sensing signaling pathways that 
are conserved across phyla and include the insulin/IGF-1, AMPK/TOR and cAMP/PKA pathways (see text 
in section 1.2 for details). Reproduced from Fontana, L., Partridge, L. and Longo, V.D. (2010). Extending 
healthy life span - from yeast to humans. Science 328:321-326. 
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1.3. Certain diets and pharmacological interventions can extend longevity 
          By defining the organismal and intracellular nutrient and energy status, nutrient 
intake plays an important role in modulating life span and influences a wide spectrum of 
age-related pathologies [9, 65 – 67]. Two dietary regimens are known to have the most 
profound life-extending effects across species and, in some cases, to improve overall 
health by delaying the onset of age-related diseases. These dietary interventions extend 
life span in evolutionarily distant organisms ranging from yeast to rhesus monkeys and 
include: 1) caloric restriction (CR), a diet in which only calorie intake is reduced but the 
supply of amino acids, vitamins and other nutrients is not compromised [66 - 69]; and 2) 
dietary restriction (DR), in which the intake of nutrients (but not necessarily of calories) 
is reduced by limiting food supply without causing malnutrition (Figure 1.2) [65, 70 - 
72]. 
          In a “TOR-centric” view of longevity regulation, TORC1 alone governs the life-
extending and health-improving effects of CR/DR by: 1) integrating the flow of 
information on the organismal and intracellular nutrient and energy status from the 
protein kinases AMPK, PKA, PKB/AKT (the insulin/IGF-1 pathway) and ERK1/2 (the 
Raf/MEK/ERK cascade) as well as from the mitochondrial redox protein P66
Shc
; 2) 
sensing the intracellular levels of amino acids in an AMPK-independent manner; and 3) 
operating as a control center which, based on the information it has gathered and 
processed, modulates a plethora of longevity-related processes in a sirtuin-independent 
fashion [73 – 75]. The inability of CR to increase the replicative life spans of yeast 
mutants lacking components of the TOR signaling pathway [76] and the lack of the 
beneficial effect of DR on life span in worms with reduced TOR signaling [77, 78] 
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support the proposed central role for TOR in orchestrating the life-extending effect of 
CR/DR in these two longevity paradigms. Moreover, although the postulated by the 
TOR-centric model dispensability of sirtuins for the longevity benefit associated with DR 
has been confirmed in worms [78], the importance of the sirtuin Sir2p in mediating the 
life-extending effect of CR in replicatively aging yeast is controversial [79, 80]. Some 
data imply that Sir2p is not required for such effect under severe CR conditions [76, 81]. 
In contrast, other data demonstrate that Sir2p plays an essential role in the extension of 
yeast replicative life span under moderate CR [82, 83], perhaps by being a downstream 
effector of the nutrient- and energy-sensing cAMP/PKA signaling pathway acting parallel 
to TOR [49].  
          It should be stressed that, while TOR is a central regulator of the life-extending 
effect of CR in replicatively aging yeast, the longevity benefit associated with CR in 
chronologically aging yeast is mediated by a signaling network that includes: 1) the TOR 
and cAMP/PKA pathways converged on the protein kinase Rim15p, which therefore acts 
as a nutritional integrator; and 2) some other, currently unknown signaling pathways that 
are not centered on Rim15p [26]. Considering the well-established convergence of the 
insulin/IGF-1, AMPK/TOR and cAMP/PKA signaling pathways into a complex network 
regulating longevity in worms, fruit flies and mammals [7, 9, 27, 34, 35], it is 
conceivable that – akin to TOR – the insulin/IGF-1 and cAMP/PKA pathways may 
contribute to the beneficial effect of CR/DR on their longevity. Although some data 
supports the involvement of the insulin/IGF-1 pathway in the longevity benefit associated 
with CR/DR [7, 84 - 87], other data imply that such benefit is independent of 
insulin/IGF-1 signaling in worms, fruit flies and mammals [88 - 93]. The role of 
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cAMP/PKA signaling in the life-extending effect of CR/DR in these multicellular 
eukaryotes remains to be tested. It should be stressed that a recently reported in worms 
involvement of both independent and overlapping pathways in life span extension by 
different DR regimens [94] supports the notion that the longevity benefit associated with 
nutrient limitation is mediated by a signaling network that regulates longevity by 
coordinating information flow along its convergent, divergent and multiply branched 
signaling pathways. 
          Akin to CR and DR regimens, certain pharmacological interventions can extend 
life span across phyla and, in some cases, improve overall health by beneficially 
influencing age-related pathologies (Figure 1.2). Many of the currently known anti-aging 
compounds increase life span and, some of them, promote healthy aging by targeting the 
AMPK/TOR signaling pathway responsive to the intracellular nutrient and energy status. 
By activating AMPK and thereby reducing TORC1 signaling, the type 2 diabetes 
therapeutics metformin extends longevity in worms [95] and mice [96]. The glutamine 
synthetase inhibitor methionine sulfoximine decreases the intracellular level of 
glutamine, an activator of TORC1, thus attenuating TORC1 signaling and extending the 
chronological life span of yeast [97, 98]. By inhibiting upstream TORC1 activators PI3K 
and MEK, LY294002 and U0126 (respectively) increase the replicative life span of 
cultured human fibrosarcoma cells by lowering TORC1 signaling [99]. Through its 
FKBP12-mediated inhibition of TORC1, the potent life-extending compound rapamycin 
extends 1) the replicative and chronological life spans of yeast [49, 98, 100]; 2) the 
replicative life spans of cultured rodent fibroblasts, human epithelium cells and human 
fibrosarcoma cells [101]; and 3) longevity in fruit flies and mice [36, 38]. The xanthine 
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alkaloid caffeine increases yeast chronological life span by decreasing the catalytic 
activity of Tor1p [102].  
          Mianserin, a serotonin receptor antagonist used as an antidepressant in humans, 
increases life span in worms by modulating an upstream step in the insulin/IGF-1 
signaling pathway responsive to the organismal nutrient status, perhaps by mimicking a 
DR-like physiological state through the inhibition of neurotransmission related to food 
sensing [103]. In contrast, valproic acid, a mood stabilizer and an anticonvulsant in 
humans, targets a downstream step in this pathway by promoting the translocation of the 
FoxO transcriptional factor DAF-16 into the nucleus [104].  
          Several anti-aging compounds increase life span and, some of them, promote 
healthy aging by targeting a compendium of longevity-related processes that currently are 
not assigned to the insulin/IGF-1, AMPK/TOR and/or cAMP/PKA pathways. Being 
specifically modulated by such life-extending compounds, these processes extend 
longevity due to their integration into a longevity signaling network that coordinates 
information flow along its convergent, divergent and multiply branched signaling 
pathways. One of these compounds is resveratrol. By activating the protein deacetylase 
activities of the sirtuins Sir2p (yeast), SIR-2.1 (worms), dSir2 (fruit flies) and SIRT1 
(mammals) [79, 105] (the ability of resveratrol to activate sirtuins in vivo is disputed 
[106, 107]) and/or by interacting with and modulating activities of its many other protein 
targets [108, 109], resveratrol extends 1) the replicative, but not chronological, life span 
of yeast [110]; 2) the replicative life span of cultured human fibroblasts [111]; and 3) 
longevity in worms, fruit flies, fishes and mice [112 - 115]. The life-extending and 
health-improving effects of resveratrol across species are due to its ability to modulate a 
 11 
plethora of longevity-related processes [110, 113, 115 - 119]. Longevity can also be 
extended by a pharmacological intervention that raises the intracellular level of a sirtuin. 
In fact, the ability of sodium nitroprusside to increase the replicative life span of cultured 
human peripheral blood mononuclear cells (PMBC) correlates with its ability to activate 
expression of the sirtuin SIRT1; the resulting enhancement of SIRT1-dependent histone 
H4 lysine 16 deacetylation may induce an anti-aging pattern of transcription [120]. 
Another anti-aging compound that increases life span by reducing the extent of histone 
acetylation is spermidine. This natural polyamine extends 1) the chronological life span 
of yeast; 2) the replicative life span of cultured human PMBC; and 3) longevity in worms 
and fruit flies [121]. The life-extending effect of spermidine is due to its ability to inhibit 
histone acetyltransferases and promote histone H3 deacetylation; the resulting activation 
of transcription of numerous autophagy-related genes suppresses age-related necrotic cell 
death [105, 121]. Moreover, histone modification is also modulated by Li
+
, an anti-aging 
compound in worms and a mood stabilizer in humans, that influences the age-related 
chromatin reorganization by altering transcription of genes involved in histone 
methylation, nucleosome composition and chromatin structure [122].  
          The plastoquinone derivate SkQ1 extends longevity in fungi, daphnias and fruit 
flies as well as increases life span and promotes healthy aging in mice by influencing 
longevity-related processes confined to mitochondria [123], organelles whose functional 
state modulates a complex signaling network governing longevity regulation [27, 62, 64, 
124]. Following its specific targeting to mitochondria, SkQ1 acts as an antioxidant that 
prevents oxidative damage to mitochondrial proteins and lipids, alters mitochondrial 
morphology, and reduces hydrogen peroxide-induced apoptosis and necrosis controlled 
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by mitochondria [123]. Moreover, the thermal stress mimetics lipoic acid, propyl gallate, 
trolox and taxifolin function as antioxidants that increase life span in worms (all of them) 
and fruit flies (lipoic acid), perhaps by detoxifying free radicals and/or enhancing 
resistance to age-related oxidative stress [125, 126].  
 
Figure 1.2. Certain diets and pharmacological interventions can extend longevity and improve overall 
health by delaying the onset of age-related diseases in evolutionarily distant organisms (see text in section 
1.3 for details). Reproduced from Fontana, L., Partridge, L. and Longo, V.D. (2010). Extending healthy life 
span - from yeast to humans. Science 328:321-326. 
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          All of the currently known anti-aging compounds increase life span under non-CR 
or non-DR conditions. Under such conditions, many of these molecules have been shown 
to 1) provide the longevity and health benefits associated with CR and DR, but without 
restricting caloric and nutrient intake; and 2) mimic numerous life-extending effects of 
CR and DR on gene expression pattern, metabolic and physiological processes, and stress 
response pathways. Therefore, the names “CR mimetics” and “DR mimetics” have been 
coined for such life-extending compounds [127 - 129]. Importantly, nearly all CR 
mimetics and DR mimetics are known to target the signaling pathways that modulate 
longevity in response to the organismal and intracellular nutrient and energy status, 
including the insulin/IGF-1 and AMPK/TOR pathways as well as the sirtuin-governed 
protein deacetylation module of the longevity signaling network integrating these 
pathways. Furthermore, such compounds as resveratrol, metformin and mianserin 
increase life span only under non-CR or non-DR conditions, but are unable to do so if the 
supply of calories or nutrients is limited [95, 103, 110, 112, 113]. Hence, one could 
envision that most, if not all, of the existing longevity pathways - currently known and 
those that, perhaps, remain to be discovered – are “adaptable” by nature, i.e., that they 
modulate longevity only in response to certain changes in the extracellular and 
intracellular nutrient and energy status of an organism. However, Li
+
 in worms and 
rapamycin in fruits flies have been recently shown to extend life span even under DR 
conditions [38, 122]. It is conceivable therefore that certain longevity pathways could be 
“constitutive” or “housekeeping” by nature, that is, that they 1) modulate longevity 
irrespective of the organismal and intracellular nutrient and energy status; and 2) do not 
overlap (or only partially overlap) with the longevity pathways that are under the 
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stringent control of calorie and/or nutrient availability. The challenge is to identify such 
housekeeping longevity pathway(s), perhaps by using a chemical screen for anti-aging 
compounds that can extend longevity even under CR/DR conditions. Because under such 
conditions the adaptable pro-aging pathways would be fully suppressed and the adaptable 
anti-aging pathways would be fully activated, a compound that can further increase life 
span is expected to target the housekeeping longevity pathway(s). It seems conceivable 
that such a compound can also increase life span under non-CR or non-DR conditions, 
although perhaps to a lesser extent than it does if the supply of calories or nutrients is 
limited. 
 
1.4. Yeast is a valuable model organism for studying the basic biology of aging and 
revealing longevity regulation mechanisms in multicellular eukaryotes 
          The budding yeast Saccharomyces cerevisiae, a genetically and biochemically 
manipulable unicellular eukaryote with annotated genome, is a valuable model for 
unveiling mechanisms of cellular aging in multicellular eukaryotes [130 - 132]. Yeast 
aging can be measured in two different ways. Replicative aging is defined by the 
maximum number of daughter cells that a mother cell can produce before senescence and 
models aging of a mitotically active cell in a multicellular organism (Figure 1.3) [131, 
133]. In contrast, chronological aging is measured by the length of time a yeast cell 
remains viable in a nondividing state and models aging of postmitotic mammalian cells 
(e.g., neurons) (Figure 1.3) [56, 131, 132]. In a simple clonogenic assay for measuring  
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 Figure 1.3. Two different ways to monitor yeast aging and age-related macromolecular damage to yeast 
cells. Yeast replicative aging is measured by the maximum number of daughter cells that a mother cell can 
produce before senescence, thereby modeling aging of a mitotically active cell in a multicellular eukaryotic 
organism. Yeast chronological aging is measured by the length of time a yeast cell remains viable in a 
nondividing state, thereby modeling aging of postmitotic mammalian cells (e.g., neurons). (See text in 
section 1.4 for details). Reproduced from Kaeberlein, M. (2010). Lessons on longevity from budding yeast. 
Nature 464:513-519. 
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yeast chronological aging, the percentage of viable yeast cells in their aging population is 
monitored at different time points before and after this population enters the non-prolife- 
rative stationary phase [56]. Both replicative and chronological aging of yeast can be 
decelerated by caloric restriction (CR), a low-calorie dietary regimen that extends life 
span in various multicellular eukaryotic organisms and delays the onset or reduces the 
incidence of many age-related diseases in mice and primates [66 - 69, 131, 134 - 136]. 
Because the fundamental mechanisms of aging are conserved across phyla [1, 3, 5, 20 - 
23], the relatively short and easily measured life span of yeast - in combination with their 
amenability to comprehensive biochemical, genetic, cell biological, chemical biological 
and system biological analyses - enabled for the first time to identify numerous longevity 
genes later shown to govern aging process in multicellular eukaryotes, define the nature 
of the molecular damage to biological macromolecules that contributes to aging and age-
related disorders in higher eukaryotic organisms, and reveal potent anti-aging compounds 
later demonstrated to extend longevity in a wide range of eukaryotic organisms [130 - 
137].          
 
1.5. The deposition and lipolytic degradation of neutral lipids contribute to 
longevity regulation and age-related pathologies 
          Proper control of the deposition and mobilization of neutral lipids is mandatory for 
maintaining energy homeostasis and, thus, may play an important role in longevity 
regulation [138 - 141]. The molecular and cellular mechanisms linking metabolism of 
neutral lipids and longevity are yet to be defined. The establishment of such mechanisms 
operating in chronologically aging yeast was one of the major objectives of my thesis.  
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          Triacylglycerols (TAG) and ergosteryl esters (EE) are the two major species of 
neutral lipids that in yeast cells are deposited in so-called lipid bodies (LBs) [142 - 144]. 
TAG and EE serve as the main storage molecules for free fatty acids (FFA), 
diacylglycerols (DAG) and ergosterol (ERG). Lipolysis of TAG generates FFA, which 
can be either incorporated into newly synthesized phospholipids and cardiolipins or 
degraded through β-oxidation in the peroxisome of yeast [143, 144]. Lipolysis of TAG 
also produces various DAG species, which not only serve as building blocks for synthesis 
of the phospholipids phosphatidylethanolamine (PE) and phosphatidylcholine (PC) but 
also operate as potent signaling molecules modulating a protein kinase C (PKC)-
dependent signal transduction network governing multiple stress response- and longevity-
related processes [145, 146]. Lipolysis of EE in yeast results in the formation of FFA and 
ERG, a sterol lipid known to play an important role in numerous essential functions of 
cellular membranes [142 - 144, 147, 148]. Thus, the ability of yeast to modulate the 
biosynthesis and degradation of neutral lipids is crucial for regulating 1) energy 
homeostasis; 2) phospholipid and cardiolipin biosynthesis; 3) neutralization of excessive 
amounts of membrane-perturbing species of FFA, ERG and TAG; 4) the FFA- and DAG-
induced lipoapoptotic and necrotic forms of cell death; and 5) a DAG-modulated, PKC-
dependent signal transduction network that governs multiple stress response- and 
longevity-related processes [142 - 148]. All these processes are currently viewed as vital 
for modulating the aging process in evolutionarily distant organisms [138 - 141, 145, 146, 
149 - 151].  
          Neutral lipid synthesis in yeast cells takes place in the endoplasmic reticulum (ER) 
[143, 144, 147, 152]. TAG is formed through several acylation and dephosphorylation 
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steps from lysophosphatidic acid (LPA), which itself can be formed in one of the 
following two ways: 1) acylation of glycerol-3-phosphate by either Gpt2p or Sct1p 
protein or 2) acylation of dihydroxyacetone phosphate (DHAP), also by Gpt2p or Sct1p, 
followed by reduction of 1-acyl-DHAP in an Ayr1p-catalyzed reaction [143, 144, 147, 
152]. Another acyl group is transferred to the sn-2 position of LPA to form phosphatidic 
acid (PA). PA is then dephosphorylated by one of three dephosphorylases, Pah1p, Dpp1p 
or Lpp1p, to form DAG; DAG can also be formed from glycerophospholipids by removal 
of the head group-phosphate. TAG is formed from DAG by acylation of the sn-3 position 
either with acyl-CoA (catalyzed by Dga1p, Are1p or Are2p) or with acyl groups 
transferred from glycerophospholipids (catalyzed by Lro1p). EE synthesis in the ER is 
driven by Are1p or Are2p, which catalyze the transfer of an acyl group from acyl-CoA to 
ERG [143, 144, 147, 152]. 
          TAG degradation in yeast cells takes place in LBs and is driven by the Tgl2p, 
Tgl3p, Tgl4p and Tgl5p lipases, whereas EE hydrolysis occurs either within the plasma 
membrane in a Yeh2p-catalyzed reaction or within LBs in a reaction that is catalyzed by 
the Tgl1p lipase [143, 144, 147, 152]. 
          Growing evidence supports the view that the deposition and lipolytic degradation 
of neutral lipids in LBs of fat storage tissues define longevity of multicellular eukaryotic 
organisms [153]. Found in most eukaryotic and some prokaryotic cells, LBs have been 
also referred to as lipid droplets, lipid particles, oil bodies and by many other different 
names that reflect their cellular and biochemical context in various biological systems 
[154, 155]. LBs have long been viewed as relatively inert organellar compartments [156, 
157]. They were believed to function only as a site for storing excess energy and 
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stockpiling FFA and sterols in the form of neutral lipids, mainly TAG and steryl esters 
[154, 160, 161]. Surrounded by a monolayer of phospholipids and associated proteins, the 
neutral lipid core of LBs can be hydrolyzed in a regulated fashion by lipases [160, 161]. 
The resulting retrieval of stored FFA, phospholipids and sterols provides energy via fatty 
acid oxidation during times of nutrient scarcity, maintains the homeostasis of membrane 
lipids during cell growth and division, and modulates the levels of free sterols inside and 
outside of the cell [154 - 161]. 
          An important recent advance in our understanding of the cell biology of LBs is that 
they constitute highly dynamic organellar compartments whose protein and lipid 
composition, de novo formation from the ER template, growth, fragmentation, shrinkage 
due to lipolysis, movement, and association with other organelles is regulated by a 
complex network of protein machines [157 - 159, 161 - 172]. It has also become clear 
that LBs are dynamically integrated into several vital processes and can serve both as an 
intracellular signaling compartment and as an organizing platform orchestrating these 
processes. In yeast, the phosphorylation and activation of the LBs-associated lipase Tgl4p 
by cyclin-dependent kinase 1 controls cell-cycle progression by mobilizing 
triacylglycerols, thereby providing fatty acids and phospholipids for the secretory vesicle-
dependent bud formation and ultimately enabling the G1/S phase transition [173]. 
Furthermore, it appears that LBs in white adipose tissue (WAT) of mice function as a hub 
in a regulatory network that, by modulating the synthesis and secretion of adipokines and 
the lipokine C16:1n7-palmitoleate, is central to the multiple defects in metabolic 
homeostasis associated with obesity, insulin resistance, type 2 diabetes, atherosclerosis 
and inflammatory disorders [165, 167, 174 - 178]. Moreover, by recruiting certain 
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proteins from other cellular locations, temporally housing them, managing their 
availability and modulating their activities, LBs have been proposed to play important 
roles in the regulation of various cellular processes [157, 167, 171]. It has been suggested 
that, by sequestering proteins, LBs function as an organizing platform that 1) removes 
excess proteins from other organellar compartments, inactivates them and/or stores them 
for later use; 2) promotes the refolding of unfolded proteins targeted to LBs by recruiting 
molecular chaperones from the cytosol; 3) provides a surface for the ordered degradation 
of partially unfolded and misfolded LBs-bound proteins that otherwise can form toxic 
aggregates in the cytosol; and 4) delivers some LBs-associated proteins to their target 
organellar compartments via permanent or transient contact sites [157, 167, 171, 179 - 
181]. 
          One of the recently discovered new and unexpected functions of LBs is the 
essential role they play in longevity regulation. It appears that various interventions that 
inhibit the deposition of neutral lipids in LBs or activate their lipolytic degradation in fat 
storage tissues of the nematode Caenorhabditis elegans, the fruit fly Drosophila 
melanogaster or laboratory mice also extend the life spans of these organisms. In fact, 
presently unknown humoral signals produced and secreted by somatic cells in the gonad 
of C. elegans promote the nuclear localization of the forkhead transcription factor DAF-
16 in intestinal cells, the principal site of neutral lipid storage in this organism [182]. 
DAF-16 then induces the expression of a gene encoding a specific lipase, thereby 
promoting the lipolysis of neutral lipids stored in LBs of intestinal cells and extending 
longevity by a yet-to-be established mechanism [182]. Furthermore, the elimination of 
LBs-associated lipases Brummer or ATGL (adipose triacylglycerol lipase) in the fat body 
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of flies or WAT of mice, respectively, shortens life span [183, 184]. Moreover, by greatly 
diminishing the levels of stored neutral lipids in WAT, both the elimination of WAT-
specific insulin receptor and the replacement of the C/EBP (CCAAT/enhancer-binding 
protein) protein with its paralogue C/EBPβ extend longevity in mice [185 - 187]. 
Importantly, a low-calorie dietary regimen known as caloric restriction (CR) extends life 
span in a wide spectrum of organisms and delays the onset of age-related diseases in 
rodent models [174]. The life-extending effect of CR in worms and flies is mediated by 
so-called sirtuins, a family of NAD
+
-dependent protein deacetylases and ADP ribosylases 
[174, 186]. In mice, CR diet increases the abundance of the sirtuin SIRT1, which has 
been shown to repress transcription of genes that are required for the LBs-confined 
accumulation of neutral lipids in WAT [174, 188]. It has been therefore proposed that 
SIRT1 delays aging of CR mice by shifting a balance between the opposing processes of 
LBs’ formation and degradation in WAT towards lipolytic degradation of neutral lipids in 
this fat storage tissue [174, 188]. 
          Altogether, these findings imply that the LBs-confined deposition and lipolytic 
degradation of neutral lipids in fat storage tissues define longevity of multicellular 
eukaryotic organisms. A key challenge for the future will be to establish the molecular 
mechanisms by which a delicate balance between the opposing processes of neutral lipids 
accumulation and their lipolytic degradation regulates longevity in these organisms. 
Recent studies suggested three such mechanisms (Figures 1.4, 1.5 and 1.6). First, the size 
of LBs in WAT of mice modulates the ability of the ER in this tissue to synthesize and 
send for secretion various anti-hyperglycaemic and pro-hyperglycaemic protein 
hormones that control metabolic homeostasis in other tissues [174, 175, 189, 190]. In 
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intestine of worms, LBs that accumulate in this fat storage tissue contribute sterols for the 
biosynthesis in the ER and the subsequent secretion of the lipophilic hormones 
dafachronic acids and pregnenolone, both of which delay cellular aging in other tissues 
[190]. Thus, it is conceivable that the dynamics of LBs-confined deposition and lipolytic 
degradation of neutral lipids in fat storage tissues modulates their ability to synthesize in 
the ER and then secrete humoral signals that control longevity-related processes in other 
tissues (Figure 1.4). 
 
Figure 1.4. The first possible mechanism by which the deposition and lipolytic degradation of neutral 
lipids in lipid bodies (LBs) of fat storage tissues define longevity of multicellular eukaryotic 
organisms. The size of LBs in white adipose tissue (WAT) of mice modulates the ability of the 
endoplasmic reticulum (ER) in this tissue to synthesize and send for secretion various pro- and anti-aging 
adipokines that control longevity-related processes in other tissues. Overloading LBs in WAT with neutral 
lipids results in the recruitment of macrophages to this fat storage tissue. Macrophages that infiltrate WAT 
secrete some of the pro-aging adipokines, whereas adipocytes of WAT secrete others. In intestine of 
worms, LBs that accumulate in this fat storage tissue contribute sterols for the biosynthesis in the ER and 
the subsequent secretion of the lipophilic hormones dafachronic acids and pregnenolone, both of which 
delay cellular aging in other tissues. 
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          Second, the lipolysis of LB-deposited neutral lipids results in the release of the 
lipokine C16:1n7-palmitoleate, an unsaturated FFA, from WAT of mice [177]. This 
recently discovered lipid hormone regulates systemic carbohydrate and lipid homeostasis 
in muscle and liver by promoting muscle insulin sensitivity and attenuating hepatic 
steatosis [177]. Hence, the LBs-derived C16:1n7-palmitoleate produced in and then 
secreted by WAT of mice could function as a signaling molecule that plays an important 
role in longevity regulation (Figure 1.5). 
 
Figure 1.5. The second possible mechanism by which the deposition and lipolytic degradation of 
neutral lipids in lipid bodies (LBs) of fat storage tissues define longevity of multicellular eukaryotic 
organisms. The lipolysis of LB-deposited neutral lipids results in the release of the lipokine C16:1n7-
palmitoleate, an unsaturated fatty acid, from WAT of mice. This LB-derived lipid hormone regulates 
longevity-related processes in muscle and liver. 
 
Third, in response to enhanced lipolysis of LB-deposited neutral lipids, WAT of mice and 
the fat body of flies activate certain regulatory networks that stimulate mitochondrial 
biogenesis and β-oxidation of FFA in mitochondria [178, 187, 191]. This, in turn, 
decreases the levels of saturated FFA secreted by these fat storage tissues, thereby 
reducing the risk of lipotoxicity in other tissues and preventing muscle insulin resistance 
and hepatic steatosis [176 - 178, 192]. Importantly, such stimulation of mitochondrial 
biogenesis and β-oxidation of FFA in WAT of mice expressing the β paralogue of C/EBP 
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increases their life span [187]. Therefore, it is likely that this third mechanism, which is 
confined to fat storage tissues, plays an important role in delaying cellular aging in 
peripheral tissues and increasing longevity of the entire organism (Figure 1.6). 
 
Figure 1.6. The third possible mechanism by which the deposition and lipolytic degradation of 
neutral lipids in lipid bodies (LBs) of fat storage tissues define longevity of multicellular eukaryotic 
organisms. In response to enhanced lipolysis of LB-deposited neutral lipids, adipocytes in WAT of mice 
increase the level of the G protein  stimulatory subunit (Gs), whereas cells in the fat body of flies activate 
transcription of numerous genes positively regulated by the hepatocyte nuclear factor 4. This, in turn, 
stimulates mitochondrial biogenesis and β-oxidation of free fatty acids (FFA) in mitochondria, thereby 
decreasing the levels of saturated FFA secreted by these fat storage tissues. Saturated FFA are lipotoxic in 
peripheral tissues and cause muscle insulin resistance and hepatic steatosis. Thus, the stimulation of 
mitochondrial biogenesis and FFA β-oxidation in fat storage tissues displaying enhanced lipolysis of 
neutral lipids plays an important role in delaying cellular aging in peripheral tissues. Other abbreviations: 
Ac-CoA, acetyl-CoA. 
 
1.6. Cardiolipin lipid species in the mitochondrial membrane modulate 
mitochondria-governed processes whose dysfunction underlies aging and age-
related pathologies 
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Cardiolipin (CL) is the mitochondria-specific dimeric glycerophospholipid, which 
contains three glycerol backbones and four acyl chains and almost exclusively localized 
in the mitochondrial inner membrane [193 - 200]. Various molecular species of this 
signature lipid of the mitochondrial inner membrane have been shown to 1) associate 
with and modulate activities of all five complexes of the mitochondrial respiratory chain, 
also promoting their organization into supramolecular assemblies; 2) bind to and 
modulate the activity of cytochrome c, a heme-containing mobile component of the 
mitochondrial respiratory chain also known for its essential role in mitochondria-
controlled apoptosis; 3) associate with and regulate the activity of the adenine nucleotide 
translocator; 4) play an essential role in maintaining the electrochemical gradient across 
the mitochondrial inner membrane; 5) confer fluidity and stability to the inner membrane 
of mitochondria; 6) be primary targets of an ROS-inflicted damage because of their 
highly unsaturated acyl chains; 7) regulate the protein import into mitochondria [193 - 
200]. Due to its ability to interact by non-covalent bonds with a number of unrelated 
proteins in the mitochondrial inner membrane, CL operates as a molecular chaperone that 
governs the assembly of a number of protein assemblies involved in a plethora of 
biological processes [194 - 200]. Moreover, the conversion of CL to phosphatidic acid 
(PA) is essential for mitochondrial fission and fusion [201 - 203].  
          Because of the involvement of CL in all these basic biological processes, specific 
alterations in its content and/or composition have been reported in pathological states 
characteristic of various disorders. A distinct set of mutations in the tafazzin gene, which 
in humans encodes an enzyme involved in the remodeling of CL acyl chains, causes so-
called Barth Syndrome by reducing total CL levels, elevating monolysocardiolipin 
 26 
concentrations and decreasing the levels of unsaturated fatty acyl species of CL [193, 
195, 198]. The clinical manifestations of this X-linked recessive disorder include 
cardioskeletal myopathy, neutropenia and abnormal growth [193, 195]. Furthermore, 
reduced levels of CL and the resulting accumulation of dysfunctional mitochondria are 
characteristic of the early stages of aging in rodents and humans [194, 195, 198]. It 
should be stressed that CL is particularly susceptible to the age-related accumulation of 
mitochondrially produced ROS – due to its high content of oxidative damage-vulnerable 
unsaturated fatty acids and its proximity to the sites of ROS generation in mitochondria 
[194, 196 - 199]. Moreover, alterations in CL content and/or composition have been 
linked to several other disorders, including Tangier disease, diabetic cardiomyopathy, 
dilated cardiomyopathy with ataxia and non-alcoholic fatty liver disease [195, 198]. 
          Little is known about the molecular mechanisms underlying the essential role of 
CL in regulating various mitochondria-governed processes whose dysfunction underlies 
aging and age-related pathologies. It has been proposed that CL modulates the ability of 
prohibitins Phb1p and Phb2p - two evolutionarily conserved proteins that form large 
complexes with each other in the mitochondrial inner membrane - to maintain the 
organization and functional integrity of this membrane [197, 200, 204 - 207]. The 
multimeric, high-molecular weight complexes of prohibitins function as protein scaffolds 
that control the integrity and functionality of the mitochondrial inner membrane [197, 
200, 204 - 207]. Such scaffolding function of prohibitins relies on their ability to 
coordinate activities of numerous protein components of the mitochondrial inner and 
outer membranes. These physically and/or functionally interacting protein partners of 
prohibitins include: 1) proteins that function in the assembly of the respiratory chain; 2) 
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proteins that are essential for both the maintenance of mitochondrial morphology and the 
assembly of β-barrel proteins in the outer membrane; 3) the m-AAA protease, an ATP-
dependent protease with a critical role in protein quality control within the inner 
mitochondrial membrane; and 4) proteins that regulate, in a highly coordinated fashion,  
the levels of CL and the glycerophospholipid phosphatidylethanolamine (PE) [197, 200, 
204 - 207]. One of the major objectives of my thesis was therefore to define the 
molecular mechanisms underlying the essential role of CL in regulating longevity of 
chronologically aging yeast. 
 
1.7. Thesis outline and contributions of colleagues 
Chapter 2 describes my successful attempt to solve the inherent limitations of the 
currently used methods for lipidomic analysis (including the limitations characteristic of 
the mass spectrometry-based analysis) by developing a survey-scan method for 
quantitative assessment of the entire complement of lipids in yeast cells using 
electrospray ionization mass spectroscopy (ESI/MS). The survey-scan ESI/MS method of 
lipidomic analysis that I developed demonstrated that: 1) yeast has a relatively simple 
lipidome with 7 major lipid classes; 2) the majority of individual molecular forms within 
each of these different lipid classes have chain length of 16 or 18 carbon atoms; and 3) 
the fatty acyl moieties of all of lipid species composing yeast lipidome are either mono-
unsaturated or saturated, perhaps due to the presence of a single acyl desaturase enzyme 
in yeast. Furthermore, the method that I developed is highly sensitive as it is: 1) sensitive 
to the low µM range (0.6 to 2 µM depending on lipid class) for all lipid species tested; 
and 2) linear to the hundreds of µM range, with the concentration linearity spreading over 
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2 to 3 orders of magnitude. Moreover, the method that I developed enables very accurate 
quantitation of different lipid species within a wide range of lipid concentrations. 
Importantly, if compared to the currently used ESI/MS-MS-based method of lipidomic 
analysis, my method has the following important advantages: 1) unlike the ESI/MS-MS-
based method, it can be carried out within a very limited period of time; 2) unlike the 
ESI/MS-MS-based method, it does not require to maintain stable spray conditions at the 
ESI source for long periods of time; 3) unlike the ESI/MS-MS-based method, it does not 
have a bias towards certain lipid species, thereby being sufficiently sensitive to 
unexpected changes in lipid spectra of analyzed cells; 4) it is more sensitive than the 
ESI/MS-MS-based method and, thus, does not require abundant quantities of cells for 
lipid extraction and analysis; and 5) it has lower than the ESI/MS-MS-based method 
limits of detection and quantitation for all yeast lipid species. I have successfully applied 
this method to quantitatively assess not only the lipidomes of whole yeast cells and their 
highly purified organelles, but also the entire complement of lipids in cultured human 
microglial cells. My findings presented in Chapter 2 support the notion that the survey-
scan ESI/MS method of lipidomic analysis that I developed enables within a very limited 
period of time and using a very low number of cells to resolve, unequivocally identify 
and accurately quantitate all molecular forms of lipid species composing yeast lipidome 
and the majority of molecular forms of lipid species composing the lipidome of cultured 
human microglial cells.   
          Chapter 3 describes how I used a combination of functional genetic, cell biological, 
electron and fluorescence microscopical, proteomic, lipidomic, and metabolomic 
analyses to establish the molecular mechanism underlying the ability of CR to extend 
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longevity of chronologically aging yeast by specifically remodelling lipid metabolism in 
the ER, LBs and peroxisomes. In this mechanism, LBs in yeast cells function as a hub in 
a regulatory network that modulates neutral lipids synthesis in the ER and fatty acid 
oxidation in peroxisomes. Ethanol accumulated in yeast placed on a calorie-rich diet 
represses the synthesis of Fox1p, Fox2p and Fox3p, thereby suppressing peroxisomal 
oxidation of FFA that originate from TAG synthesized in the ER and deposited within 
LBs. The resulting build-up of arrays of FFA (called gnarls) within LBs of non-CR yeast 
initiates several negative feedback loops regulating the metabolism of TAG. Due to the 
action of these negative feedback loops, chronologically aging non-CR yeast not only 
amass TAG in LBs but also accumulate FFA and DAG in the ER. FFA and DAG 
regulate longevity by two different mechanisms that operate at two different stages of the 
aging process. One mechanism involves sensing the concentration of DAG maintained by 
cells (in a diet- and genotype-dependent fashion) during diauxic (D) and post-diauxic 
(PD) growth phases. DAG concentration during D and PD phases programs cell viability 
during the non-proliferative stationary (ST) growth phase by modulating the FFA- and 
DAG-induced necrotic cell death pathway, but not by influencing the mitochondria-
controlled apoptotic pathway of cell death. Another mechanism involves sensing the 
concentrations of FFA and DAG during ST phase. Any diet or genetic manipulation that 
causes the build-up of these two lipids during ST phase shortens the chronological life 
span of yeast in part by promoting rapid mitochondria-controlled apoptotic cell death, but 
not by activating FFA- and DAG-induced necrotic cell death pathway. 
          Chapter 4 describes how I used a combination of functional genetic, cell biological, 
electron and fluorescence microscopical, proteomic, lipidomic, and metabolomic 
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analyses to find a short-lived mutant strain most suitable for conducting a high-
throughput screen of novel anti-aging compounds that can extend longevity by altering 
lipid metabolism under CR conditions. Based on my findings, I proposed to use pex5 as 
such mutant strain. As described in Chapter 4, I found that in yeast placed on a CR diet 
this mutation leads to: 1) increase in FFA, DAG, TAG and EE and their build-up in the 
ER and LBs; 2) excessive accumulation of the ER membranes and ER-originated LBs; 
and 3) enhanced susceptibility to necrotic cell death caused to a short-term exposure to 
exogenously added FFA and DAG. Using the short-lived pex5 mutant strain, Alexander 
Goldberg in Dr. Titorenko’s laboratory conducted a high-throughput screen of novel anti-
aging compounds that can extend the chronological life span (CLS) of yeast by targeting 
these longevity-defining aspects of lipid metabolism under CR conditions. One of the 
life-extending compounds identified in such screen was lithocholic acid (LCA), a bile 
acid. LCA greatly extends the CLS of wild-type (WT) strain of yeast placed on a CR diet. 
As described in Chapter 4, by elucidating how LCA influences the metabolism of lipids 
as well as age-related forms of necrotic and apoptotic death in chronologically aging 
yeast and how it alters yeast proteome, I established the molecular mechanism underlying 
the ability of LCA to extend yeast CLS by targeting these longevity-defining aspects of 
lipid metabolism confined to the ER, LBs and peroxisomes. In such mechanism, under 
CR conditions LCA accelerates the biosynthesis of TAG from FFA and DAG in the ER 
as well as decelerates the FFA- and DAG-generating lipolysis of TAG in LBs. The 
resulting reduction of the ER- and LB-confined levels of FFA and DAG during diauxic 
(D), post-diauxic (PD) and stationary (ST) growth phases affects both mechanisms by 
which these two lipid species regulate longevity. First, by lowering the intracellular 
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concentration of DAG during D and PD phases, LCA attenuates the FFA- and DAG-
induced necrotic cell death pathway – thereby impairing the age-related form of necrotic 
cell death and ultimately extending longevity of chronologically aging yeast placed on a 
CR diet. Second, by reducing the intracellular concentrations of FFA and DAG during ST 
phase, LCA attenuates the mitochondria-controlled apoptotic cell death pathway – 
thereby impairing the age-related form of apoptotic cell death and ultimately extending 
longevity of chronologically aging yeast under CR conditions. 
          Chapter 5 describes how I used a combination of functional genetic, cell biological, 
electron and fluorescence microscopical, and lipidomic analyses to establish the 
molecular mechanism underlying the ability of LCA to extend yeast life span by targeting 
the metabolism of membrane lipids in mitochondria. My findings imply that under CR 
conditions LCA extends yeast longevity by remodeling the composition of mitochondrial 
membrane lipids and thereby modulating longevity-defining processes confined to and/or 
governed by mitochondria. I concluded that LCA extends the CLS of WT yeast by: 1) 
increasing the level of phosphatidylserine (PS) in the mitochondrial membrane, thereby 
enhancing its positive effect on longevity-defining processes in this membrane; 2) 
decreasing the level of phosphatidylethanolamine (PE) in the mitochondrial membrane, 
thereby weakening its negative effect on longevity-defining processes in this membrane; 
and 3) proportionally decreasing the levels of PE and cardiolipin (CL) in the 
mitochondrial membrane, thereby increasing PS/CL and PS/PE ratios but maintaining 
PE/CL ratio of mitochondrial membrane lipids and causing some longevity-extending 
changes in this membrane. My analysis of the biological implications of these LCA-
driven specific changes in mitochondrial membrane lipids revealed that, by altering the 
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levels of PS, CL and PE, LCA: 1) changes the curvature of the inner mitochondrial 
membrane; and 2) enhances the positive effect of PS and weakens the negative effect of 
PE on membrane proteins whose activity depends on these two lipid species - thereby 
enhancing the ability of the inner mitochondrial membrane to form cristae and activating 
protein machines involved in mitochondrial respiration, the maintenance of mitochondrial 
membrane potential and ROS production in mitochondria. 
          Some of the findings described in Chapter 2 have been published in The Journal of 
Visualized Experiments [Bourque, S.D. and Titorenko, V.I. (2009). A quantitative 
assessment of the yeast lipidome using electrospray ionization mass spectrometry. J. Vis. 
Exp. 30:1-3]. I carried out all experiments described in this publication and prepared the 
first draft of the manuscript. Dr. V. Titorenko provided intellectual leadership of this 
project and edited the manuscript. Furthermore, my presented in Chapter 2 data on 
characteristic changes in the lipidome of human microglia exposed to various pro-
inflammatory and anti-inflammatory interventions constitute an integral part of a soon-to-
be submitted to FASEB Journal manuscript [Khatchadourian, A., Bourque, S.D., Richard, 
V.R., Titorenko, V.I. and Maysinger, D.
*
corresponding author (2011). LPS induces lipid 
droplet accumulation and perilipin-2 expression in microglia. FASEB Journal]. I carried 
out and supervised about 50% of the work on lipidomic analysis of human microglia 
described in this publication and prepared the first draft of sections relevant to my work. 
Dr. Maysinger and Dr. V. Titorenko provided intellectual leadership of this project and 
edited the manuscript. Moreover, most of the findings described in Chapter 2 are 
presented in the manuscript of a paper [Bourque, S.D., Richard, V.R., Beach, A. and 
Titorenko, V.I. Analysis of the Saccharomyces cerevisiae lipidome using survey-scan 
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electrospray-ionization mass spectroscopy] that is currently in preparation for submission 
to The Journal of Lipid Research. I expect this manuscript to be submitted for publication 
in late April or early May 2011. 
          Some of the findings described in Chapter 3 have been published in The 
Biochemical Society Transactions [Goldberg, A.A., Bourque, S.D., Kyryakov, P., Boukh-
Viner, T., Gregg, C., Beach, A., Burstein, M.T., Machkalyan, G., Richard, V., 
Rampersad, S. and Titorenko, V.I. (2009). A novel function of lipid droplets in regulating 
longevity. Biochem. Soc. Trans. 37:1050-1055] and Experimental Gerontology 
[Goldberg, A.A., Bourque, S.D., Kyryakov, P., Gregg, C., Boukh-Viner, T., Beach, A., 
Burstein, M.T., Machkalyan, G., Richard, V., Rampersad, S., Cyr, D., Milijevic, S. and 
Titorenko, V.I. (2009). Effect of calorie restriction on the metabolic history of 
chronologically aging yeast. Exp. Gerontol. 44:555-571]. I carried out and supervised 
more than 30% of all of the work described in each of these publications and prepared the 
first draft of sections relevant to my work. I am an equally contributed first co-author on 
both these publications. Dr. V. Titorenko provided intellectual leadership of these 
projects and edited both manuscripts. Moreover, most of the findings described in 
Chapter 3 are presented in the manuscript of a paper [Bourque, S.D., Richard, V.R., 
Beach, A., Burstein, M.T., Goldberg, A.A., Kyryakov, P. and Titorenko, V.I. A 
mechanism linking lipid metabolism and longevity in chronologically aging yeast] that is 
currently in preparation for submission to Cell Metabolism. I expect this manuscript to be 
submitted for publication in late July or early August 2011. 
          Some of the findings described in Chapter 4 have been published in Aging 
[Goldberg, A.A., Richard, V.R., Kyryakov, P., Bourque, S.D., Beach, A., Burstein, M.T., 
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Glebov, A., Koupaki, O., Boukh-Viner, T., Gregg, C., Juneau, M., English, A.M., 
Thomas, D.Y. and Titorenko, V.I. (2010). Chemical genetic screen identifies lithocholic 
acid as an anti-aging compound that extends yeast chronological life span in a TOR-
independent manner, by modulating housekeeping longevity assurance processes. Aging 
2:393-414]. I carried out and supervised approximately 25% of the work described in this 
publication and prepared the first draft of sections relevant to my work. I am an equally 
contributed first co-author on this publication. Dr. V. Titorenko provided intellectual 
leadership of this project and edited the manuscript. Moreover, most of the findings 
described in Chapter 4 are presented in the manuscript of a paper [Bourque, S.D., 
Richard, V.R., Beach, A., Burstein, M.T., Goldberg, A.A., Kyryakov, P. and Titorenko, 
V.I. Lithocholic acid extends yeast longevity in part by targeting the longevity-defining 
aspects of lipid metabolism confined to the endoplasmic reticulum, lipid bodies and 
peroxisomes] that is currently in preparation for submission to Developmental Cell. I 
expect this manuscript to be submitted for publication in late September or early October 
2011. 
          Findings described in Chapter 5 are presented in the manuscript of a paper 
[Bourque, S.D., Richard, V.R., Beach, A., Burstein, M.T., Koupaki, O., Goldberg, A.A., 
Kyryakov, P. and Titorenko, V.I. Lithocholic acid extends yeast longevity in part by 
altering the composition of mitochondrial membrane lipids] that is currently in 
preparation for submission to The Journal of Cell Biology. I expect this manuscript to be 
submitted for publication in late October or early November 2011. I am the first author 
on this manuscript. I carried out and supervised approximately 40% of the work 
described in it and prepared the first draft of sections relevant to my work. Dr. V. 
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Titorenko provided intellectual leadership of this project and is currently editing the 
manuscript.            
          All abbreviations, citations, and the numbering of figures and tables that have been 
used in the published paper and in the manuscripts in preparation have been changed to 
the format of this thesis. 
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2. Development of a method for quantitative assessment of the lipidomes of yeast 
and cultured human cells using survey-scan electrospray ionization mass 
spectrometry (ESI/MS)  
2.1. Abstract 
          Existing methods for lipid identification and quantification - such as fluorescence 
microscopy, high performance liquid chromatography (HPLC), thin-layer 
chromatography (TLC) and gas chromatography followed by mass spectrometry 
(GC/MS) - are well established but suffer from low sensitivity, are time consuming, 
insufficiently separate various molecular forms of lipids and require lipid derivatization 
prior to analysis. In order to overcome these inherent limitations of the currently used 
methods for lipidomic analysis, I have devised a method for quantitative assessment of 
the the entire complement of lipids in yeast cells using survey-scan ESI/MS. This method 
exceeds currently available methods for lipid identification and quantification in the 
ability to resolve various molecular forms of lipids, sensitivity, and speed. I have 
successfully applied this method to quantitatively assess not only the lipidomes of whole 
yeast cells and their highly purified organelles, but also the entire complement of lipids in 
cultured human microglial cells.   
 
2.2. Introduction 
          Lipids are one of the major classes of biomolecules and play important roles in 
membrane dynamics, energy storage and signaling [208 - 211]. The budding yeast 
Saccharomyces cerevisiae, a genetically and biochemically manipulable unicellular 
eukaryote with annotated genome and very simple lipidome, is a valuable model for 
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studying biological functions of various lipid species in multicellular eukaryotes [208, 
211, 212]. S. cerevisiae has a relatively simple lipidome, with the normal compliment of 
glycerophospholipids, neutral lipids and ceramides [213, 214]. Due to the presence of 
only one acyl desaturase enzyme in yeast, the fatty acyl moieties of all of its lipid species 
are either mono-unsaturated or saturated [212 - 215]. Furthermore, about 95% of the 
glycerophospholipid and neutral lipid species found in yeast cells have chain length of 16 
or 18 carbon atoms [212 - 215]. Of note, the lipid makeups of yeast and mammalian cells 
have some differences. Specifically, yeast has ergosterol and ergosteryl esters instead of 
cholesterol and cholesteryl esters found in mammalian cells [212 - 215]. In addition, 
unlike glucosyl-based sphingolipids in mammalian cells, sphingolipids in yeast cells 
carry mannosyl residues [213 - 215]. Despite these differences, the pathways of lipid 
synthesis and degradation are among the most evolutionarily conserved metabolic 
pathways known [212 - 216].  
          Existing methods for lipid identification and quantification - such as fluorescence 
microscopy, HPLC, TLC and GC/MS - are well established but have low sensitivity, 
insufficiently separate various molecular forms of lipids, require lipid derivatization prior 
to analysis and are quite time consuming. Electrospray ionization mass spectroscopy 
(ESI/MS) is particularly suited to lipid analysis due to its high sensitivity, ability to 
distinguish between different lipid species, ease of sample preparation and speed [213, 
214]. This method is advantageous for quantitative lipidomics because 1) the 
decomposition spectra of the major lipid classes are well established [217]; and 2) 
although the head groups of different molecular forms of the same lipid species and the 
degrees of unsaturation and/or lengths of their acyl chains lengths vary and thus can 
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complicate the acquisition of quantitative data, these pitfalls are easily to overcome by 
using specific and well established protocols for sample preparation and lipid standards 
selection [213, 214, 217 - 219]. However, it should be stressed that the ESI/MS-MS-
based quantitative assessment of lipidomes has the following limitations and 
disadvantages as a method relying on the use of tandem MS: 1) it is time consuming; 2) it 
requires to maintain stable spray conditions at the ESI source for long periods of time; 3) 
because it relies on lipid decomposition, it has a bias towards some lipid species – 
thereby being insufficiently sensitive to unexpected changes in lipid spectra of analyzed 
cells; 4) it has a limit of sensitivity and hence requires abundant quantities of cells for 
lipid extraction and analysis; and 5) it has fairly high limits of detection and quantitation 
for some lipid species [213 - 220]. I decided to solve these inherent limitations of the 
currently used methods for lipidomic analysis (including the limitations characteristic of 
the ESI/MS-MS-based analysis) by developing a survey-scan method for quantitative 
assessment of the the entire complement of lipids in yeast and cultured human cells using 
ESI/MS.    
 
2.3. Materials and Methods 
Reagents 
Various molecular forms of the glycerophospholipids phosphatidylcholine (PC), 
phosphatidylethanolamine (PE), phosphatidylinositol (PI), phosphatidylserine (PS) and 
phosphatidic acid (PA), as well as of cardiolipin (CL), were from Avanti Polar Lipid 
(Alabaster, AL, USA). Different species of free fatty acids (FFA) and triacylglycerols 
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(TAG) were from Larodan (Malmo, Sweden). Biotech grade chloroform and methanol 
were form Sigma-Aldrich (St. Louis, MO, USA). 
 
Yeast strains and growth conditions 
The wild-type strain BY4742 (MATα his31 leu20 lys20 ura30) and single-gene-
deletion mutant strains in the BY4742 genetic background (all from Open Biosystems; 
Huntsville, AL, USA) were grown in rich YEPD medium (1% yeast extract, 2% peptone, 
2% glucose). Cells were cultured at 30
o
C with rotational shaking at 200 rpm in 
Erlenmeyer flasks at a “flask volume/medium volume” ratio of 5:1. 
 
Collection and storage of yeast cells for lipid extraction 
A 50-ml culture of yeast cells was harvested by centrifugation at 3000 ×x g for 5 min and 
then washed twice with 25 ml of ice-cold water. The cell pellet was resuspended in 1.5 
ml of ice-cold water, and the resulting cell suspension was transferred to Eppendorf tube. 
Cells were harvested by centrifugation at 16, 000 × g for 2 min, the supernatant was 
discarded, and the cell pellet was frozen at -80
o
C until use. For freezing cells quickly, a 
beaker of isopropyl alcohol kept in the -80
o
C freezer was used. 
 
Lipid extraction from yeast cells 
Lipids were extracted using a modification of the protocol described by Bligh and Dyer 
[221]. All manipulations with extracted lipids were performed using glass pipettes or 
syringes because a contact of plastics with chloroform resulted in a large background 
signal. The exact volumes of chloroform and MeOH used for lipid extraction were not 
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critical as long as the ratios of 1:2:0.8 and 2:2:1.8 for chloroform - MeOH - H2O at the 
described below steps 3 and 7 (respectively) of lipid extraction were conserved. 
          Lipid extraction was performed as follows: 
1. Resuspend frozen cells in 1.6 ml of ice-cold distilled H2O. 
2. Transfer 1.6 ml of the cell suspension to high-speed glass centrifuge tubes. 
3. Add 6 ml of chloroform and MeOH (1:2) mix and 0.8 ml of glass beads to the cell 
suspension. 
4. Vortex the cell suspension with glass beads two times for 1 min.  
5. Add 2 ml of chloroform and mix gently. 
6. Incubate for 5 min at room temperature with occasional mixing. 
7. Add 2 ml of distilled H2O and mix gently. 
8. Incubate for 5 min at room temperature with occasional mixing. 
9. Centrifuge for 5 min at 3000 × g at room temperature. 
10. Collect the entire liquid phase into a new high-speed glass centrifuge tube. 
11. Add 3.2 ml of chloroform to the cell pellets from step 9. 
12. Vortex two times for 1 min. 
13. Centrifuge for 5 min at 3000 × g at room temperature. 
14. Add the supernatant to the liquid phase from step 10. 
15. Centrifuge for 5 min at 3000 × g at room temperature. 
16. Discard the upper (aqueous) phase and transfer the lower (organic) phase into a new 
high-speed glass centrifuge tube. 
17. Centrifuge for 5 min at 3000 × g at room temperature. 
18. Transfer the entire supernatant into a glass vial and dry under nitrogen. 
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19. Dissolve the lipid film in 50-200 µl of fresh chloroform, place in a glass vial and store 
at -20ºC for a maximum of two weeks. 
 
Analysis of lipids by ESI/MS 
A stock mix of lipid standards in chloroform was prepared beforehand as per Table 2.1, 
as well as a stock solution of MeOH - chloroform (1:1) with 0.1% (v/v) ammonium 
hydroxide, all in glass vials.  
          The ESI/MS analysis was performed as follows: 
1. Prior to injection, combine 10 µl of a sample with 10 µl of the standard mix of lipids in 
200 µl of MeOH - chloroform (1:1) with 0.1% ammonium hydroxide. The standard to 
sample ratio can be changed as needed. 
2. Resolve lipids using a Micromass Q-TOF 2 mass spectrometer equipped with a nano-
electrospray
 source operating at a flow rate of 1 μl/min. Although we have taken 
advantage of the high resolution of a Q-TOF type of mass spectrometer, it is not a 
mandatory requirement. Exact instrument parameters will vary from instrument to 
instrument. See Table 2.2 for the settings for a Micromass Q-ToF 2 (Waters, Milford, 
MA, USA) equipped with a nano-electrospray
 
source. To analyze PC and TAG, the cone 
voltage was set to 28 v and the capillary voltage to 3.0 kv in positive mode. For the 
analysis of FFA, CL, PE, PS, PA and PI, the cone voltage was set to 30 v and the 
capillary voltage to 3.2 kv in negative mode. In both modes, the collision gas was set to 
10 (arbitrary units). Survey MS data were acquired for up to 3 minutes or until the ion 





Post-processing of MS data  
After acquisition, the mass spectra were smoothed and background subtracted and 
centred using the MassLynx software package (Waters, Milford, MA, USA). The peak 
list was then imported into Microsoft Excel for deconvolution and deisotoping. The list 
was first searched using equation 2.1 to determine the peaks of interest. The resulting 
peak list was then deconvoluted and deisotoped using a lookup table, which represented 
the relative intensities of the isotope peaks (see Table 2.2). The peak list was first 
scanned specifically for CL species and, using the I1 isotope, the contribution of these 
lipid species to isobaric peaks was determined and subtracted. The peak list was then 
scanned for other lipid classes from low to high mass, the peaks deisotoped and the 
contribution to isobaric isotope peaks subtracted. Peak intensities were then normalized 
to the internal standard of the appropriate lipid class. The molecular forms of various 
lipid classes detected following lipid extraction from whole yeast cells are listed in Table 
2.3.   
Table 2.1. Internal lipid standards, their concentrations in the standard mix and the MS mode for their 
analysis. 








Phosphatidic acid 14:0/14:0 591.40 100 Negative 
Phosphatidylethanolamine 14:0/14:0 634.45 200 Negative 
Phosphatidylinositol N/A N/A N/A Negative 
Phosphatidylserine 14:0/14:0 622.37 40 Negative 
Cardiolipin 4x14:0 619.92 100 Negative 
Free fatty acids 19:0 297.28 100 Negative 
Phosphatidylcholine 14:0/14:0 650.48 100 Positive 
Triacylglycerols 13:0/13:0/13:0 698.63 200 Positive 
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 Flow rate Cone voltage Capillary 
voltage 
Collision gas 
Positive mode 1µl/min -28 v 3.0 kv 10 
Negative mode 1µl/min 30 v -32 kv 10 
 
 
Equation 2.1. The following Excel function was used to search the column LookUpVector and return the 




Table 2.3. The molecular forms of various lipid classes detected following lipid extaction from whole yeast 
























































































































































































2.4.1. Survey-scan ESI/MS enables to resolve and unequivocally identify 
all molecular forms of lipid species extracted from whole yeast cells 
           Figure 2.1 shows the typical negative (A) and positive (B) mass spectra of lipid 
species extracted from whole yeast cells and identified using survey-scan ESI/MS; the 
positions of various molecular forms of these lipids are indicated. Confirming previously 
published data [212 - 219], the survey-scan ESI/MS method of lipidomic analysis that I 
developed demonstrated that the yeast S. cerevisiae has a relatively simple lipidome with 
7 major lipid classes, namely PA, PE, PS, PI, CL, PC and TAG (Figure 2.1). 
Furthermore, my survey-scan ESI/MS method of lipidomic analysis revealed that the 
majority of individual molecular forms within each of these different lipid classes have 
chain length of 16 or 18 carbon atoms (Figure 2.1). Moreover, my survey-scan ESI/MS 
lipidomic analysis showed that the fatty acyl moieties of all of lipid species composing 
yeast lipidome are either mono-unsaturated or saturated (Figure 2.1), perhaps due to the 
presence of a single acyl desaturase enzyme in yeast [212 - 215]. In sum, the survey-scan 
ESI/MS method of lipidomic analysis that I developed enables within a very limited 
period of time and using a very low number of yeast cells to resolve and unequivocally 
identify all molecular forms of lipid species composing the lipidome of yeast. Of note,  
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Figure 2.1. The typical negative (A) and positive (B) mass spectra of lipid species extracted from whole 
yeast cells and identified using survey-scan ESI/MS. The positions of various molecular forms of 
phosphatidic acid (PA), phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidylinositol (PI), 
cardiolipin (CL), phosphatidylcholine (PC) and triacylglycerols (TAG) are indicated. 
 
this method allows the unequivocal identification of all molecular forms of yeast lipid 
species despite the following two theoretically possible cases of isobaric peak overlap 
within the S. cerevisiae lipidome: 1) an overlap between PS and PE species - due to the 
fact that the difference in mass between their head groups is equivalent to 3 carbon 
atoms; the observed lack of overlap between yeast species of PS and PE (Figure 2.1) can 
be attributed to the fact that fatty acyl chain moieties with odd numbers of carbon atoms 
are not naturally present in eukaryotes [212 - 215]; and 2) an overlap between doubly 
charged CL species and some species of PA, PE and PS; to by-pass this overlap, the 
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survey-scan ESI/MS method of lipidomic analysis that I developed uses the I1 isotope of 
CL for deconvolution.  
 
2.4.2. The survey-scan ESI/MS method of lipidomic analysis is highly 
sensitive  
To determine the limit of sensitivity for the survey-scan ESI/MS method of lipidomic 
analysis, I used it to determine concentrations of commercially available standard lipids 
within a very wide concentration range. The commercially available standard lipids, each 
belonging to a different major class of yeast lipids, were added to a whole-cell yeast lipid 
extract in known concentrations spreading over 2 to 3 orders of magnitude. For each 
standard lipid, the limit of detection (LOD) was determined as 3 SD (standard deviation) 
of the background and the limit of quantitation (LOQ) as 10 SD of the background (Table 
2.4). I found that the survey-scan ESI/MS method of lipidomic analysis that I developed 
is 1) sensitive to the low µM range (0.6 to 2 µM depending on lipid class) for all lipid 
species tested; and 2) linear to the hundreds of µM range, with the concentration linearity 
spreading over 2 to 3 orders of magnitude; of note, the useful quantitative range for each 
lipid species tested was different (Figures 2.2 and 2.3).   
 
2.4.3. The survey-scan ESI/MS method of lipidomic analysis enables very 
accurate lipid quantitation within a wide range of lipid concentrations  
To determine the accuracy and precision of the survey-scan ESI/MS method of lipidomic 
analysis, the experimentally determined concentrations of the standard lipids (which were 
added to a whole-cell yeast lipid extract as described in section 2.4.2) were plotted 
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against the known concentrations (Figures 2.2 and 2.3). For all lipid species tested, I 
observed 1) linearity through a wide range of the lipid concentrations used; and 2) a very 
good fit to the linear regression curve (R2 > 0.98) and, thus, an excellent precision 
throughout (Figures 2.2 and 2.3). Importantly, the glycerophospholipid species PE, PS, 
PA and PC all displayed similar ionization efficiencies regardless of the head group, with 
a slope of 1 +/- 0.05 (Figures 2.2 and 2.3). In contrast, some (but not all) molecular forms 
of CL and TAG had variable slopes, thereby making the quantitation of these forms a 
challenging task. However, it should be stressed that the experimental to known 
concentrations ratio was constant for all molecular species of CL and TAG, thereby 
enabling the quantitative comparison of their concentrations in different biological 
samples (Figures 2.2 and 2.3). Of note, because appropriate PI standards are not 
commercially available, the quantitative analysis of this lipid class cannot be performed. 
However, I found that the PI species present in whole-cell extracts of yeast lipids 
displayed linearity through a range of the extract dilutions used and, thus, that the relative 
concentrations of these lipid species in different biological samples can be determined 
semi-quantitatively. 
 
2.4.4. Survey-scan ESI/MS enables high-throughput quantitative analysis 
of the lipidome of cultured human microglial cells   
Within a framework of Dr. Titorenko’s ongoing collaboration with Dr. Dusica Maysinger 
in the Department of Pharmacology and Therapeutics at McGill University, I am 
successfully using the survey-scan ESI/MS method of lipidomic analysis that I developed 
to resolve, unequivocally identify and accurately quantitate - within a very limited period 
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of time and using a very low number of cells - the majority of molecular forms of lipid 
species composing the lipidome of cultured human microglial cells. My data on 
characteristic changes in the lipidome of human microglia exposed to various pro-
inflammatory and anti-inflammatory interventions constitute an integral part of: 1) a 
soon-to-be submitted to FASEB Journal manuscript (Khatchadourian, A., Bourque, S.D., 
Richard, V.R., Titorenko, V.I. and Maysinger, D.
*
corresponding author (2011). LPS 
induces lipid droplet accumulation and perilipin-2 expression in microglia. FASEB 
Journal); and 2) an ongoing collaborative project with Dr. Dusica Maysinger’s laboratory 
on opposite and opposing effects that lipopolysaccharide (a pro-inflammatory endotoxin 
produced by gram-negative bacteria) and docosahexaenoic acid (an anti-inflammatory 
omega-3 fatty acid) have in cultured human microglial cells.  
 
2.5. Discussion 
          To solve the inherent limitations of the currently used methods for lipidomic 
analysis (including the limitations characteristic of the ESI/MS-MS-based analysis; see 
section 2.2), I have developed a survey-scan method for quantitative assessment of the 
the entire complement of lipids in yeast cells using ESI/MS. The survey-scan ESI/MS 
method of lipidomic analysis that I developed demonstrated that: 1) yeast has a relatively 
simple lipidome with 7 major lipid classes, namely PA, PE, PS, PI, CL, PC and TAG; 2) 
the majority of individual molecular forms within each of these different lipid classes 
have chain length of 16 or 18 carbon atoms; and 3) the fatty acyl moieties of all of lipid  
 
Table 2.4. The limits of detection (LOD) and quantitation (LOQ) for different lipid classes. The LOD is 3 
SD (standard deviation) of the background signal, whereas the LOQ is 10 SD of the background. N/A, not 
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applicable (because appropriate PI standards are not commercially available, the quantitative analysis of 
this lipid class cannot be performed). 
 
Lipid class LOD (μM) LOQ (μM) 
Phosphatidic acid (PA)  0.2 0.6 
Phosphatidylethanolamine (PE) 0.2 0.6 
Phosphatidylinositol (PI) N/A N/A 
Phosphatidylserine (PS) 0.3 1.1 
Cardiolipin (CL) 0.3 0.9 
Free fatty acids (FFA) 0.6 2.0 
Phosphatidylcholine (PC) 0.4 1.2 
Triacylglycerols (TAG) 0.6 2.0 
 
species composing yeast lipidome are either mono-unsaturated or saturated, perhaps due 
to the presence of a single acyl desaturase enzyme in yeast [212 - 215]. Furthermore, the 
method that I developed is highly sensitive as it is: 1) sensitive to the low µM range (0.6 
to 2 µM depending on lipid class) for all lipid species tested; and 2) linear to the hundreds 
of µM range, with the concentration linearity spreading over 2 to 3 orders of magnitude. 
Moreover, the method that I developed enables very accurate quantitation of different 
lipid species within a wide range of lipid concentrations. Importantly, if compared to the 
currently used ESI/MS-MS-based method of lipidomic analysis [213 - 220], my method 
has the following important advantages: 1) unlike the ESI/MS-MS-based method, it can 





Figure 2.2. Calibration curves for PA, PC, PE and PS. Peak areas of individual lipid spikes were 
normalized to an internal standard of the same lipid class (see Table 2.1). For a 36:2 species of PA spike, 
slope = 0.92 and R2 = 1.00. For a 30:0 species of PC spike, slope = 1.04 and R2 = 1.00. For a 34:0 species 
of PE, slope = 1.03 and R2 = 1.00. For a 32:0 species of PS spike, slope = 1.00 and R2 = 1.00. 
Experimentally determined concentrations (in µM) are on the ordinate axis and known concentrations (in 




Figure 2.3. Calibration curves for CL, FFA and TAG. Peak areas of individual lipid spikes were 
normalized to an internal standard of the same lipid class (see Table 2.1). For a 72:4 species of CL spike, 
slope = 1.70 and R2 = 1.00. For an 18:1 species of FFA spike (dashed line), slope = 0.72 and R2 = 1.00; for 
a 16:1 species of FFA spike (solid line), slope = 0.56, R2= 1.00. For a 36:0 species of TAG spike (dashed 
line), slope = 1.23 and R2 = 1.00. For a 42:0 species of TAG spike (solid line), slope = 0.26 and R2 = 1.0. 
Experimentally determined concentrations (in µM) are on the ordinate axis and known concentrations (in 
µM) on the abscissa. Error bars represent standard deviations. 
 
method, it does not require to maintain stable spray conditions at the ESI source for long 
periods of time; 3) unlike the ESI/MS-MS-based method, it does not have a bias towards 
certain lipid species, thereby being sufficiently sensitive to unexpected changes in lipid 
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spectra of analyzed cells; 4) it is more sensitive than the ESI/MS-MS-based method and, 
thus, does not require abundant quantities of cells for lipid extraction and analysis; and 5) 
it has lower than the ESI/MS-MS-based method limits of detection and quantitation for 
all yeast lipid species. 
 
2.6. Conclusions 
          My findings support the notion that the survey-scan ESI/MS method of lipidomic 
analysis that I developed enables within a very limited period of time and using a very 
low number of cells to resolve, unequivocally identify and accurately quantitate all 
molecular forms of lipid species composing yeast lipidome and the majority of molecular 
forms of lipid species composing the lipidome of cultured human microglial cells.   
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3. A mechanism underlying the ability of caloric restriction to extend yeast 
longevity by remodeling lipid metabolism  
3.1. Abstract 
          Growing evidence supports the view that the deposition and lipolytic degradation 
of neutral lipids play an important role in longevity regulation across phyla [18, 138 - 
141, 153, 177, 182 - 192, 222, 223]. In yeast, longevity can be extended by caloric 
restriction (CR), a low-calorie dietary regimen that extends life span in a wide spectrum 
of organisms and delays the onset or reduces the incidence of many age-related diseases 
in rodents and primates [65 - 72, 131, 134 - 136]. A CR diet can be imposed in yeast by 
reducing the glucose concentration from 2% to 0.5% [8]. The molecular and cellular 
mechanisms linking longevity-defining changes in lipid metabolism and longevity-
extending effect of CR are yet to be characterized. The establishment of such 
mechanisms operating in chronologically aging yeast was the objective of my 
experiments described in this Chapter.  
          I first elucidated the effect of CR on the metabolic history of chronologically aging 
yeast. My comparison of the metabolic histories of long-lived CR yeast and short-lived 
non-CR yeast suggests that, by designing a diet-specific pattern of lipid metabolism in the 
endoplasmic reticulum (ER), lipid bodies (LBs) and peroxisomes prior to entry into a 
non-proliferative state, yeast define their long-term viability. I therefore proposed that 
longevity in chronologically aging yeast is programmed by the level of metabolic 
capacity and organelle organization they developed, in a diet-specific fashion, prior to 
reproductive maturation.  
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          Using a combination of functional genetic, cell biological, electron and 
fluorescence microscopical, proteomic, lipidomic, and metabolomic experimental 
approaches, I deciphered the molecular mechanism underlying the essential role of lipid 
metabolism in modulating programmed by calorie availability chronological aging in 
yeast. In this mechanism, LBs in yeast cells function as a hub in a regulatory network that 
modulates neutral lipids synthesis in the ER and fatty acid oxidation in peroxisomes. 
Ethanol accumulated in yeast placed on a calorie-rich diet represses the synthesis of 
Fox1p, Fox2p and Fox3p, thereby suppressing peroxisomal oxidation of FFA that 
originate from triacylglycerols (TAG) synthesized in the ER and deposited within LBs. 
The resulting build-up of arrays of free fatty acids (gnarls) within LBs of non-CR yeast 
initiates several negative feedback loops regulating the metabolism of TAG. Due to the 
action of these negative feedback loops, chronologically aging non-CR yeast not only 
amass TAG in LBs but also accumulate FFA and diacylglycerol (DAG) in the ER. FFA 
and DAG regulate longevity by two different mechanisms that operate at two different 
stages of the aging process. One mechanism involves sensing the concentration of DAG 
maintained by cells (in a diet- and genotype-dependent fashion) during diauxic (D) and 
post-diauxic (PD) growth phases. DAG concentration during D and PD phases programs 
cell viability during stationary (ST) growth phase by modulating the FFA- and DAG-
induced necrotic cell death pathway, but not by influencing the mitochondria-controlled 
apoptotic pathway of cell death. Another mechanism involves sensing the concentrations 
of FFA and DAG during ST phase. Any diet or genetic manipulation that causes the 
build-up of these two lipids during ST phase shortens the chronological life span of yeast 
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in part by promoting rapid mitochondria-controlled apoptotic cell death, but not by 
activating FFA- and DAG-induced necrotic cell death pathway. 
3.2. Introduction 
          Aging is a highly complex biological phenomenon, which affects numerous 
processes within cells [1 - 10]. These cellular processes include cell cycle, cell growth, 
stress response, protein folding, apoptosis, autophagy, proteasomal protein degradation, 
actin organization, signal transduction, nuclear DNA replication, chromatin assembly and 
maintenance, ribosome biogenesis and translation, lipid and carbohydrate metabolism, 
oxidative metabolism in mitochondria, NAD
+
 homeostasis, amino acid biosynthesis and 
degradation, and ammonium and amino acid uptake [2-4, 7, 22 - 25]. Some of these 
processes damage cellular macromolecules and organelles, while the others prevent the 
collapse of cellular homeostasis by repairing the damage [1, 3 - 5]. A lifelong 
accumulation of unrepaired cellular damage increases a risk of disease and death [1, 4, 6, 
11]. A challenge is to understand how the spatiotemporal organization of damage-
producing and damage-repairing processes influences longevity and how cells integrate 
and control these processes. The most important unanswered question is whether aging is 
the final step of a developmental program governed by a certain signaling network [12 - 
18] or merely a result of the lifelong accumulation of unrepaired cellular and molecular 
damage [1, 5, 19]. To identify the cellular processes that play a critical role in longevity 
regulation and to rank their relative contributions to aging, the concepts and 
methodologies of so-called metabolic control analysis (MCA) can be useful [224 - 225]. 
It has been envisioned that the application of these concepts and methodologies to the 
analysis of empirical data on the cell metabolic histories of model organisms will enable 
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to 1) infer the relative contributions of various cellular processes to aging; and 2) define 
how interventions such as dietary restriction delay aging by modulating these processes 
[224 - 225]. 
          The budding yeast Saccharomyces cerevisiae, a genetically and biochemically 
manipulable unicellular eukaryote with annotated genome, is a valuable model for 
unveiling mechanisms of cellular aging in multicellular eukaryotes [130 - 132]. Yeast 
aging can be measured in two different ways. Replicative aging is defined by the 
maximum number of daughter cells that a mother cell can produce before senescence and 
models aging of a mitotically active cell in a multicellular organism [131, 133]. In 
contrast, chronological aging is measured by the length of time a yeast cell remains 
viable in a nondividing state and models aging of postmitotic mammalian cells (e.g., 
neurons) [56, 131, 132]. In a simple clonogenic assay for measuring yeast chronological 
aging, the percentage of viable yeast cells in their aging population is monitored at 
different time points before and after this population enters the non-proliferative 
stationary phase [56]. Both replicative and chronological aging of yeast can be 
decelerated by CR, a low-calorie dietary regimen that extends life span in various 
multicellular eukaryotic organisms and delays the onset or reduces the incidence of many 
age-related diseases in mice and primates [66 - 69, 131, 134 - 136]. 
          In studies described in this chapter, I made a first step towards the use of MCA for 
defining the molecular causes of cellular aging by elucidating the effect of CR on the 
metabolic history of chronologically aging yeast. My comparison of the metabolic 
histories of long-lived CR yeast and short-lived non-CR yeast led me to the conclusion 
that longevity in chronologically aging yeast is programmed by the level of metabolic 
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capacity and organelle organization they developed, in a diet-specific fashion, prior to 
reproductive maturation. I found that the developmental program of chronological aging 
in yeast is governed, in part, by a specific pattern of lipid metabolism in the ER, LBs and 
peroxisomes that yeast design in a diet-dependent fashion prior to entry into a non-
proliferative state. I therefore focused my study on establishing the molecular mechanism 
underlying the essential role of lipid metabolism in modulating programmed by calorie 
availability chronological aging in yeast.   
 
3.3. Materials and Methods 
Strains and media  
The wild-type strain Saccharomyces cerevisiae BY4742 (MAT his31 leu20 lys20 
ura30) and mutant strains pex1 (MAT his31 leu20 lys20 ura30 
pex1::kanMX4), pex5 (MAT his31 leu20 lys20 ura30 pex5::kanMX4), pex6 
(MAT his31 leu20 lys20 ura30 pex6::kanMX4), pex7 (MAT his31 leu20 
lys20 ura30 pex7::kanMX4), fox1 (MAT his31 leu20 lys20 ura30 
fox1::kanMX4), cta1 (MAT his31 leu20 lys20 ura30 cta1::kanMX4), fox2 
(MAT his31 leu20 lys20 ura30 fox2::kanMX4), fox3 (MAT his31 leu20 
lys20 ura30 fox3::kanMX4), adh1 (MAT his31 leu20 lys20 ura30 
adh1::kanMX4), adh2 (MAT his31 leu20 lys20 ura30 adh2::kanMX4), gpt2 
(MAT his31 leu20 lys20 ura30 gpt2::kanMX4), sct1 (MAT his31 leu20 
lys20 ura30 sct1::kanMX4), ayr1 (MAT his31 leu20 lys20 ura30 
ayr1::kanMX4), slc1 (MAT his31 leu20 lys20 ura30 slc1::kanMX4), lpp1 
(MAT his31 leu20 lys20 ura30 lpp1::kanMX4), dpp1 (MAT his31 leu20 
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lys20 ura30 mdh3::kanMX4), fox3 (MAT his31 leu20 lys20 ura30 
dpp1::kanMX4) 
 
dga1 (MAT his31 leu20 lys20 ura30 dga1::kanMX4), are1 (MAT his31 
leu20 lys20 ura30 are1::kanMX4), are2 (MAT his31 leu20 lys20 ura30 
are2::kanMX4), lro1 (MAT his31 leu20 lys20 ura30 lro1::kanMX4), tgl1 
(MAT his31 leu20 lys20 ura30 tgl1::kanMX4), tgl2 (MAT his31 leu20 
lys20 ura30 tgl2::kanMX4), tgl3 (MAT his31 leu20 lys20 ura30 
rgl3::kanMX4), tgl4 (MAT his31 leu20 lys20 ura30 tgl4::kanMX4), and 
tgl5 (MAT his31 leu20 lys20 ura30 tgl5::kanMX4) were used in this study. 
Media components were as
 
follows: 1) YEPD (0.2% Glucose), 1% yeast extract, 2% 
peptone, 0.2% glucose; and 2) YEPD (2% Glucose), 1% yeast extract, 2% peptone, 2% 
glucose.  
 
A plating assay for the analysis of chronological life span 
Cells were grown in YEPD (0.2% Glucose) medium at 30
o
C with rotational shaking at 
200 rpm in Erlenmeyer flasks at a flask volume/medium volume ratio of 5:1. A sample of 
cells was removed from each culture at various time points. A fraction of the cell sample 
was diluted in order to determine the total number of cells per ml of culture using a 
hemacytometer. 10 l of serial dilutions (1:10 to 1:103) of cells were applied to the 
hemacytometer, where each large square is calibrated to hold 0.1 l. The number of cells 
in 4 large squares was then counted and an average was taken in order to ensure greater 
accuracy. The concentration of cells was calculated as follows: number of cells per large 
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square x dilution factor × 10 × 1,000 = total number of cells per ml of culture. A second 




) of cells were 
plated onto YEPD (2% Glucose) plates in triplicate in order to count the number of viable 
cells per ml of each culture. 100 l of diluted culture was plated onto each plate. After a 
48-h incubation at 30
o
C, the number of colonies per plate was counted. The number of 
colony forming units (CFU) equals to the number of viable cells in a sample. Therefore, 
the number of viable cells was calculated as follows: number of colonies × dilution factor 
× 10 = number of viable cells per ml. For each culture assayed, % viability of the cells 
was calculated as follows: number of viable cells per ml / total number of cells per ml × 
100%. The % viability of cells in mid-logarithmic phase was set at 100% viability for that 
particular culture.  
 
Plating assays for the analysis of resistance to various stresses 





type and mutant cells removed from mid-logarithmic phase (day 1) and from diauxic 
phase (days 2 and 3) in YEPD (0.2% Glucose) were spotted onto two sets of plates. One 
set of plates contained YEPD (2% Glucose) medium alone, whereas the other set 
contained YEPD (2% Glucose) medium supplemented with 5 mM hydrogen peroxide. 
Pictures were taken after a 3-day incubation at 30
o
C.   





wild-type and mutant cells removed from mid-logarithmic phase (day 1) and from 
diauxic phase (days 2 and 3) in YEPD (0.2% Glucose) were spotted onto two sets of 
plates. One set of plates contained YEPD (2% Glucose) medium alone, whereas the other 
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set contained YEPD (2% Glucose) medium supplemented with 2.5 mM of the 
superoxide/hydrogen peroxide-generating agent paraquat. Pictures were taken after a 3-
day incubation at 30
o
C.  





type and mutant cells removed from mid-logarithmic phase (day 1) and from diauxic 
phase (days 2 and 3) in YEPD (0.2% Glucose) were spotted onto two sets of YEPD (2% 
Glucose) plates. One set of plates was incubated at 30oC. The other set of plates was 
initially incubated at 55
o
C for 30 min, and was then transferred to 30
o
C. Pictures were 
taken after a 3-day incubation at 30
o
C.  





type and mutant cells removed from mid-logarithmic phase (day 1) and from diauxic 
phase (days 2 and 3) in YEPD (0.2% Glucose) were spotted onto two sets of plates. One 
set of plates contained YEPD (2% Glucose) medium alone, whereas the other set 
contained YEPD (2% Glucose) medium supplemented with 0.5 M NaCl. Pictures were 
taken after a 3-day incubation at 30
o
C.  





wild-type and mutant cells removed from mid-logarithmic phase (day 1) and from 
diauxic phase (days 2 and 3) in YEPD (0.2% Glucose) were spotted onto two sets of 
plates. One set of plates contained YEPD (2% Glucose) medium alone, whereas the other 
set contained YEPD (2% Glucose) medium supplemented with 1 M sorbitol. Pictures 




Monitoring the formation of ROS  
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Wild-type and mutant cells grown in YEPD (0.2% Glucose) were tested microscopically 
for the production of ROS by incubation with dihydrorhodamine 123 (DHR). In the cell, 
this nonfluorescent compound can be oxidized to the fluorescent chromophore rhodamine 
123 by ROS. Cells were also probed with a fluorescent counterstain Calcofluor White 
M2R (CW), which stains the yeast cell walls fluorescent blue. CW was added to each 
sample in order to label all cells for their proper visualization. DHR was stored in the 
dark at –20oC as 50 l aliquots of a 1 mg/ml solution in ethanol. CW was stored in the 
dark at –20oC as the 5 mM stock solution in anhydrous DMSO (dimethylsulfoxide). 
          The concurrent staining of cells with DHR and CW was carried out as follows. The 
required amounts of the 50 l DHR aliquots (1 mg/ml) and of the 5 mM stock solution of 
CW were taken out of the freezer and warmed to room temperature. The solutions of 
DHR and CW were then centrifuged at 21,000 × g for 5 min in order to clear them of any 
aggregates of fluorophores. For cell cultures with a titre of ~ 10
7
 cells/ml, 100 l was 
taken out of the culture to be treated. If the cell titre was lower, proportionally larger 
volumes were used. 6 l of the 1 mg/ml DHR and 1 l of the 5 mM CW solutions were 
added to each 100 l aliquot of culture. After a 2-h incubation in the dark at room 
temperature, the samples were centrifuged at 21,000 × g for 5 min. Pellets were 
resuspended in 10 l of PBS buffer (20 mM KH2PO4/KOH, pH 7.5, and 150 mM NaCl). 
Each sample was then supplemented with 5 l of mounting medium, added to a 
microscope slide, covered with a coverslip, and sealed using nail polish. Once the slides 
were prepared, they were visualized under the Zeiss Axioplan fluorescence microscope 
mounted with a SPOT Insight 2 megapixel color mosaic digital camera. Several pictures 
of the cells on each slide were taken, with two pictures taken of each frame. One of the 
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two pictures was of the cells seen through a rhodamine filter in order to detect cells dyed 
with DHR. The second picture was of the cells seen through a DAPI filter in order to 
visualize CW, and therefore all the cells present in the frame. 
          For evaluating the percentage of DHR-positive cells, the UTHSCSA Image Tool 
(Version 3.0) software was used to calculate both the total number of cells and the 
number of stained cells. Fluorescence of individual DHR-positive cells in arbitrary units 
was determined by using the UTHSCSA Image Tool software (Version 3.0). In each of 3-
5 independent experiments, the value of median fluorescence was calculated by analyzing 
at least 800-1000 cells that were collected at each time point. The median fluorescence 
values were plotted as a function of the number of days cells were cultured. 
 
Visualization of intracellular lipid bodies (LBs) 
Wild-type and mutant cells grown in YEPD (0.2% Glucose) were tested microscopically 
for the presence of intracellular LBs by incubation with BODIPY 493/503. Cells were 
also probed with a fluorescent counterstain CW in order to visualize all cells in the 
population. BODIPY 493/503 was stored in the dark at –20oC as 100 l aliquots of a 1 
mM solution in ethanol. CW was stored in the dark at –20oC as the 5 mM stock solution 
in anhydrous DMSO. 
          The concurrent staining of cells with BODIPY 493/503 and CW was carried out as 
follows. The required amounts of the 100 l BODIPY 493/503 aliquots (1 mM) and of 
the 5 mM stock solution of CW were taken out of the freezer and warmed to room 
temperature. The solutions of DHR and CW were then centrifuged at 21,000 × g for 5 




 cells/ml, 100 l was taken out of the culture to be treated. If the cell titre was 
lower, proportionally larger volumes were used. The samples were then centrifuged at 
21,000 × g for 1 min, and pelleted cells were resuspended in 100 l of TNT buffer (25 
mM Tris/HCl (pH 7.5), 150 mM NaCl and 0.2 % Triton X-100). After a 10-min 
incubation at room temperature, the samples were centrifuged at 21,000 × g for 1 min. 
Pellets were then resuspended in 100 l of TN buffer (25 mM Tris/HCl (pH 7.5), 150 
mM NaCl), and the samples were subjected to centrifugation at 21,000 × g for 1 min. 
Pelleted cells were finally resuspended in 100 l of TN buffer. Each 100 l aliquot of 
cells was then supplemented with 1 μl of the 1 mM BODIPY 493/503 and 1 l of the 5 
mM CW solutions. After a 15-min incubation in the dark at room temperature, the 
samples were centrifuged at 21,000 × g for 5 min. Pellets were resuspended in 100 l of 
TN buffer. The samples were centrifuged again at 21,000 × g for 5 min, and pellets were 
resuspended in 100 l of TN buffer. 10 l of the BODIPY 493/503- and CW-treated cell 
suspension was then added to a microscope slide and covered with a coverslip. The slides 
were then sealed using nail polish. Once the slides were prepared, they were visualized 
under the Zeiss Axioplan fluorescence microscope mounted with a SPOT Insight 2 
megapixel color mosaic digital camera.  Several pictures of the cells on each slide were 
taken, with two pictures taken of each frame. One of the two pictures was of the cells 
seen through a fluorescein filter in order to detect cells dyed with BODIPY 493/503. The 
second picture was of the cells seen through a DAPI filter in order to visualize CW, and 
therefore all the cells present in the frame. For evaluating the percentage of BODIPY 
493/503-positive cells, the UTHSCSA Image Tool (Version 3.0) software was used to 
calculate both the total number of cells and the number of stained cells. 
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Immunofluorescence microscopy 
Cell cultures were fixed in 3.7% formaldehyde for 45 min at room temperature. The cells 
were washed in solution B (100 mM KH2PO4/KOH pH 7.5, 1.2 M sorbitol), treated with 
Zymolyase 100T (MP Biomedicals, 1 μg Zymolyase 100T/1 mg cells) for 30 min at 30oC 
and then processed as previously described [66]. Monoclonal antibody raised against 
porin (Invitrogen, 0.25 μg/μl in TBSB buffer [20 mM Tris/HCl pH 7.5, 150 mM NaCl, 
1mg/ml BSA]) was used as a primary antibody. Alexa Fluor 568 goat anti-mouse IgG 
(Invitrogen, 2 μg/μl in TBSB buffer) was used as a secondary antibody. The labeled 
samples were mounted in mounting solution (16.7 mM Tris/HCl pH 9.0, 1.7 mg/ml p-
phenylenediamine, 83% glycerol). Images were collected with a Zeiss Axioplan 
fluorescence microscope (Zeiss) mounted with a SPOT Insight 2 megapixel color mosaic 
digital camera (Spot Diagnostic Instruments). 
  
Oxygen consumption assay 
The rate of oxygen consumption by yeast cells recovered at various time points was 
measured continuously in a 2-ml stirred chamber using a custom-designed biological 
oxygen monitor (Science Technical Center of Concordia University) equipped with a 
Clark-type oxygen electrode. 1 ml of YEPD medium supplemented with 0.2% glucose 
was added to the electrode for approximately 5 minutes to obtain a baseline. Cultured 
cells of a known titre were spun down at 3,000 × g for 5 minutes. The resulting pellet was 
resuspended in YEPD medium supplemented with 0.2% glucose and then added to the 
electrode with the medium that was used to obtain a baseline. The resulting slope was 




 cells.  
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Electron microscopy and morphometric analysis 
Cells were fixed in 1.5% KMnO4 for 20 min at room temperature, dehydrated by 
successive incubations in increasing concentrations of ethanol, and embedded in 
Poly/Bed 812 epoxy resin (Polysciences). Ultrathin sections were cut using an Ultra-Cut 
E Microtome (Reichert-Jung). Silver/gold thin sections from the embedded blocks were 
examined in a JEOL JEM-2000FX transmission electron microscope. For morphometric 
analysis of random electron microscopic sections of cells, digitized images were analyzed 
using the UTHSCSA Image Tool (Version 3.0) software. In each of 2 independent 
experiments, the percentage of cells that contain pexopodia and/or accumulate gnarled 
LBs was calculated by analyzing at least 300 cells that were collected at each time point. 
The values of the percentage of cells containing pexopodia and/or accumulating gnarled 
LBs were plotted as a function of the number of days cells were cultured. 
 
Preparation of total cell lysates 
An aliquot containing 1 × 10
9 
cells was centrifuged for 7 min at 3,000 rpm at room 
temperature. Pelleted cells were washed twice with distilled water and further centrifuged 
for 3 min at 16,000 × g at room temperature. The recovered cell pellet was then 
resuspended in 500 μl of 4% CHAPS in 25 mM Tris/HCl buffer (pH 8.5) and centrifuged 
for 15 sec at 16,000 × g at room temperature. The cells were then washed again, first by 
resuspending them in 500 μl of 4% CHAPS in 25 mM Tris/HCl buffer (pH 8.5) and then 
by centrifuging for 15 sec at 16,000 × g at room temperature. The pellet of washed cells 
was then resuspended in 1 ml of ice-cold 4% CHAPS in 25 mM Tris/HCl buffer (pH 8.5), 
divided into 5 equal aliquots of 200 μl each and placed in Eppendorf tubes kept on ice. 
 69 
Each 200 μl aliquot was supplemented with ~100 μl of glass beads and vortexed three 
times for 1 minute. Apart from the vortexing steps, the samples were kept on ice at all 
times. Glass beads and cell debris were then pelleted by 5 min centrifugation at 16,000 × 
g at 4
o
C.  The resulting supernatant of the glass bead lysate was immediately transferred 
into a pre-chilled Eppendorf tube and stored at -20
o
C for further analysis. 
 
Isolation of the crude mitochondrial fraction 
Yeast cells were pelleted at 3,000 × g for 5 min at room temperature, washed twice with 
distilled water, resuspended in DTT buffer (100 mM Tris-H2SO4, pH 9.4, 10 mM 
dithiothreitol [DTT]), and incubated for 20 min at 30
o
C to weaken the cell wall. The cells 
were then washed with Zymolyase buffer (1.2 M sorbitol, 20 mM potassium phosphate, 
pH 7.4), centrifuged at 3,000 × g for 5 min at room temperature, and incubated with 3 
mg/g (wet wt) of Zymolyase-100T in 7 ml/g (wet wt) Zymolyase buffer for 45 min at 
30°C.  Following an 8-min centrifugation at 2,200 × g at 4
o
C, the isolated spheroplasts 
were washed in ice-cold homogenization buffer (5 ml/g) (0.6 M sorbitol, 10 mM Tris-
HCl, pH7.4, 1 mM EDTA, 0.2% (w/v) BSA) and then centrifuged at 2,200 × g for 8 min 
at 4
o
C. Washed spheroplasts were homogenized in ice-cold homogenization buffer using 
15 strokes. The cell debris was removed by centrifuging the resulting homogenates at 
1,500 × g for 5 min at 4°C. The supernatant was further centrifuged at 3,000 × g for 5 
min at 4°C to remove residual cell debris. The resulting supernatant was then centrifuged 
at 12,000 × g for 15 min at 4°C to pellet mitochondria. The remnant cell debris was 
removed by centrifuging the mitochondrial fraction at 3,000 × g for 5 min at 4°C. The 
resulting supernatant was then centrifuged at 12,000 × g for 15 min at 4°C to obtain the 
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crude mitochondrial pellet, which was then resuspended in 3 ml of SEM Buffer (250 mM 
sucrose, 1 mM EDTA, 10 mM MOPS, pH 7.2) and used for the purification of 
mitochondria as described below. 
 
Purification of mitochondria devoid of microsomal and cytosolic contaminations 
A sucrose gradient was made by carefully overlaying 1.5 ml of 60% sucrose with 4 ml of 
32% sucrose, 1.5 ml of 23% sucrose, and then 1.5 ml of 15% sucrose (all in EM buffer; 1 
mM EDTA, 10 mM MOPS, pH 7.2). Finally, a 3-ml aliquot of the crude mitochondrial 
fraction in SEM buffer was applied to the gradient and centrifuged at 134,000 × g 
(33,000 rpm) overnight at 2°C in vacuum (Rotor SW50Ti, Beckman). The purified 
mitochondria found at the 60%/32% sucrose interface were carefully removed and stored 
at - 80°C. 
 
Purification of the ER 
Reagents and solutions 
1. TSD reduction buffer: 0.1 M Tris/Sulfate (pH 9.4), 10 mM DTT 
2. HEPES lysis buffer: 20 mM HEPES/KOH, pH 6.8, 50 mM KCl, 200 mM sorbitol, 2 
mM EDTA, 1 mM DTT 
3. Spheroplast medium A (pH 7.5): 0.67% yeast nitrogen base (w/o) amino acids, 2 % 
(w/v) glucose, 1 M sorbitol, 20 mM Tris/HCl (pH 7.5) 
4. Spheroplast medium B: 0.67% yeast nitrogen base (w/o) amino acids, 2 % (w/v) 
glucose, 1 M sorbitol 
5. 1.2 M sucrose/ HEPES, 36% (w/w): 7.2 g sucrose + 12.8 ml HEPES lysis buffer 
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6. 1.5 M sucrose/ HEPES, 43% (w/w): 8.6 g sucrose + 11.4 ml HEPES lysis buffer 
7. MES buffer 1 (MES breaking buffer): 10 mM MES/Tris (pH 6.9), 12 % (w/w) Ficoll 
400, 0.2 mM EDTA 
8. MES buffer 2: 10 mM MES/Tris (pH 6.9), 8 % (w/w) Ficoll 400, 0.2 mM EDTA 
9. MES buffer 3: 10 mM MES/Tris (pH 6.9), 0.6 M sorbitol, 8 % (w/w) Ficoll 400, 0.2 
mM EDTA 
10. MES buffer 4: 10 mM MES/Tris (pH 6.9), 0.25 M sorbitol, 0.2 mM EDTA 
11. KPi buffer (pH 7.4): 20 mM KH2PO4/KOH (pH 7.4), 1.2 M sorbitol 
 
Procedure 
Wild-type and mutant cells were grown in YEPD (0.2% glucose) medium. Cultures were 
harvested at mid-exponential and diauxic phases, checked for contamination by bright-
field microscopy and used to measure cell density at OD600. The non-contaminated wild-
type and mutant cells were pelleted at 4,000 × g for 5 min at room temperature. Cells 
were then resuspended at 10 OD600 units/ml in TSD reduction buffer, incubated for 10 
min at room temperature and centrifuged for 5 min at 4,000 × g at room temperature. 
Pelleted cells were then resuspended at 20 OD600 units/ml in Spheroplast medium A and 
supplemented with Zymolyase 100T at a concentration of 7.5 μg per OD600 units of cells. 
10 μl of each cell suspension was then removed, diluted in 990 μl of H2O and used to 
measure the OD600. The remaining cell suspensions were incubated at 30°C for 30 min 
and the efficiency of cell wall removal was monitored by measuring the OD600. Cell wall 
digestion was allowed to proceed until the OD600 measurement of the diluted cell 
suspension became 5% of the original value, with the total digestion time not exceeding 1 
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hour. Spheroplasts were then harvested by centrifugation at 1,500 × g for 5 min at room 
temperature, followed by resuspending at 1 to 5 OD600 units/ml in Spheroplast medium B 
by gentle swirling of the tube or gentle stirring with a glass rod. Spheroplasts were then 
harvested by centrifugation at 1,500 × g for 5 min at 4°C and then resuspended at a 
concentration of 1,000 OD600 units/ml of ice-cold HEPES lysis buffer with freshly-added 
DTT. Spheroplasts were then homogenized using 20 strokes and resulting lysates were 
centrifuged at 1, 000 × g for 10 min at 4°C. The supernatants (S1000) were subjected to 
another round of centrifugation at 1, 000 × g for 10 min at 4°C, and resulting 
supernatants were further centrifuged at 27,000 × g for 10 min at 4°C. The pelleted 
membranes (P27,000) were resuspended in 1.0 ml of HEPES lysis buffer (5,000 OD600 
equivalents per ml) using a trimmed 1-ml pipette tip and carefully layered on top of a 
sucrose gradient prepared in advance (2.1 ml of 1.5 M sucrose/HEPES solution was 
deposited to the bottom of a Beckman Ultra-Clear centrifuge tube for the Beckman MLS-
50 rotor, and then overlaid with 2.1 ml of 1.2 M sucrose/HEPES solution). The gradient 
tubes were then placed in the pre-chilled swinging bucket Beckman MLS-50 rotor and 
centrifuged at 100,000 × g (36,000 rpm) for 1 hr at 4°C using the slow acceleration and 
deceleration setting to minimize disruption of gradients. 18 gradient fractions of 227 μl 
each were then collected starting from the top of the sucrose gradient and stored at -20°C 
for further analyses.  
 
Purification of LBs 
Reagents and solutions 
1. TSD reduction buffer: 0.1 M Tris/Sulfate (pH 9.4), 10 mM DTT 
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2. HEPES lysis buffer: 20 mM HEPES/KOH, pH 6.8, 50 mM KCl, 200 mM sorbitol, 2 
mM EDTA, 1 mM DTT 
3. Spheroplast medium A (pH 7.5): 0.67% yeast nitrogen base (w/o) amino acids, 2 % 
(w/v) glucose, 1 M sorbitol, 20 mM Tris/HCl (pH 7.5) 
4. Spheroplast medium B: 0.67% yeast nitrogen base (w/o) amino acids, 2 % (w/v) 
glucose, 1 M sorbitol 
5. 1.2 M sucrose/ HEPES, 36% (w/w): 7.2 g sucrose + 12.8 ml HEPES lysis buffer 
6. 1.5 M sucrose/ HEPES, 43% (w/w): 8.6 g sucrose + 11.4 ml HEPES lysis buffer 
7. MES buffer 1 (MES breaking buffer): 10 mM MES/Tris (pH 6.9), 12 % (w/w) Ficoll 
400, 0.2 mM EDTA 
8. MES buffer 2: 10 mM MES/Tris (pH 6.9), 8 % (w/w) Ficoll 400, 0.2 mM EDTA 
9. MES buffer 3: 10 mM MES/Tris (pH 6.9), 0.6 M sorbitol, 8 % (w/w) Ficoll 400, 0.2 
mM EDTA 
10. MES buffer 4: 10 mM MES/Tris (pH 6.9), 0.25 M sorbitol, 0.2 mM EDTA 
11. KPi buffer (pH 7.4): 20 mM KH2PO4/KOH (pH 7.4), 1.2 M sorbitol 
 
Procedure 
Wild-type and mutant cells were grown in YEPD (0.2% glucose) medium. Cultures were 
harvested at mid-exponential and diauxic phases, checked for contamination by bright-
field microscopy and used to measure cell density at OD600. The non-contaminated wild-
type and mutant cells were pelleted at 4,000 × g for 5 min at room temperature. The cells 
were then washed once with distilled water and resuspended in the TSD reduction buffer 
at 10 x OD600 units/ml. Following a 10-min incubation at room temperature, the cells 
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were pelleted by centrifugation at 4,000 × g for 5min at room temperature and then 
washed once in Spheroplasts medium A. The cells were then resuspended in Spheroplasts 
medium A at 20 × OD600 units/ml, supplemented with Zymolyase 100T at a concentration 
of 2.5 μg per OD600 units of cells, and incubated at 30°C for 45 min on a shaker set at 75 
rpm. Spheroplasts were then pelleted by 5min centrifugation at 1,500 × g at room 
temperature, resuspended in the ice-cold Spheroplasts medium B at 5 × OD600 units/ml 
using pipettes with cut tips, and centrifuged for 5 min at 1,500 × g at 4
o
C. Spheroplasts 
were then washed twice by resuspending the pellets in ice-cold KPi buffer at a 
concentration of 5 OD600 units/ml followed by centrifugation for 5 min at 1,500 × g at 
4
o
C. After the second wash and centrifugation step, clean spheroplasts were resuspended 
in ice-cold MES Buffer 1 at a concentration of 1,000 OD600 units/ml using pipettes with 
non-cut tips. Spheroplasts were then lysed in a homogenizer using 20 strokes at 4°C. 
Lysates were centrifuged for 5 min at 5,000 × g at 4°C and the resulting supernatants 
(S5,000) were transferred to pre-chilled centrifuge tubes kept on ice. LBs were then 
purified by subjecting the spheroplast lysates to a series of flotation gradient 
centrifugations using a MLS 50 swinging bucket rotor (Beckman). The first flotation 
gradient was prepared by placing 2.5 ml of the S5,000 fraction to the bottom of a centrifuge 
tube (Ultra-Clear Beckman tubes for MLS 50 rotor) and overlaying it with 2.5 ml of ice-
cold MES Buffer 1. Following 1 hour centrifugation at 100,000 × g (36,000 rpm) at 4°C,  
the floating layer from the top portions of the gradients was collected with a cut tip and 
transferred to the bottom of a new centrifuge tube, which was then supplemented with 
MES buffer 2 to a total volume of 2.5 ml and gently mixed by pipetting. Resulting 
suspension was overlaid with 2.5 ml of ice-cold MES buffer 2 and then centrifuged for 1 
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hr at 100,000 × g (36,000 rpm) at 4°C. The floating layer from the top portions of the 
gradients was again collected with a cut tip and transferred to the bottom of a new 
centrifuge tube, which was then supplemented with MES buffer 3 to a total volume of 2.5 
ml and gently mixed by pipetting. Resulting suspension was overlaid with 2.5 ml of ice-
cold MES buffer 4 and then centrifuged for 1 hr at 100,000 × g (36,000 rpm) at 4°C. The 
floating layer from the top portions of the gradients was collected with a cut tip and 
purified lipid bodies were stored -20°C for further analyses.  
 
Protein precipitation, SDS-PAGE and silver staining of gels 
Protein concentration was determined using the RC DC protein assay kit (Bio-Rad) 
according to the manufacturer's instructions. Proteins were precipitated by adding 
trichloroacetic acid (TCA) to the final concentration of 10%, incubated on ice for 30 min, 
pelleted by centrifugation, and then washed with ice-cold 80% acetone. Dried protein 
pellets were then resuspended in the SDS-PAGE sample buffer and the pH was adjusted 
to neutral using 2 M Tris/HCl (pH 8.8). The samples were boiled for 5 min at 63°C, 
centrifuged for 30 sec at 16,000 x g, loaded onto a 7.5%, 10%, 12.5% or 16% gel and 
resolved by SDS-PAGE. Following an overnight incubation of the gels in 50% methanol, 
proteins were visualized by silver staining using the mass spectrometry-compatible silver 
staining kit (Bio-Rad Silver Staining Plus) according to the manufacturer’s instructions. 
The Bio-Rad unstained molecular marker and a 0.1 mg/ml solution of BSA in the SDS-
PAGE sample buffer were also subjected to SDS-PAGE. The proteins were then 
visualized by silver staining. 
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Analysis of proteins by mass spectrometry 
Proteins were resolved by SDS-PAGE and visualized by silver staining [226]. Protein 
bands were excised from the gel, reduced, alkylated and in-gel digested with trypsin 
[226]. The proteins were identified by matrix-assisted laser desorption/ionization mass 
spectrometric (MALDI MS) peptide mapping [227], using a Micromass M@LDI time-of-
flight (TOF) mass spectrometer (Waters). Database searching using peptide masses was 
performed with the Mascot web-based search engine. For evaluating relative levels of 
individual proteins recovered in total cell lysates or purified mitochondria, a selected 
protein band was excised from the silver-stained gel and placed into an Eppendorf tube. 
A band of BSA containing 2 μg of this protein, which was also excised from the silver-
stained gel, was added to each of the protein bands to be analyzed. Protein bands were 
reduced, alkylated and in-gel digested with trypsin [226]. The desalted peptide mixture 
was added to the surface of a MALDI target plate and allowed to air dry. The sample spot 
was then overlaid with MALDI matrix solution containing the Angiotensin I peptide 
standard (1:1 ratio). The presence of Angiotensin I in the sample carrying the analyzed 
mixture of peptides provided an additional estimate of the mass measurement accuracy 
after calibration, giving an opportunity to calculate the value of peptide mass tolerance 
for each individual mass spectrum. After the desalted peptide mixture was analyzed by 
MALDI-TOF, the monoisotopic masses of recovered BSA peptides and the intensities of 
their monoisotopic peaks were grouped separately from the masses and intensities of 
peptides originated from the protein of interest. These data provided an additional 
estimate of the mass measurement accuracy and were used for the quantitation of relative 
levels of the same protein recovered in different samples. For evaluating relative levels of 
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the protein of interest found in the samples to be compared, a ratio “the intensity of the 
monoisotopic peak of a peptide originated from the protein of interest/the intensity of the 
monoisotopic peak of a BSA peptide with the monoisotopic mass closest to the mass of 
the peptide of interest” was calculated for each peptide originated from the protein of 
interest. Based on these data, the average value for relative levels of the protein of 
interest found in the two compared samples was calculated. The method for evaluating 
relative levels of the protein of interest recovered in different samples was validated by 
calculating relative levels of several standard proteins in the samples supplemented with 
different quantities of each of these proteins. 
 
Analysis of lipids by mass spectrometry 
1 × 10
10
 cells were harvested by centrifugation and washed three times with cold water. 
The lipids were extracted by resuspending the cells in 3.8 ml of chloroform - methanol - 
water (1:2:0.8) and by vortexing the cell suspension with glass beads two times for 1 min. 
1 ml of chloroform was then added, and the extract was incubated for 5 min with 
occasional mixing. 1 ml of water was then added, and the extract was incubated for 5 min 
with occasional mixing. The extract was centrifuged and the entire supernatant was 
collected. The pellet was resuspended in 1.6 ml of chloroform, and the lipids were 
extracted by vortexing the suspension with glass beads two times for 1 min. The extract 
was then centrifuged and the entire supernatant was collected. The pooled supernatants 
were centrifuged and the organic phase was collected. The lipid extract was dried under 
nitrogen. The lipid film was dissolved in 400 μl of chloroform - methanol (1:1) 
containing either 3 mM ammonium hydroxide for positive-ion analyses
 
or no additive for 
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negative-ion measurements. Mass spectrometric analyses were performed with a 
Micromass Q-TOF 2 mass spectrometer equipped with a nano-electrospray
 
source 
operating at a flow rate of 1 μl/min. The instrument was used in the single-stage mass 
spectrometry mode for positive- or negative-ion analyses as described in Chapter 2 of this 
thesis. For quantification of individual lipid molecular species, the commercially 
available lipids (Avanti Polar Lipids, Larodan AB and Sigma) with non-natural fatty acid 
compositions were used as internal standards that do not occur in a significant
 
amount in 
the sample to be analyzed. Lipid quantification was performed as described in Chapter 2 
of this thesis. 
 
Miscellaneous procedures 
SDS-PAGE and immunoblotting using a Trans-Blot SD semi-dry electrophoretic transfer 
system (Bio-Rad) were performed as previously described [228]. Blots were decorated 
with monoclonal antibodies raised against actin (Abcam) or porin (Invitrogen) or 
polyclonal antisera raised against Aco1p (kind gift of Dr. Ronald A. Butow, University of 
Texas Southwestern Medical Center) or cytochrome c (kind gift of Dr. Roland Lill, 
Philipps Universität Marburg). Antigen-antibody complexes were detected by enhanced 
chemiluminescence using an Amersham ECL Western blotting detection reagents (GE 
Healthcare). Enzymatic activities of cytochrome c oxidase [229], succinate 
dehydrogenase [230] and aconitase [231] were determined by established methods. For 
measuring ethanol and acetic acid concentrations, 1-ml aliquots of yeast cultures were 
centrifuged and supernatants frozen at -80
o
C. The supernatants were subjected to gas 
chromatography using an Agilent 6890 Networked GC system equipped with a Supelco 
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Equity-1 (0.32 mm × 30 cm) column and FID detector. Ethanol and acetic acid 
concentrations were calculated using the Chemstation 3 software (Agilent). Protocols for 
lipid extraction, separation by TLC, visualization by 5% phosphomolybdic acid in 
ethanol, and quantitation by densitometric analysis of TLC plates have been described 
elsewhere [232]. Preparation of cellular extracts and microanalytic biochemical assays 
for measuring ATP, glucose, trehalose and glycogen concentrations was performed as 
previously described [233]. 
 
3.4. Results 
3.4.1. CR extends the chronological life span of yeast 
To study the effect of CR on the chronological life span, I incubated the wild-type (WT) 
strain BY4742 in rich YP medium initially containing 0.2%, 0.5%, 1% or 2% glucose. 
The full growth cycle of WT culture in each of these four media began with logarithmic 
(L) phase and progressed through diauxic (D) and post-diauxic (PD) phases to stationary 
(ST) phase (Figure 3.1A). Notably, the rates of growth (Figure 3.1A) and glucose 
consumption (Figure 3.1B) in L phase were similar for WT cells cultured in any of the 
four media, whereas the maximum cell density in ST-phase cultures varied within a 28-% 
range and correlated with the initial glucose concentration (Figure 3.1A). CR cells of WT 
grown on 0.2% or 0.5% glucose lived significantly longer than WT cells grown under 
non-CR conditions on 1% or 2% glucose (Figure 3.1C). The mean chronological life span 
of cells grown on 0.2% glucose was extended by more than 60% and that of cells grown 
on 0.5% glucose was extended by almost 2-fold, as compared to the mean chronological 
life span of cells grown on 2% glucose (Figure 3.1D). Of note, CR yeast grown on 0.5%  
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Figure 3.1. CR extends the chronological life span of yeast. (A and B) Kinetics of growth (A) and glucose 
consumption (B) for the WT strain BY4742. Each plot shows a representative experiment repeated 4-6 
times in triplicate with similar results. (C) Survival of chronologically aging WT cells. Data are presented 
as mean  SEM (n = 16-28). p < 0.001 at days 10 to 33 for cells grown on 0.2% or 0.5% glucose vs. cells 
grown on 2% glucose. (D) The mean chronological life spans of WT cells. Data are presented as mean  
SEM (n = 16-28); *p < 0.01, **p < 0.001. (E) ATP levels in chronologically aging WT cells. Data are 
presented as mean  SEM (n = 3-5). (A-E) Cells were cultured in YP medium containing 0.2%, 0.5%, 1% 
or 2% glucose. Abbreviations: Diauxic (D), logarithmic (L), post-diauxic (PD) or stationary (ST) phase. 
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glucose lived longer than CR yeast grown on 0.2% glucose (Figure 3.1D).  
          Noteworthy, unlike yeast cells grown in the nutrient-limited SC medium [234, 
235], cells cultured in the nutrient-rich YP medium with 0.5% glucose lived longer than 
cells cultured in YP medium containing 0.05% glucose (Figure 3.2). Thus, the largest 
increase in the chronological life span of yeast grown under CR conditions in YP medium 
occurs at 0.5% glucose. The observed difference in the lowest concentration of glucose 
that is optimal for life-span extension under CR conditions between yeast grown in SC or 
YP medium could be due to at least two factors. First, YP medium is enriched, as 
compared to SC medium, in amino acids, nucleotides, vitamins and other essential 
nutrients. It is conceivable that at least some of these nutrients could modulate the effect 
of different glucose concentrations on chronological life span by influencing certain 
metabolic and/or nutrient-sensing signaling pathways operating in CR yeast. Second, the 
initial pH in yeast cultures grown in SC medium was 3.9-4.0 [236], whereas in yeast 
cultures grown in YP medium it was 6.9 (Figure 3.3). Furthermore, both the dynamics of 
age-related changes in the pH of culture medium and the final medium pH reached after 
several days of growth in SC with 0.5% or 0.05% glucose [236] differ from those 
observed for yeast that aged chronologically in YP medium containing either of these two 
glucose concentrations (Figure 3.3). It is feasible that such differences between SC and 
YP in the initial pH and/or its age-related homeostasis could contribute to the observed 
difference between these two media in the lowest concentration of glucose at which the 
highest beneficial effect of CR on chronological life span can be achieved. 
          Importantly, ATP levels and the dynamics of their change during chronological 






























































































































Figure 3.2. Survival of the chronologically aging wild-type strain BY4742 (A) and the mean chronological 
life spans of different cultures of BY4742 (B) grown in YP medium initially containing 0.02%, 0.05%, 
0.1%, 0.2% or 0.5% glucose. Data are presented as mean  SEM (n = 3 for cells grown on 0.02%, 0.05% or 
0.1% glucose; n = 35 for cells grown on 0.2% glucose; n = 24 for cells grown on 0.5% glucose). *p < 0.01 
(for cells grown on 0.02%, 0.05%, 0.1% or 0.2% glucose vs. cells grown on 0.5% glucose). Abbreviations: 
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Figure 3.3. (A) The dynamics of age-related changes in the pH of culture medium for the wild-type strain 
BY4742 grown in YP medium initially containing 0.05%, 0.2%, 0.5%, 1.0% or 2.0% glucose. Data are 
presented as mean  SEM (n = 3). (B) Survival of chronologically aging BY4742 grown either in YP 
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medium initially containing 2% glucose or in YP medium with 2% glucose to which HEPES-KOH buffer 
(pH 7.0) was added at day 1 to the final concentration of 25 mM. Data are presented as mean  SEM (n = 
22 for cells grown on 2% glucose; n = 3 for cells grown on 2% glucose and supplemented with a pH 7 
HEPES buffer at day 1). Abbreviations: Diauxic (D), logarithmic (L), post-diauxic (PD) or stationary (ST) 
phase. 
 
starving. Based on this important conclusion, I hypothesized that: 1) CR yeast remodel 
their metabolism in order to match the level of ATP produced in non-CR yeast; and 2) 
such specific remodeling of metabolism in CR yeast prolongs their life span. 
 
3.4.2. CR promotes the consumption of neutral lipids deposited in LBs 
I sought to define a specific pattern of metabolism that is responsible for the anti-aging 
effect of CR. In laboratory mice, the biosynthesis and degradation of TAG in white 
adipose tissue and mitochondrial fatty acid oxidation in skeletal muscle may play a role 
in longevity regulation [138 -141, 185 - 187]. I therefore assessed the dynamics of age-
dependent changes in levels of TAG and ergosteryl esters (EE), the two major neutral 
lipids that in yeast are synthesized in the ER and then deposited in LBs [212]. TAG and 
EE serve as the main storage molecules for FFA, DAG and ergosterol (ERG). Hence, the 
ability of yeast to modulate the biosynthesis and degradation of neutral lipids is crucial 
for regulating 1) energy homeostasis; 2) phospholipid and cardiolipin biosynthesis; 3) 
neutralization of excessive amounts of membrane-perturbing species of FFA and ERG; 4) 
FFA- and DAG-induced lipoapoptosis or necrosis; and 5) DAG-dependent signal 
transduction networks [148, 212, 222]. 
          Using TLC for measuring total cell lipids, I found that the concentrations of neutral  
lipids in WT cells increased gradually in logarithmic (L) and diauxic (D) phases, reaching  
 84 
 
Figure 3.4. CR promotes the consumption of neutral lipids deposited in LBs. A) Spectra of lipids 
extracted from equal numbers of WT cells and analyzed by TLC. A representative of 4 independent 
experiments is shown. (B) WT cells were visualized using Calcofluor White M2R (CW) and stained with 
BODIPY 493/503 to detect neutral lipids of lipid bodies (LB). (C) Percent of cells that contain lipid bodies. 
Images similar to the representative images shown in (B) were quantitated. Data are presented as mean  
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SEM (n = 5). p < 0.001 at days 5 to 21 for cells grown on 0.2% or 0.5% glucose vs. cells grown on 2% 
glucose. (D-G) Lipid species shown in (A) were quantitated by densitometric analysis of TLC plates. Data 
are presented as mean  SEM (n = 4). p < 0.001 at days 2 to 21 (for TAG, EE and FFA) or at days 5 to 21 
(for DAG) for cells grown on 0.2% or 0.5% glucose vs. cells grown on 2% glucose. (H and I) Spectra of 
lipids (H) that were extracted from purified ER and lipid bodies of WT cells. The equivalent of 200 μg of 
ER proteins and 20 μg of lipid body proteins was used for lipid extraction at each time point. Lipids were 
analyzed by TLC and quantitated by densitometric analysis of TLC plates (I). Each plot shows a 
representative experiment repeated 3 times with similar results. (A, C-G) Cells were cultured in YP 
medium containing 0.2%, 0.5%, 1% or 2% glucose. (B, H and I) Cells were cultured in YP medium 
containing 0.2% or 2% glucose. Abbreviations: DAG, diacylglycerols; EE, ergosteryl esters; ERG, 
ergosterol; FFA, free fatty acids; TAG, triacylglycerols. 
 
higher levels in non-CR yeast than in CR yeast (Figures 3.4A, 3.4D and 3.4E). During the 
subsequent post-diauxic (PD) phase, CR yeast completely consumed neutral lipids, 
whereas non-CR yeast continued to accumulate them. In contrast to yeast under CR, non-
CR yeast began to consume their deposited neutral lipids only after they have entered 
stationary (ST) phase (Figures 3.4A, 3.4D and 3.4E). The data of TLC analysis were 
supported by a quantitative assessment of the age-dependent changes in levels of 55 
different species of TAG, predominantly present as the 16:1/16:1/16:1, 16:1/16:1/18:1 
and 16:1/18:1/18:1 molecular forms, with the help of electrospray ionization mass 
spectrometry (ESI/MS; Figure 3.5). Live-cell fluorescence microscopy further supported 
the notion that CR accelerates the consumption of neutral lipids deposited in lipid bodies 
(Figures 3.4B and 3.4C). 
          I then examined the spatial dynamics of lipids in aging yeast. Consistent with the 
ER origin of LBs [160], neutral lipids were synthesized in the ER during L and D phases, 
prior to being relocated to and accumulated in LBs (Figures 3.4H and 3.4I). CR yeast 
completely consumed neutral lipids during the following PD phase, whereas non-CR 
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yeast continued to deposit them in LBs. The age-dependent buildup of neutral lipids in 
















































































































































































































Triacylglycerols (TAG); Day 7 (ST phase)
10
Figure 3.5. CR decreases the levels of various molecular species of triacylglycerols (TAG) in 
chronologically aging WT cells. Different molecular forms of TAG were identified and quantitated using 
electrospray ionization mass spectrometry. The plot shows a representative experiment repeated 3 times 
with similar results. Cells were cultured in rich YP medium initially containing 0.2%, 0.5%, 1% or 2% 
glucose. 
 
LBs (Figures 3.4H and 3.4I). 
          The biosynthesis of FFA and DAG during early D phase was followed by their 
incorporation into TAG within the ER during late D phase (Figures 3.4F-3.4I). Soon after 
their relocation from the ER to LBs, TAG in CR yeast were hydrolyzed to yield FFA and 
DAG, both of which were rapidly degraded during PD phase (Figures 3.4F-3.4I). 
Alternatively, non-CR yeast accumulated both FFA and DAG within the ER (Figures 
3.4F-3.4I). The data of TLC analysis were supported by the ESI/MS-assisted quantitative 
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assessment of the age-dependent changes in concentrations of 25 different forms of FFA, 










































































































































Free fatty acids (FFA); Day 7 (ST phase)
Figure 3.6. CR decreases the levels of various molecular species of free fatty acids (FFA) in 
chronologically aging WT cells. Different molecular forms of FFA were identified and quantitated using 
electrospray ionization mass spectrometry. The plot shows a representative experiment repeated 3 times 
with similar results. Cells were cultured in rich YP medium initially containing 0.2%, 0.5%, 1% or 2% 
glucose.  
 
My findings suggest that, due to the deceleration of the exit of TAG from and their 
resulting buildup within the ER, significant quantities of both FFA and DAG in non-CR 
yeast were unable to be used for the biosynthesis of TAG, perhaps because of a feedback 
inhibition of this process. 
 
3.4.3. CR alters the levels of proteins that function in carbohydrate and 
lipid metabolism 
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The described in section 3.4.2 measurement of lipids revealed that CR yeast undergo 
specific remodeling of lipid metabolism prior to entry into the non-proliferative ST 
phase. My MS-based quantitative proteomics of aging CR and non-CR yeast further 
supported this notion (Figure 3.7; Tables 3.1 and 3.2). In fact, as one can expect judging 
from the age-dependent dynamics of neutral lipids, I found that CR elevates the levels of 
enzymes that function in the degradation of these lipid species within LBs, concomitantly 
lowering the levels of ER- and LB-confined enzymes involved in their biosynthesis 
(Figure 3.7B). Moreover, the fact that CR elevated the levels of enzymes functioning in 
the formation of CoA esters of fatty acids (FA-CoA) and in their uptake and oxidation by 
peroxisomes (Figure 3B) can satisfactorily explain our observation that CR promoted 
fatty acids consumption during D and PD phases (Figures 2A and 2F). My proteomic 
analysis also implies that aging CR yeast re-design carbohydrate metabolism. 
Specifically, I found that the CR diet increases the levels of key enzymes that function in 
the biosynthesis of trehalose and glycogen, concurrently decreasing the levels of key 
enzymes catalyzing their degradation (Figure 3.7B). My data on the age-dependent 
dynamics of trehalose and glycogen (Figures 3.8B and 3.8C) support the notion that CR 
promotes the accumulation of these two major glucose stores in aging yeast. Furthermore, 
by decreasing the level of Adh1p, an enzyme that is required for ethanol synthesis, and 
by increasing the level of Adh2p, an enzyme that catalyzes ethanol degradation (Figure 
3.7B), CR greatly accelerated the depletion of ethanol from yeast cells (Figure 3.8D). 
Moreover, I found that CR elevates the levels of the three key enzymes of 
gluconeogenesis, a reverse to glycolysis process of synthesizing glucose from pyruvate 
(Figure 3.7B). The resulting shift of CR yeast toward glucose formation, away from its  
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Figure 3.7. CR yeast undergo remodeling of carbohydrate and lipid metabolism prior to entry into the non-
proliferative ST phase. (A) The spectra of proteins recovered in total lysates of WT cells. Cells were 
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cultured in YP medium containing 0.2%, 0.5%, 1% or 2% glucose. A representative of 2 independent 
experiments is shown. (B) Relative levels (fold difference relative to that on 2% glucose) of proteins 
recovered in total lysates of WT cells. Proteins were identified and quantitated using mass spectrometry. 
The complete list of proteins and their relative levels are provided in Tables 3.1 and 3.2, respectively. (C) 
Outline of metabolic pathways and interorganellar communications that were accelerated (red arrows) or 
decelerated (green arrows) by CR prior to entry into the non-proliferative ST phase. Abbreviations: AcOH, 
acetic acid; Ac-CoA, acetyl-CoA; DAG, diacylglycerols; EE, ergosteryl esters; ERG, ergosterol; EtOH, 
ethanol; FA-CoA, CoA esters of fatty acids; FFA, free fatty acids; LB, lipid bodies; ROS, reactive oxygen 
species; TAG, triacylglycerols. 
 
Table 3.1. List of proteins recovered in total lysates of WT cells cultured in YP medium initially containing 
0.2%, 0.5%, 1% or 2% glucose. For making total lysates, cells were collected at day 1 (L phase), day 2 (D 
phase), day 4 (PD phase) and day 9 (ST phase). Proteins were identified using matrix-assisted laser 
desorption/ionization mass spectrometric (MALDI MS) peptide mapping. 
 


















YP + 0.2% glucose; Day 1 (L phase) 
Tps1p NP_009684 Trehalose biosynthesis 7 18 114 6e-08 
Tps2p NP_010359 Trehalose biosynthesis 9 9 115 1.7e-05   
Ath1p NP_015351 Trehalose degradation 10 8 122 9.5e-09 
Nth1p NP_010284 Trehalose degradation 8 11 108 2.4e-07 
Nth2p NP_009555 Trehalose degradation 9 13 127 3e-09 
Glg2p NP_012398 Glycogen biosynthesis 7 18 120 1.5e-08 
Glc3p NP_010905 Glycogen biosynthesis 10 15 143 2.7e-08 
Gsy2p NP_013359 Glycogen biosynthesis 9 14 131 1.2e-09 
Gph1p NP_015486 Glycogen degradation 12 15 164 6e-13 
Gpt2p NP_012993 Biosynthesis of TAG 10 14 135 4.8e-10 
Ayr1p NP_012142 Biosynthesis of TAG 6 28 112 9.5e-08 
Slc1p NP_010231 Biosynthesis of TAG 8 32 138 2.4e-10 
Pah1p NP_013888 Biosynthesis of TAG 7 9 97 2.9e-06   
Lpp1p NP_010791 Biosynthesis of TAG 5 19 93 8.3e-06 
Dga1p NP_014888 Biosynthesis of TAG 6 17 102 9.5e-07   
Are2p NP_014416 Biosynthesis of TAG and EE 7 10 106 3.8e-07 
Tgl1p NP_012782 Degradation of EE 6 15 103 7.6e-07 
Tgl3p NP_014044 Degradation of TAG 7 12 105 4.8e-07 
Tgl4p NP_013015 Degradation of TAG 9 12 128 2.4e-09 
Tgl5p NP_014724 Degradation of TAG 7 10 96 3.4e-06 
Yeh1p NP_013089 Degradation of EE 6 13 94 5.7e-06 
Fat1p NP_009597 Conversion of FFA to FA-
CoA 
5 10 74 0.00057   
Faa1p NP_014962 Conversion of FFA to FA-
CoA 
6 10 89 1.9e-05 
Faa2p NP_010931 Conversion of FFA to FA-
CoA 
7 12 102 9.5e-07   
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Faa4p NP_013974 Conversion of FFA to FA-
CoA 
10 15 147 3e-11  
Fox1p NP_011310 Peroxisomal oxidation of FA-
CoA 
7 11 93 7.6e-06   
Fox2p NP_012934 Peroxisomal oxidation of FA-
CoA 
8 12 115 4.8e-08 
Fox3p NP_012106 Peroxisomal oxidation of FA-
CoA 
6 21 105 4.8e-07 
Adh1p NP_014555 Ethanol biosynthesis 8 27 145 4.8e-11 
Adh2p NP_014032 Ethanol oxidation 9 29 142 9.5e-11   
Pyc1p NP_011453 Gluconeogenesis 8 9 98 2.3e-06 
Pck1p NP_013023 Gluconeogenesis 7 17 115 4.8e-08 
Fbp1p NP_013481 Gluconeogenesis 6 22 107 3e-07 
Pda1p NP_011105 Mitochondrial PDH complex 7 17 109 1.9e-07 
Aco1p NP_013407 Mitochondrial TCA cycle 11 17 160 1.5e-12 
Ndi1p NP_013586 Mitochondrial ETC 8 18 128 2.4e-09 
Sdh1p NP_012774 Mitochondrial TCA cycle and 
ETC 
7 12 105 4.8e-07   
Cyt1p NP_014708 Mitochondrial ETC 6 26 113 7.6e-08 
Hem14p NP_010930 Heme synthesis in 
mitochondria 
9 20 140 1.5e-10 
Cyc3p NP_009361 Heme attachment to apo-
cytochrome c 
6 22 113 7.6e-08 
Ssq1p NP_013473 Assembly of Fe/S clusters into 
proteins 
7 12 102 9.5e-07 
Sod2p NP_011872 Detoxification of ROS in 
mitochondria 
6 30 119 1.9e-08 
Prx1p NP_009489 Detoxification of ROS in 
mitochondria 
5 21 93  6.9e-06 
Atp1p NP_009453 Mitochondrial ATP synthase 8 19 132 9.5e-10 
Atp2p NP_012655 Mitochondrial ATP synthase 7 17 116 3.8e-08 
Pet9p NP_009523 Mitochondrial ADP/ATP 
carrier 
6 20 102 9.5e-07 
Mir1p NP_012611 Mitochondrial phosphate 
carrier 
5 20 93 7.2e-06 
YP + 0.5% glucose; Day 1 (L phase) 
Tps1p NP_009684 Trehalose biosynthesis 8 18 133 7.6e-10 
Tps2p NP_010359 Trehalose biosynthesis 7 8 90 1.4e-05 
Ath1p NP_015351 Trehalose degradation 9 7 113 7.6e-08 
Nth1p NP_010284 Trehalose degradation 10 13 137 3e-10 
Nth2p NP_009555 Trehalose degradation 8 12 117 3e-08 
Glg2p NP_012398 Glycogen biosynthesis 8 22 140 1.5e-10 
Glc3p NP_010905 Glycogen biosynthesis 9 13 133 7.6e-10 
Gsy2p NP_013359 Glycogen biosynthesis 10 16 149 1.9e-11 
Gph1p NP_015486 Glycogen degradation 9 12 127 3e-09 
Gpt2p NP_012993 Biosynthesis of TAG 8 11 110 1.5e-07 
Ayr1p NP_012142 Biosynthesis of TAG 5 25 97 3.2e-06 
Slc1p NP_010231 Biosynthesis of TAG 7 28 126 3.8e-09 
Pah1p NP_013888 Biosynthesis of TAG 6 8 86 3.5e-05 
Lpp1p NP_010791 Biosynthesis of TAG 4 16 76 0.0004 
Dga1p NP_014888 Biosynthesis of TAG 7 19 121 1.2e-08 
Are2p NP_014416 Biosynthesis of TAG and EE 5 7 76 0.00041 
Tgl1p NP_012782 Degradation of EE 5 12 83 8.1e-05 
Tgl3p NP_014044 Degradation of TAG 6 10 92 8.9e-06 
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Tgl4p NP_013015 Degradation of TAG 11 14 154 6e-12 
Tgl5p NP_014724 Degradation of TAG 6 9 84 6.7e-05 
Yeh1p NP_013089 Degradation of EE 5 11 81 0.00012 
Fat1p NP_009597 Conversion of FFA to FA-
CoA 
7 13 108 2.4e-07 
Faa1p NP_014962 Conversion of FFA to FA-
CoA 
5 9 76 0.00035 
Faa2p NP_010931 Conversion of FFA to FA-
CoA 
6 10 90 1.3e-05 
Faa4p NP_013974 Conversion of FFA to FA-
CoA 
8 13 121 1.2e-08 
Fox1p NP_011310 Peroxisomal oxidation of FA-
CoA 
6 9 85 4.7e-05 
Fox2p NP_012934 Peroxisomal oxidation of FA-
CoA 
7 11 102 9.5e-07 
Fox3p NP_012106 Peroxisomal oxidation of FA-
CoA 
7 23 125 4.8e-09 
Adh1p NP_014555 Ethanol biosynthesis 6 21 110 1.5e-07 
Adh2p NP_014032 Ethanol oxidation 8 27 145 4.8e-11 
Pyc1p NP_011453 Gluconeogenesis 7 8 90 1.6e-05 
Pck1p NP_013023 Gluconeogenesis 9 20 146 3.8e-11 
Fbp1p NP_013481 Gluconeogenesis 5 20 92 8.9e-06 
Pda1p NP_011105 Mitochondrial PDH complex 6 15 91 1.2e-05 
Aco1p NP_013407 Mitochondrial TCA cycle 9 14 134 6e-10 
Ndi1p NP_013586 Mitochondrial ETC 6 15 98 2.7e-06 
Sdh1p NP_012774 Mitochondrial TCA cycle and 
ETC 
9 15 134 6e-10 
Cyt1p NP_014708 Mitochondrial ETC 5 28 99 1.8e-06 
Hem14p NP_010930 Heme synthesis in 
mitochondria 
8 18 125 4.8e-09 
Cyc3p NP_009361 Heme attachment to apo-
cytochrome c 
5 19 95 5.2e-06 
Ssq1p NP_013473 Assembly of Fe/S clusters into 
proteins 
9 14 128 2.4e-09 
Sod2p NP_011872 Detoxification of ROS in 
mitochondria 
5 26 100 1.7e-06 
Prx1p NP_009489 Detoxification of ROS in 
mitochondria 
4 18 75 0.00046 
Atp1p NP_009453 Mitochondrial ATP synthase 7 17 116 3.8e-08 
Atp2p NP_012655 Mitochondrial ATP synthase 6 15 100 1.6e-06 
Pet9p NP_009523 Mitochondrial ADP/ATP 
carrier 
5 17 85 5.2e-05 
Mir1p NP_012611 Mitochondrial phosphate 
carrier 
7 26 129 1.9e-09   
YP + 1% glucose; Day 1 (L phase) 
Tps1p NP_009684 Trehalose biosynthesis 6 15 100 1.6e-06 
Tps2p NP_010359 Trehalose biosynthesis 8 8 107  3e-07   
Ath1p NP_015351 Trehalose degradation 9 7 110 1.5e-07 
Nth1p NP_010284 Trehalose degradation 6 9 84 5.9e-05 
Nth2p NP_009555 Trehalose degradation 10 14 145 4.8e-11 
Glg2p NP_012398 Glycogen biosynthesis 6 17 105 4.8e-07 
Glc3p NP_010905 Glycogen biosynthesis 8 12 115 4.8e-08 
Gsy2p NP_013359 Glycogen biosynthesis 7 12 106 3.8e-07 
Gph1p NP_015486 Glycogen degradation 10 13 141 1.2e-10 
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Gpt2p NP_012993 Biosynthesis of TAG 8 11 116 3.8e-08 
Ayr1p NP_012142 Biosynthesis of TAG 7 34 135 4.8e-10 
Slc1p NP_010231 Biosynthesis of TAG 6 26 107 3e-07 
Pah1p NP_013888 Biosynthesis of TAG 8 11 114 6e-08 
Lpp1p NP_010791 Biosynthesis of TAG 4 16 76 0.00041 
Dga1p NP_014888 Biosynthesis of TAG 7 19 121 1.2e-08 
Are2p NP_014416 Biosynthesis of TAG and EE 6 9 91 1.2e-05 
Tgl1p NP_012782 Degradation of EE 5 13 83 7.6e-05  
Tgl3p NP_014044 Degradation of TAG 6 10 92 8.9e-06 
Tgl4p NP_013015 Degradation of TAG 10 14 141 1.2e-10   
Tgl5p NP_014724 Degradation of TAG 5 7 69 0.0017   
Yeh1p NP_013089 Degradation of EE 8 17 129 1.9e-09 
Fat1p NP_009597 Conversion of FFA to FA-
CoA 
7 14 109 1.9e-07 
Faa1p NP_014962 Conversion of FFA to FA-
CoA 
5 9 77 0.00032 
Faa2p NP_010931 Conversion of FFA to FA-
CoA 
6 11 92 1.1e-05 
Faa4p NP_013974 Conversion of FFA to FA-
CoA 
9 14 135 4.8e-10 
Fox1p NP_011310 Peroxisomal oxidation of FA-
CoA 
9 14 124 6e-09   
Fox2p NP_012934 Peroxisomal oxidation of FA-
CoA 
7 11 102 9.5e-07 
Fox3p NP_012106 Peroxisomal oxidation of FA-
CoA 
4 16 74 0.00064 
Adh1p NP_014555 Ethanol biosynthesis 6 22 110  1.5e-07 
Adh2p NP_014032 Ethanol oxidation 8 27 145 4.8e-11 
Pyc1p NP_011453 Gluconeogenesis 10 10 127 3e-09   
Pck1p NP_013023 Gluconeogenesis 6 14 99 1.9e-06   
Fbp1p NP_013481 Gluconeogenesis 5 18 92 1.1e-05  
Pda1p NP_011105 Mitochondrial PDH complex 7 17 109 1.9e-07   
Aco1p NP_013407 Mitochondrial TCA cycle 10 15 143 7.6e-11   
Ndi1p NP_013586 Mitochondrial ETC 6 14 97 3.2e-06   
Sdh1p NP_012774 Mitochondrial TCA cycle and 
ETC 
9 15 134 6e-10   
Cyt1p NP_014708 Mitochondrial ETC 5 23 95 4.8e-06   
Hem14p NP_010930 Heme synthesis in 
mitochondria 
11 23 169 1.9e-13 
Cyc3p NP_009361 Heme attachment to apo-
cytochrome c 
5 18 94 5.6e-06   
Ssq1p NP_013473 Assembly of Fe/S clusters into 
proteins 
9 15 129 1.9e-09   
Sod2p NP_011872 Detoxification of ROS in 
mitochondria 
5 26 99 1.7e-06   
Prx1p NP_009489 Detoxification of ROS in 
mitochondria 
8 31 148 2.4e-11   
Atp1p NP_009453 Mitochondrial ATP synthase 7 17 116 3.8e-08   
Atp2p NP_012655 Mitochondrial ATP synthase 9 20 148 2.4e-11   
Pet9p NP_009523 Mitochondrial ADP/ATP 
carrier 
5 17 85 5.2e-05 
Mir1p NP_012611 Mitochondrial phosphate 
carrier 
7 27 130 1.5e-09   
YP + 2% glucose; Day 1 (L phase) 
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Tps1p NP_009684 Trehalose biosynthesis 7 18 117 3e-08   
Tps2p NP_010359 Trehalose biosynthesis 8 8 107 3e-07   
Ath1p NP_015351 Trehalose degradation 9 7 113 7.6e-08   
Nth1p NP_010284 Trehalose degradation 8 11 111 1.2e-07   
Nth2p NP_009555 Trehalose degradation 7 11 101 1.2e-06   
Glg2p NP_012398 Glycogen biosynthesis 9 21 139 1.9e-10   
Glc3p NP_010905 Glycogen biosynthesis 10 15 146 3.8e-11   
Gsy2p NP_013359 Glycogen biosynthesis 7 12 106 3.8e-07   
Gph1p NP_015486 Glycogen degradation 10 13 141 1.2e-10   
Gpt2p NP_012993 Biosynthesis of TAG 8 11 110 1.5e-07   
Ayr1p NP_012142 Biosynthesis of TAG 7 34 135 4.8e-10 
Slc1p NP_010231 Biosynthesis of TAG 8 32 142 9.5e-11   
Pah1p NP_013888 Biosynthesis of TAG 6 8 86 3.6e-05   
Lpp1p NP_010791 Biosynthesis of TAG 5 19 94 5.7e-06 
Dga1p NP_014888 Biosynthesis of TAG 8 20 136 3.8e-10 
Are2p NP_014416 Biosynthesis of TAG and EE 6 9 91 1.2e-05 
Tgl1p NP_012782 Degradation of EE 5 12 83 8.1e-05  
Tgl3p NP_014044 Degradation of TAG 5 8 76 0.00041   
Tgl4p NP_013015 Degradation of TAG 8 11 114 6e-08   
Tgl5p NP_014724 Degradation of TAG 6 9 84 6.7e-05   
Yeh1p NP_013089 Degradation of EE 8 16 128 2.4e-09   
Fat1p NP_009597 Conversion of FFA to FA-
CoA 
5 10 77 0.0003   
Faa1p NP_014962 Conversion of FFA to FA-
CoA 
8 12 120 1.5e-08   
Faa2p NP_010931 Conversion of FFA to FA-
CoA 
7 12 106 3.8e-07   
Faa4p NP_013974 Conversion of FFA to FA-
CoA 
9 14 135 4.8e-10  
Fox1p NP_011310 Peroxisomal oxidation of FA-
CoA 
9 13 125 4.8e-09   
Fox2p NP_012934 Peroxisomal oxidation of FA-
CoA 
7 11 102 9.5e-07   
Fox3p NP_012106 Peroxisomal oxidation of FA-
CoA 
6 21 108 2.4e-07   
Adh1p NP_014555 Ethanol biosynthesis 7 24 127 3e-09   
Adh2p NP_014032 Ethanol oxidation 11 37 199 1.9e-16  
Pyc1p NP_011453 Gluconeogenesis 10 10 126 3.8e-09   
Pck1p NP_013023 Gluconeogenesis 6 15 99 1.7e-06   
Fbp1p NP_013481 Gluconeogenesis 8 27 145 4.8e-11   
Pda1p NP_011105 Mitochondrial PDH complex 6 14 96 4.2e-06   
Aco1p NP_013407 Mitochondrial TCA cycle 10 15 145 4.8e-11 
Ndi1p NP_013586 Mitochondrial ETC 7 16 113 7.6e-08 
Sdh1p NP_012774 Mitochondrial TCA cycle and 
ETC 
10 17 147 3e-11   
Cyt1p NP_014708 Mitochondrial ETC 5 22 94 5.5e-06   
Hem14p NP_010930 Heme synthesis in 
mitochondria 
8 18 124 6e-09   
Cyc3p NP_009361 Heme attachment to apo-
cytochrome c 
5 19 95 5.2e-06   
Ssq1p NP_013473 Assembly of Fe/S clusters into 
proteins 
10 16 145 4.8e-11   
Sod2p NP_011872 Detoxification of ROS in 
mitochondria 
5 29 102 9.5e-07 
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Prx1p NP_009489 Detoxification of ROS in 
mitochondria 
8 30 147 3e-11   
Atp1p NP_009453 Mitochondrial ATP synthase 10 22 164 6e-13   
Atp2p NP_012655 Mitochondrial ATP synthase 6 15 100 1.6e-06  
Pet9p NP_009523 Mitochondrial ADP/ATP 
carrier 
8 27 136 8.1e-08   
Mir1p NP_012611 Mitochondrial phosphate 
carrier 
7 26 129 1.9e-09   
YP + 0.2% glucose; Day 2 (D phase) 
Tps1p NP_009684 Trehalose biosynthesis 7 18 117 3e-08   
Tps2p NP_010359 Trehalose biosynthesis 7 8 90 1.4e-05 
Ath1p NP_015351 Trehalose degradation 9 7 110 1.5e-07 
Nth1p NP_010284 Trehalose degradation 8 11 109 2e-07 
Nth2p NP_009555 Trehalose degradation 9 13 122 1.2e-09 
Glg2p NP_012398 Glycogen biosynthesis 8 22 141 1.1e-10 
Glc3p NP_010905 Glycogen biosynthesis 10 15 143 2.7e-08 
Gsy2p NP_013359 Glycogen biosynthesis 7 12 106 3.8e-07 
Gph1p NP_015486 Glycogen degradation 10 13 142 1.5e-10 
Gpt2p NP_012993 Biosynthesis of TAG 10 14 136 5.4e-10 
Ayr1p NP_012142 Biosynthesis of TAG 5 25 99 4.1e-06 
Slc1p NP_010231 Biosynthesis of TAG 8 32 140 4.8e-10 
Pah1p NP_013888 Biosynthesis of TAG 7 9 99 3.9e-06   
Lpp1p NP_010791 Biosynthesis of TAG 5 19 94 5.7e-06 
Dga1p NP_014888 Biosynthesis of TAG 8 20 129 1.4e-09 
Are2p NP_014416 Biosynthesis of TAG and EE 5 7 76 0.00041 
Tgl1p NP_012782 Degradation of EE 5 12 83 8.1e-05 
Tgl3p NP_014044 Degradation of TAG 6 10 92 8.9e-06 
Tgl4p NP_013015 Degradation of TAG 11 14 154 6e-12 
Tgl5p NP_014724 Degradation of TAG 5 7 69 0.0017   
Yeh1p NP_013089 Degradation of EE 8 17 129 2.1e-09   
Fat1p NP_009597 Conversion of FFA to FA-
CoA 
7 13 108 2.4e-07 
Faa1p NP_014962 Conversion of FFA to FA-
CoA 
5 9 77 0.00032 
Faa2p NP_010931 Conversion of FFA to FA-
CoA 
6 11 91 1.2e-05 
Faa4p NP_013974 Conversion of FFA to FA-
CoA 
10 15 147 3e-11  
Fox1p NP_011310 Peroxisomal oxidation of FA-
CoA 
9 14 125 5.4e-09   
Fox2p NP_012934 Peroxisomal oxidation of FA-
CoA 
7 11 102 9.5e-07 
Fox3p NP_012106 Peroxisomal oxidation of FA-
CoA 
7 22 110 4.8e-08 
Adh1p NP_014555 Ethanol biosynthesis 7 23 119 2.5e-08 
Adh2p NP_014032 Ethanol oxidation 9 29 142 9.5e-11   
Pyc1p NP_011453 Gluconeogenesis 10 10 126 3.8e-09   
Pck1p NP_013023 Gluconeogenesis 9 20 146 3.8e-11 
Fbp1p NP_013481 Gluconeogenesis 5 20 92 8.9e-06 
Pda1p NP_011105 Mitochondrial PDH complex 6 15 91 1.2e-05 
Aco1p NP_013407 Mitochondrial TCA cycle 10 15 144 2.6e-11   
Ndi1p NP_013586 Mitochondrial ETC 8 18 128 2.4e-09 
Sdh1p NP_012774 Mitochondrial TCA cycle and 
ETC 
9 15 134 6e-10   
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Cyt1p NP_014708 Mitochondrial ETC 5 23 95 4.8e-06   
Hem14p NP_010930 Heme synthesis in 
mitochondria 
8 18 125 5.4e-09   
Cyc3p NP_009361 Heme attachment to apo-
cytochrome c 
6 22 113 7.6e-08 
Ssq1p NP_013473 Assembly of Fe/S clusters into 
proteins 
9 15 129 1.9e-09   
Prx1p NP_009489 Detoxification of ROS in 
mitochondria 
4 18 75 0.00046 
Atp1p NP_009453 Mitochondrial ATP synthase 7 17 116 3.8e-08   
Atp2p NP_012655 Mitochondrial ATP synthase 9 20 148 2.4e-11   
Pet9p NP_009523 Mitochondrial ADP/ATP 
carrier 
5 17 85 5.2e-05 
Mir1p NP_012611 Mitochondrial phosphate 
carrier 
5 20 93 7.2e-06 
YP + 0.5% glucose; Day 2 (D phase) 
Tps1p NP_009684 Trehalose biosynthesis 7 18 115 4.6e-08 
Tps2p NP_010359 Trehalose biosynthesis 7 8 90 1.4e-05 
Ath1p NP_015351 Trehalose degradation 9 7 110 1.5e-07 
Nth1p NP_010284 Trehalose degradation 8 11 109 1.8e-07 
Nth2p NP_009555 Trehalose degradation 8 12 117 3e-08 
Glg2p NP_012398 Glycogen biosynthesis 7 18 120 1.5e-08 
Glc3p NP_010905 Glycogen biosynthesis 10 15 146 3.8e-11   
Gsy2p NP_013359 Glycogen biosynthesis 10 16 149 1.9e-11 
Gph1p NP_015486 Glycogen degradation 12 15 164 6e-13 
Gpt2p NP_012993 Biosynthesis of TAG 10 14 135 4.8e-10 
Ayr1p NP_012142 Biosynthesis of TAG 5 25 97 3.2e-06 
Slc1p NP_010231 Biosynthesis of TAG 8 32 138 2.4e-10 
Pah1p NP_013888 Biosynthesis of TAG 6 8 86 3.5e-05 
Lpp1p NP_010791 Biosynthesis of TAG 5 19 94 5.7e-06 
Dga1p NP_014888 Biosynthesis of TAG 7 19 121 1.2e-08 
Are2p NP_014416 Biosynthesis of TAG and EE 7 10 106 3.8e-07 
Tgl1p NP_012782 Degradation of EE 5 12 83 8.1e-05 
Tgl3p NP_014044 Degradation of TAG 5 8 76 0.00041   
Tgl4p NP_013015 Degradation of TAG 9 12 128 2.4e-09 
Tgl5p NP_014724 Degradation of TAG 6 9 84 6.7e-05   
Yeh1p NP_013089 Degradation of EE 8 17 129 1.9e-09 
Fat1p NP_009597 Conversion of FFA to FA-
CoA 
7 14 109 1.9e-07 
Faa1p NP_014962 Conversion of FFA to FA-
CoA 
6 10 89 1.9e-05 
Faa2p NP_010931 Conversion of FFA to FA-
CoA 
7 12 106 3.8e-07   
Faa4p NP_013974 Conversion of FFA to FA-
CoA 
8 13 121 1.2e-08 
Fox1p NP_011310 Peroxisomal oxidation of FA-
CoA 
9 13 125 4.8e-09   
Fox2p NP_012934 Peroxisomal oxidation of FA-
CoA 
8 12 115 4.8e-08 
Fox3p NP_012106 Peroxisomal oxidation of FA-
CoA 
6 21 108 2.4e-07   
Adh1p NP_014555 Ethanol biosynthesis 6 22 110 1.5e-07 
Adh2p NP_014032 Ethanol oxidation 11 37 199 1.9e-16  
Pyc1p NP_011453 Gluconeogenesis 10 10 126 3.8e-09   
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Pck1p NP_013023 Gluconeogenesis 7 17 115 4.8e-08 
Fbp1p NP_013481 Gluconeogenesis 5 20 92 8.9e-06 
Pda1p NP_011105 Mitochondrial PDH complex 6 14 96 4.2e-06   
Aco1p NP_013407 Mitochondrial TCA cycle 11 17 160 1.5e-12 
Ndi1p NP_013586 Mitochondrial ETC 6 15 98 2.7e-06 
Sdh1p NP_012774 Mitochondrial TCA cycle and 
ETC 
9 15 134 6e-10   
Cyt1p NP_014708 Mitochondrial ETC 5 22 94 5.5e-06   
Hem14p NP_010930 Heme synthesis in 
mitochondria 
9 20 140 1.5e-10 
Cyc3p NP_009361 Heme attachment to apo-
cytochrome c 
5 18 94 5.6e-06   
Ssq1p NP_013473 Assembly of Fe/S clusters into 
proteins 
9 14 128 2.4e-09 
Sod2p NP_011872 Detoxification of ROS in 
mitochondria 
5 29 102 9.5e-07 
Prx1p NP_009489 Detoxification of ROS in 
mitochondria 
5 21 93  6.9e-06 
Atp1p NP_009453 Mitochondrial ATP synthase 7 17 116 3.8e-08 
Atp2p NP_012655 Mitochondrial ATP synthase 6 15 100 1.6e-06 
Pet9p NP_009523 Mitochondrial ADP/ATP 
carrier 
8 27 136 8.1e-08   
Mir1p NP_012611 Mitochondrial phosphate 
carrier 
7 27 130 1.5e-09   
YP + 1% glucose; Day 2 (D phase) 
Tps1p NP_009684 Trehalose biosynthesis 6 15 100 1.6e-06 
Tps2p NP_010359 Trehalose biosynthesis 7 8 90 1.4e-05 
Ath1p NP_015351 Trehalose degradation 9 7 110 1.5e-07 
Nth1p NP_010284 Trehalose degradation 8 11 111 1.2e-07   
Nth2p NP_009555 Trehalose degradation 8 12 117 3e-08 
Glg2p NP_012398 Glycogen biosynthesis 7 18 120 1.5e-08 
Glc3p NP_010905 Glycogen biosynthesis 10 15 146 3.8e-11   
Gsy2p NP_013359 Glycogen biosynthesis 10 16 149 1.9e-11 
Gph1p NP_015486 Glycogen degradation 12 15 164 6e-13 
Gpt2p NP_012993 Biosynthesis of TAG 8 11 110 1.5e-07   
Ayr1p NP_012142 Biosynthesis of TAG 6 28 112 9.5e-08 
Slc1p NP_010231 Biosynthesis of TAG 7 28 126 3.8e-09 
Pah1p NP_013888 Biosynthesis of TAG 7 9 97 2.9e-06   
Lpp1p NP_010791 Biosynthesis of TAG 5 19 94 5.7e-06 
Dga1p NP_014888 Biosynthesis of TAG 8 20 136 3.8e-10 
Are2p NP_014416 Biosynthesis of TAG and EE 5 7 76 0.00041 
Tgl1p NP_012782 Degradation of EE 6 15 103 7.6e-07 
Tgl3p NP_014044 Degradation of TAG 5 8 76 0.00041   
Tgl4p NP_013015 Degradation of TAG 10 14 141 1.2e-10   
Tgl5p NP_014724 Degradation of TAG 6 9 84 6.7e-05   
Yeh1p NP_013089 Degradation of EE 6 13 94 5.7e-06 
Fat1p NP_009597 Conversion of FFA to FA-
CoA 
5 10 77 0.0003   
Faa1p NP_014962 Conversion of FFA to FA-
CoA 
6 10 89 1.9e-05 
Faa2p NP_010931 Conversion of FFA to FA-
CoA 
7 12 106 3.8e-07   
Faa4p NP_013974 Conversion of FFA to FA-
CoA 
8 13 121 1.2e-08 
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Fox1p NP_011310 Peroxisomal oxidation of FA-
CoA 
9 14 124 6e-09   
Fox2p NP_012934 Peroxisomal oxidation of FA-
CoA 
7 11 102 9.5e-07 
Fox3p NP_012106 Peroxisomal oxidation of FA-
CoA 
7 23 125 4.8e-09 
Adh1p NP_014555 Ethanol biosynthesis 8 27 145 4.8e-11 
Adh2p NP_014032 Ethanol oxidation 11 37 199 1.9e-16  
Pyc1p NP_011453 Gluconeogenesis 8 9 98 2.3e-06 
Pck1p NP_013023 Gluconeogenesis 6 14 99 1.9e-06   
Fbp1p NP_013481 Gluconeogenesis 5 20 92 8.9e-06 
Pda1p NP_011105 Mitochondrial PDH complex 6 15 91 1.2e-05 
Aco1p NP_013407 Mitochondrial TCA cycle 10 15 145 4.8e-11 
Ndi1p NP_013586 Mitochondrial ETC 6 15 98 2.7e-06 
Sdh1p NP_012774 Mitochondrial TCA cycle and 
ETC 
7 12 105 4.8e-07   
Cyt1p NP_014708 Mitochondrial ETC 5 22 94 5.5e-06   
Hem14p NP_010930 Heme synthesis in 
mitochondria 
8 18 125 4.8e-09 
Cyc3p NP_009361 Heme attachment to apo-
cytochrome c 
5 19 95 5.2e-06   
Ssq1p NP_013473 Assembly of Fe/S clusters into 
proteins 
9 14 128 2.4e-09 
Sod2p NP_011872 Detoxification of ROS in 
mitochondria 
5 26 99 1.7e-06   
Prx1p NP_009489 Detoxification of ROS in 
mitochondria 
5 21 93  6.9e-06 
Atp1p NP_009453 Mitochondrial ATP synthase 10 22 164 6e-13   
Atp2p NP_012655 Mitochondrial ATP synthase 7 17 116 3.8e-08 
Pet9p NP_009523 Mitochondrial ADP/ATP 
carrier 
5 17 85 5.2e-05 
Mir1p NP_012611 Mitochondrial phosphate 
carrier 
7 26 129 1.9e-09   
YP + 2% glucose; Day 2 (D phase) 
Tps1p NP_009684 Trehalose biosynthesis 7 18 117 3e-08   
Tps2p NP_010359 Trehalose biosynthesis 9 9 115 1.7e-05   
Ath1p NP_015351 Trehalose degradation 9 7 113 7.6e-08 
Nth1p NP_010284 Trehalose degradation 8 11 108 2.4e-07 
Nth2p NP_009555 Trehalose degradation 7 11 101 1.2e-06   
Glg2p NP_012398 Glycogen biosynthesis 8 22 140 1.5e-10 
Glc3p NP_010905 Glycogen biosynthesis 9 13 133 7.6e-10 
Gsy2p NP_013359 Glycogen biosynthesis 9 14 131 1.2e-09 
Gph1p NP_015486 Glycogen degradation 10 13 141 1.2e-10 
Gpt2p NP_012993 Biosynthesis of TAG 8 11 110 1.5e-07 
Ayr1p NP_012142 Biosynthesis of TAG 6 28 112 9.5e-08 
Slc1p NP_010231 Biosynthesis of TAG 8 32 142 9.5e-11   
Pah1p NP_013888 Biosynthesis of TAG 6 8 86 3.5e-05 
Lpp1p NP_010791 Biosynthesis of TAG 5 19 93 8.3e-06 
Dga1p NP_014888 Biosynthesis of TAG 8 20 136 3.8e-10 
Are2p NP_014416 Biosynthesis of TAG and EE 5 7 76 0.00041 
Tgl1p NP_012782 Degradation of EE 6 15 103 7.6e-07 
Tgl3p NP_014044 Degradation of TAG 6 10 92 8.9e-06 
Tgl4p NP_013015 Degradation of TAG 9 12 128 2.4e-09 
Tgl5p NP_014724 Degradation of TAG 6 9 84 6.7e-05   
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Yeh1p NP_013089 Degradation of EE 8 17 129 1.9e-09 
Fat1p NP_009597 Conversion of FFA to FA-
CoA 
7 13 108 2.4e-07 
Faa1p NP_014962 Conversion of FFA to FA-
CoA 
8 12 120 1.5e-08   
Faa2p NP_010931 Conversion of FFA to FA-
CoA 
7 12 102 9.5e-07   
Faa4p NP_013974 Conversion of FFA to FA-
CoA 
8 13 121 1.2e-08 
Fox1p NP_011310 Peroxisomal oxidation of FA-
CoA 
6 9 85 4.7e-05 
Fox2p NP_012934 Peroxisomal oxidation of FA-
CoA 
8 12 115 4.8e-08 
Fox3p NP_012106 Peroxisomal oxidation of FA-
CoA 
7 23 125 4.8e-09 
Adh1p NP_014555 Ethanol biosynthesis 8 27 145 4.8e-11 
Adh2p NP_014032 Ethanol oxidation 11 37 199 1.9e-16  
Pyc1p NP_011453 Gluconeogenesis 7 8 90 1.6e-05 
Pck1p NP_013023 Gluconeogenesis 9 20 146 3.8e-11 
Fbp1p NP_013481 Gluconeogenesis 6 22 107 3e-07 
Pda1p NP_011105 Mitochondrial PDH complex 6 14 96 4.2e-06   
Aco1p NP_013407 Mitochondrial TCA cycle 11 17 160 1.5e-12 
Ndi1p NP_013586 Mitochondrial ETC 7 16 113 7.6e-08 
Sdh1p NP_012774 Mitochondrial TCA cycle and 
ETC 
7 12 105 4.8e-07   
Cyt1p NP_014708 Mitochondrial ETC 5 22 94 5.5e-06   
Hem14p NP_010930 Heme synthesis in 
mitochondria 
11 23 169 1.9e-13 
Cyc3p NP_009361 Heme attachment to apo-
cytochrome c 
6 22 113 7.6e-08 
Ssq1p NP_013473 Assembly of Fe/S clusters into 
proteins 
10 16 145 4.8e-11   
Sod2p NP_011872 Detoxification of ROS in 
mitochondria 
5 26 99 1.7e-06   
Prx1p NP_009489 Detoxification of ROS in 
mitochondria 
8 31 148 2.4e-11   
Atp1p NP_009453 Mitochondrial ATP synthase 7 17 116 3.8e-08 
Atp2p NP_012655 Mitochondrial ATP synthase 6 15 100 1.6e-06 
Pet9p NP_009523 Mitochondrial ADP/ATP 
carrier 
6 20 102 9.5e-07 
Mir1p NP_012611 Mitochondrial phosphate 
carrier 
5 20 93 7.2e-06 
YP + 0.2% glucose; Day 4 (PD phase) 
Tps1p NP_009684 Trehalose biosynthesis 7 18 117 3e-08   
Tps2p NP_010359 Trehalose biosynthesis 9 9 115 1.7e-05   
Ath1p NP_015351 Trehalose degradation 10 8 122 9.5e-09 
Nth1p NP_010284 Trehalose degradation 8 11 111 1.2e-07   
Nth2p NP_009555 Trehalose degradation 8 12 117 3e-08 
Glg2p NP_012398 Glycogen biosynthesis 9 21 139 1.9e-10   
Glc3p NP_010905 Glycogen biosynthesis 10 15 143 2.7e-08 
Gsy2p NP_013359 Glycogen biosynthesis 10 16 149 1.9e-11 
Gph1p NP_015486 Glycogen degradation 10 13 141 1.2e-10 
Gpt2p NP_012993 Biosynthesis of TAG 10 14 135 4.8e-10 
Ayr1p NP_012142 Biosynthesis of TAG 7 34 135 4.8e-10 
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Slc1p NP_010231 Biosynthesis of TAG 8 32 138 2.4e-10 
Pah1p NP_013888 Biosynthesis of TAG 6 8 86 3.5e-05 
Lpp1p NP_010791 Biosynthesis of TAG 4 16 76 0.00041 
Dga1p NP_014888 Biosynthesis of TAG 6 17 102 9.5e-07   
Are2p NP_014416 Biosynthesis of TAG and EE 5 7 76 0.00041 
Tgl1p NP_012782 Degradation of EE 6 15 103 7.6e-07 
Tgl3p NP_014044 Degradation of TAG 7 12 105 4.8e-07 
Tgl4p NP_013015 Degradation of TAG 11 14 154 6e-12 
Tgl5p NP_014724 Degradation of TAG 6 9 84 6.7e-05   
Yeh1p NP_013089 Degradation of EE 6 13 94 5.7e-06 
Fat1p NP_009597 Conversion of FFA to FA-
CoA 
7 13 108 2.4e-07 
Faa1p NP_014962 Conversion of FFA to FA-
CoA 
6 10 89 1.9e-05 
Faa2p NP_010931 Conversion of FFA to FA-
CoA 
7 12 106 3.8e-07   
Faa4p NP_013974 Conversion of FFA to FA-
CoA 
9 14 135 4.8e-10 
Fox1p NP_011310 Peroxisomal oxidation of FA-
CoA 
6 9 85 4.7e-05 
Fox2p NP_012934 Peroxisomal oxidation of FA-
CoA 
8 12 115 4.8e-08 
Fox3p NP_012106 Peroxisomal oxidation of FA-
CoA 
6 21 108 2.4e-07   
Adh1p NP_014555 Ethanol biosynthesis 7 24 127 3e-09   
Adh2p NP_014032 Ethanol oxidation 9 29 142 9.5e-11   
Pyc1p NP_011453 Gluconeogenesis 8 9 98 2.3e-06 
Pck1p NP_013023 Gluconeogenesis 6 14 99 1.9e-06   
Fbp1p NP_013481 Gluconeogenesis 5 20 92 8.9e-06 
Pda1p NP_011105 Mitochondrial PDH complex 6 14 96 4.2e-06   
Aco1p NP_013407 Mitochondrial TCA cycle 11 17 160 1.5e-12 
Ndi1p NP_013586 Mitochondrial ETC 6 14 97 3.2e-06   
Sdh1p NP_012774 Mitochondrial TCA cycle and 
ETC 
7 12 105 4.8e-07   
Cyt1p NP_014708 Mitochondrial ETC 5 28 99 1.8e-06 
Hem14p NP_010930 Heme synthesis in 
mitochondria 
8 18 125 4.8e-09 
Cyc3p NP_009361 Heme attachment to apo-
cytochrome c 
5 18 94 5.6e-06   
Ssq1p NP_013473 Assembly of Fe/S clusters into 
proteins 
7 12 102 9.5e-07 
Sod2p NP_011872 Detoxification of ROS in 
mitochondria 
5 29 102 9.5e-07 
Prx1p NP_009489 Detoxification of ROS in 
mitochondria 
8 31 148 2.4e-11   
Atp1p NP_009453 Mitochondrial ATP synthase 8 19 132 9.5e-10 
Atp2p NP_012655 Mitochondrial ATP synthase 9 20 148 2.4e-11   
Pet9p NP_009523 Mitochondrial ADP/ATP 
carrier 
5 17 85 5.2e-05 
Mir1p NP_012611 Mitochondrial phosphate 
carrier 
7 26 129 1.9e-09   
YP + 0.5% glucose; Day 4 (PD phase) 
Tps1p NP_009684 Trehalose biosynthesis 7 18 115 5.2e-08 
Tps2p NP_010359 Trehalose biosynthesis 7 8 90 1.4e-05 
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Ath1p NP_015351 Trehalose degradation 9 7 111 1.2e-07 
Nth1p NP_010284 Trehalose degradation 6 9 84 5.9e-05 
Nth2p NP_009555 Trehalose degradation 7 11 101 1.2e-06   
Glg2p NP_012398 Glycogen biosynthesis 8 22 140 1.5e-10 
Glc3p NP_010905 Glycogen biosynthesis 10 15 146 3.8e-11   
Gsy2p NP_013359 Glycogen biosynthesis 10 16 149 1.9e-11 
Gph1p NP_015486 Glycogen degradation 9 12 127 3e-09 
Gpt2p NP_012993 Biosynthesis of TAG 8 11 110 1.5e-07   
Ayr1p NP_012142 Biosynthesis of TAG 6 28 112 9.5e-08 
Slc1p NP_010231 Biosynthesis of TAG 6 26 107 3e-07 
Pah1p NP_013888 Biosynthesis of TAG 6 8 86 3.5e-05 
Lpp1p NP_010791 Biosynthesis of TAG 5 19 93 8.3e-06 
Dga1p NP_014888 Biosynthesis of TAG 6 17 102 9.5e-07   
Are2p NP_014416 Biosynthesis of TAG and EE 6 9 91 1.2e-05 
Tgl1p NP_012782 Degradation of EE 5 13 83 7.6e-05  
Tgl3p NP_014044 Degradation of TAG 7 12 105 4.8e-07 
Tgl4p NP_013015 Degradation of TAG 11 14 154 6e-12 
Tgl5p NP_014724 Degradation of TAG 5 7 69 0.0017   
Yeh1p NP_013089 Degradation of EE 8 16 128 2.4e-09   
Fat1p NP_009597 Conversion of FFA to FA-
CoA 
7 13 108 2.4e-07 
Faa1p NP_014962 Conversion of FFA to FA-
CoA 
6 10 89 1.9e-05 
Faa2p NP_010931 Conversion of FFA to FA-
CoA 
7 12 106 3.8e-07   
Faa4p NP_013974 Conversion of FFA to FA-
CoA 
10 15 147 3e-11  
Fox1p NP_011310 Peroxisomal oxidation of FA-
CoA 
9 13 125 4.8e-09   
Fox2p NP_012934 Peroxisomal oxidation of FA-
CoA 
8 12 115 4.8e-08 
Fox3p NP_012106 Peroxisomal oxidation of FA-
CoA 
7 23 125 4.8e-09 
Adh1p NP_014555 Ethanol biosynthesis 8 27 145 4.8e-11 
Adh2p NP_014032 Ethanol oxidation 11 37 199 1.9e-16  
Pyc1p NP_011453 Gluconeogenesis 7 8 90 1.6e-05 
Pck1p NP_013023 Gluconeogenesis 6 14 99 1.9e-06   
Fbp1p NP_013481 Gluconeogenesis 6 22 107 3e-07 
Pda1p NP_011105 Mitochondrial PDH complex 6 15 91 1.2e-05 
Aco1p NP_013407 Mitochondrial TCA cycle 10 15 145 4.8e-11 
Ndi1p NP_013586 Mitochondrial ETC 6 15 98 2.7e-06 
Sdh1p NP_012774 Mitochondrial TCA cycle and 
ETC 
7 12 105 4.8e-07   
Cyt1p NP_014708 Mitochondrial ETC 5 22 94 5.5e-06   
Hem14p NP_010930 Heme synthesis in 
mitochondria 
9 20 140 1.5e-10 
Cyc3p NP_009361 Heme attachment to apo-
cytochrome c 
5 18 94 5.6e-06   
Ssq1p NP_013473 Assembly of Fe/S clusters into 
proteins 
10 16 145 4.8e-11   
Sod2p NP_011872 Detoxification of ROS in 
mitochondria 
6 30 119 1.9e-08 
Prx1p NP_009489 Detoxification of ROS in 
mitochondria 
4 18 75 0.00046 
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Atp1p NP_009453 Mitochondrial ATP synthase 7 17 116 3.8e-08   
Atp2p NP_012655 Mitochondrial ATP synthase 7 17 116 3.8e-08 
Pet9p NP_009523 Mitochondrial ADP/ATP 
carrier 
5 17 85 5.2e-05 
Mir1p NP_012611 Mitochondrial phosphate 
carrier 
7 27 130 1.5e-09   
YP + 1% glucose; Day 4 (PD phase) 
Tps1p NP_009684 Trehalose biosynthesis 6 15 100 1.6e-06 
Tps2p NP_010359 Trehalose biosynthesis 8 8 107  3e-07   
Ath1p NP_015351 Trehalose degradation 10 8 122 9.5e-09 
Nth1p NP_010284 Trehalose degradation 6 9 84 5.9e-05 
Nth2p NP_009555 Trehalose degradation 10 14 145 4.8e-11 
Glg2p NP_012398 Glycogen biosynthesis 7 18 120 1.5e-08 
Glc3p NP_010905 Glycogen biosynthesis 8 12 115 4.8e-08 
Gsy2p NP_013359 Glycogen biosynthesis 7 12 106 3.8e-07 
Gph1p NP_015486 Glycogen degradation 9 12 127 3e-09 
Gpt2p NP_012993 Biosynthesis of TAG 8 11 110 1.5e-07   
Ayr1p NP_012142 Biosynthesis of TAG 6 28 112 9.5e-08 
Slc1p NP_010231 Biosynthesis of TAG 6 26 107 3e-07 
Pah1p NP_013888 Biosynthesis of TAG 8 11 114 6e-08 
Lpp1p NP_010791 Biosynthesis of TAG 5 19 93 8.3e-06 
Dga1p NP_014888 Biosynthesis of TAG 6 17 102 9.5e-07   
Are2p NP_014416 Biosynthesis of TAG and EE 5 7 76 0.00041 
Tgl1p NP_012782 Degradation of EE 6 15 103 7.6e-07 
Tgl3p NP_014044 Degradation of TAG 6 10 92 8.9e-06 
Tgl4p NP_013015 Degradation of TAG 9 12 128 2.4e-09 
Tgl5p NP_014724 Degradation of TAG 6 9 84 6.7e-05   
Yeh1p NP_013089 Degradation of EE 5 11 81 0.00012 
Fat1p NP_009597 Conversion of FFA to FA-
CoA 
7 13 108 2.4e-07 
Faa1p NP_014962 Conversion of FFA to FA-
CoA 
8 12 120 1.5e-08   
Faa2p NP_010931 Conversion of FFA to FA-
CoA 
7 12 102 9.5e-07   
Faa4p NP_013974 Conversion of FFA to FA-
CoA 
8 13 121 1.2e-08 
Fox1p NP_011310 Peroxisomal oxidation of FA-
CoA 
7 11 93 7.6e-06   
Fox2p NP_012934 Peroxisomal oxidation of FA-
CoA 
7 11 102 9.5e-07 
Fox3p NP_012106 Peroxisomal oxidation of FA-
CoA 
6 21 105 4.8e-07 
Adh1p NP_014555 Ethanol biosynthesis 6 22 110 1.5e-07 
Adh2p NP_014032 Ethanol oxidation 9 29 142 9.5e-11   
Pyc1p NP_011453 Gluconeogenesis 7 8 90 1.6e-05 
Pck1p NP_013023 Gluconeogenesis 9 20 146 3.8e-11 
Fbp1p NP_013481 Gluconeogenesis 8 27 145 4.8e-11   
Pda1p NP_011105 Mitochondrial PDH complex 6 15 91 1.2e-05 
Aco1p NP_013407 Mitochondrial TCA cycle 10 15 145 4.8e-11 
Ndi1p NP_013586 Mitochondrial ETC 8 18 128 2.4e-09 
Sdh1p NP_012774 Mitochondrial TCA cycle and 
ETC 
9 15 134 6e-10   
Cyt1p NP_014708 Mitochondrial ETC 5 22 94 5.5e-06   
Hem14p NP_010930 Heme synthesis in 9 20 140 1.5e-10 
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mitochondria 
Cyc3p NP_009361 Heme attachment to apo-
cytochrome c 
5 18 94 5.6e-06   
Ssq1p NP_013473 Assembly of Fe/S clusters into 
proteins 
7 12 102 9.5e-07 
Sod2p NP_011872 Detoxification of ROS in 
mitochondria 
6 30 119 1.9e-08 
Prx1p NP_009489 Detoxification of ROS in 
mitochondria 
8 31 148 2.4e-11   
Atp1p NP_009453 Mitochondrial ATP synthase 7 17 116 3.8e-08   
Atp2p NP_012655 Mitochondrial ATP synthase 7 17 116 3.8e-08 
Pet9p NP_009523 Mitochondrial ADP/ATP 
carrier 
5 17 85 5.2e-05 
Mir1p NP_012611 Mitochondrial phosphate 
carrier 
5 20 93 7.2e-06 
YP + 2% glucose; Day 4 (PD phase) 
Tps1p NP_009684 Trehalose biosynthesis 7 18 114 6e-08 
Tps2p NP_010359 Trehalose biosynthesis 9 9 115 1.7e-05   
Ath1p NP_015351 Trehalose degradation 9 7 113 7.6e-08 
Nth1p NP_010284 Trehalose degradation 8 11 108 2.4e-07 
Nth2p NP_009555 Trehalose degradation 7 11 101 1.2e-06   
Glg2p NP_012398 Glycogen biosynthesis 8 22 140 1.5e-10 
Glc3p NP_010905 Glycogen biosynthesis 10 15 146 3.8e-11   
Gsy2p NP_013359 Glycogen biosynthesis 9 14 131 1.2e-09 
Gph1p NP_015486 Glycogen degradation 9 12 127 3e-09 
Gpt2p NP_012993 Biosynthesis of TAG 10 14 135 4.8e-10 
Ayr1p NP_012142 Biosynthesis of TAG 7 34 135 4.8e-10 
Slc1p NP_010231 Biosynthesis of TAG 6 26 107 3e-07 
Pah1p NP_013888 Biosynthesis of TAG 6 8 86 3.5e-05 
Lpp1p NP_010791 Biosynthesis of TAG 5 19 94 5.7e-06 
Dga1p NP_014888 Biosynthesis of TAG 6 17 102 9.5e-07   
Are2p NP_014416 Biosynthesis of TAG and EE 5 7 76 0.00041 
Tgl1p NP_012782 Degradation of EE 6 15 103 7.6e-07 
Tgl3p NP_014044 Degradation of TAG 6 10 92 8.9e-06 
Tgl4p NP_013015 Degradation of TAG 8 11 114 6e-08   
Tgl5p NP_014724 Degradation of TAG 7 10 96 3.4e-06 
Yeh1p NP_013089 Degradation of EE 6 13 94 5.7e-06 
Fat1p NP_009597 Conversion of FFA to FA-
CoA 
7 13 108 2.4e-07 
Faa1p NP_014962 Conversion of FFA to FA-
CoA 
6 10 89 1.9e-05 
Faa2p NP_010931 Conversion of FFA to FA-
CoA 
7 12 106 3.8e-07   
Faa4p NP_013974 Conversion of FFA to FA-
CoA 
10 15 147 3e-11  
Fox1p NP_011310 Peroxisomal oxidation of FA-
CoA 
6 9 85 4.7e-05 
Fox2p NP_012934 Peroxisomal oxidation of FA-
CoA 
7 11 102 9.5e-07 
Fox3p NP_012106 Peroxisomal oxidation of FA-
CoA 
6 21 108 2.4e-07   
Adh1p NP_014555 Ethanol biosynthesis 8 27 145 4.8e-11 
Adh2p NP_014032 Ethanol oxidation 8 27 145 4.8e-11 
Pyc1p NP_011453 Gluconeogenesis 8 9 98 2.3e-06 
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Pck1p NP_013023 Gluconeogenesis 6 14 99 1.9e-06   
Fbp1p NP_013481 Gluconeogenesis 6 22 107 3e-07 
Pda1p NP_011105 Mitochondrial PDH complex 6 14 96 4.2e-06   
Aco1p NP_013407 Mitochondrial TCA cycle 11 17 160 1.5e-12 
Ndi1p NP_013586 Mitochondrial ETC 7 16 113 7.6e-08 
Sdh1p NP_012774 Mitochondrial TCA cycle and 
ETC 
7 12 105 4.8e-07   
Cyt1p NP_014708 Mitochondrial ETC 5 28 99 1.8e-06 
Hem14p NP_010930 Heme synthesis in 
mitochondria 
8 18 124 6e-09   
Cyc3p NP_009361 Heme attachment to apo-
cytochrome c 
6 22 113 7.6e-08 
Ssq1p NP_013473 Assembly of Fe/S clusters into 
proteins 
7 12 102 9.5e-07 
Sod2p NP_011872 Detoxification of ROS in 
mitochondria 
5 29 102 9.5e-07 
Prx1p NP_009489 Detoxification of ROS in 
mitochondria 
4 18 75 0.00046 
Atp1p NP_009453 Mitochondrial ATP synthase 8 19 132 9.5e-10 
Atp2p NP_012655 Mitochondrial ATP synthase 9 20 148 2.4e-11   
Pet9p NP_009523 Mitochondrial ADP/ATP 
carrier 
5 17 85 5.2e-05 
Mir1p NP_012611 Mitochondrial phosphate 
carrier 
7 27 130 1.5e-09   
YP + 0.2% glucose; Day 9 (ST phase) 
Tps1p NP_009684 Trehalose biosynthesis 7 18 114 6e-08 
Tps2p NP_010359 Trehalose biosynthesis 9 9 115 1.7e-05   
Ath1p NP_015351 Trehalose degradation 9 7 110 1.5e-07 
Nth1p NP_010284 Trehalose degradation 6 9 84 5.9e-05 
Nth2p NP_009555 Trehalose degradation 7 11 101 1.2e-06   
Glg2p NP_012398 Glycogen biosynthesis 7 18 120 1.5e-08 
Glc3p NP_010905 Glycogen biosynthesis 9 13 133 7.6e-10 
Gsy2p NP_013359 Glycogen biosynthesis 9 14 131 1.2e-09 
Gph1p NP_015486 Glycogen degradation 10 13 141 1.2e-10 
Gpt2p NP_012993 Biosynthesis of TAG 8 11 116 3.8e-08 
Ayr1p NP_012142 Biosynthesis of TAG 6 28 112 9.5e-08 
Slc1p NP_010231 Biosynthesis of TAG 6 26 107 3e-07 
Pah1p NP_013888 Biosynthesis of TAG 7 9 97 2.9e-06   
Lpp1p NP_010791 Biosynthesis of TAG 5 19 94 5.7e-06 
Dga1p NP_014888 Biosynthesis of TAG 6 17 102 9.5e-07   
Are2p NP_014416 Biosynthesis of TAG and EE 5 7 76 0.00041 
Tgl1p NP_012782 Degradation of EE 6 15 103 7.6e-07 
Tgl3p NP_014044 Degradation of TAG 5 8 76 0.00041   
Tgl4p NP_013015 Degradation of TAG 11 14 154 6e-12 
Tgl5p NP_014724 Degradation of TAG 6 9 84 6.7e-05   
Yeh1p NP_013089 Degradation of EE 6 13 94 5.7e-06 
Fat1p NP_009597 Conversion of FFA to FA-
CoA 
5 10 77 0.0003   
Faa1p NP_014962 Conversion of FFA to FA-
CoA 
5 9 76 0.00035 
Faa2p NP_010931 Conversion of FFA to FA-
CoA 
7 12 106 3.8e-07   
Faa4p NP_013974 Conversion of FFA to FA-
CoA 
10 15 147 3e-11  
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Fox1p NP_011310 Peroxisomal oxidation of FA-
CoA 
6 9 85 4.7e-05 
Fox2p NP_012934 Peroxisomal oxidation of FA-
CoA 
8 12 115 4.8e-08 
Fox3p NP_012106 Peroxisomal oxidation of FA-
CoA 
6 21 105 4.8e-07 
Adh1p NP_014555 Ethanol biosynthesis 8 27 145 4.8e-11 
Adh2p NP_014032 Ethanol oxidation 11 37 199 1.9e-16  
Pyc1p NP_011453 Gluconeogenesis 7 8 90 1.6e-05 
Pck1p NP_013023 Gluconeogenesis 9 20 146 3.8e-11 
Fbp1p NP_013481 Gluconeogenesis 6 22 107 3e-07 
Pda1p NP_011105 Mitochondrial PDH complex 6 14 96 4.2e-06   
Aco1p NP_013407 Mitochondrial TCA cycle 10 15 143 7.6e-11   
Ndi1p NP_013586 Mitochondrial ETC 8 18 128 2.4e-09 
Sdh1p NP_012774 Mitochondrial TCA cycle and 
ETC 
10 17 147 3e-11   
Cyt1p NP_014708 Mitochondrial ETC 6 26 113 7.6e-08 
Hem14p NP_010930 Heme synthesis in 
mitochondria 
8 18 125 4.8e-09 
Cyc3p NP_009361 Heme attachment to apo-
cytochrome c 
5 19 95 5.2e-06   
Ssq1p NP_013473 Assembly of Fe/S clusters into 
proteins 
7 12 102 9.5e-07 
Sod2p NP_011872 Detoxification of ROS in 
mitochondria 
5 29 102 9.5e-07 
Prx1p NP_009489 Detoxification of ROS in 
mitochondria 
5 21 93  6.9e-06 
Atp1p NP_009453 Mitochondrial ATP synthase 7 17 116 3.8e-08   
Atp2p NP_012655 Mitochondrial ATP synthase 6 15 100 1.6e-06 
Pet9p NP_009523 Mitochondrial ADP/ATP 
carrier 
8 27 136 8.1e-08   
Mir1p NP_012611 Mitochondrial phosphate 
carrier 
5 20 93 7.2e-06 
YP + 0.5% glucose; Day 9 (ST phase) 
Tps1p NP_009684 Trehalose biosynthesis 6 15 100 1.6e-06 
Tps2p NP_010359 Trehalose biosynthesis 7 8 90 1.4e-05 
Ath1p NP_015351 Trehalose degradation 10 8 122 9.5e-09 
Nth1p NP_010284 Trehalose degradation 6 9 84 5.9e-05 
Nth2p NP_009555 Trehalose degradation 8 12 117 3e-08 
Glg2p NP_012398 Glycogen biosynthesis 6 17 105 4.8e-07 
Glc3p NP_010905 Glycogen biosynthesis 10 15 143 2.7e-08 
Gsy2p NP_013359 Glycogen biosynthesis 7 12 106 3.8e-07 
Gph1p NP_015486 Glycogen degradation 9 12 127 3e-09 
Gpt2p NP_012993 Biosynthesis of TAG 8 11 116 3.8e-08 
Ayr1p NP_012142 Biosynthesis of TAG 6 28 112 9.5e-08 
Slc1p NP_010231 Biosynthesis of TAG 8 32 142 9.5e-11   
Pah1p NP_013888 Biosynthesis of TAG 6 8 86 3.5e-05 
Lpp1p NP_010791 Biosynthesis of TAG 5 19 94 5.7e-06 
Dga1p NP_014888 Biosynthesis of TAG 6 17 102 9.5e-07   
Are2p NP_014416 Biosynthesis of TAG and EE 6 9 91 1.2e-05 
Tgl1p NP_012782 Degradation of EE 6 15 103 7.6e-07 
Tgl3p NP_014044 Degradation of TAG 6 10 92 8.9e-06 
Tgl4p NP_013015 Degradation of TAG 10 14 141 1.2e-10   
Tgl5p NP_014724 Degradation of TAG 7 10 96 3.4e-06 
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Yeh1p NP_013089 Degradation of EE 8 16 128 2.4e-09   
Fat1p NP_009597 Conversion of FFA to FA-
CoA 
7 14 109 1.9e-07 
Faa1p NP_014962 Conversion of FFA to FA-
CoA 
6 10 89 1.9e-05 
Faa2p NP_010931 Conversion of FFA to FA-
CoA 
7 12 106 3.8e-07   
Faa4p NP_013974 Conversion of FFA to FA-
CoA 
8 13 121 1.2e-08 
Fox1p NP_011310 Peroxisomal oxidation of FA-
CoA 
7 11 93 7.6e-06   
Fox2p NP_012934 Peroxisomal oxidation of FA-
CoA 
7 11 102 9.5e-07 
Fox3p NP_012106 Peroxisomal oxidation of FA-
CoA 
4 16 74 0.00064 
Adh1p NP_014555 Ethanol biosynthesis 8 27 145 4.8e-11 
Adh2p NP_014032 Ethanol oxidation 11 37 199 1.9e-16  
Pyc1p NP_011453 Gluconeogenesis 8 9 98 2.3e-06 
Pck1p NP_013023 Gluconeogenesis 9 20 146 3.8e-11 
Fbp1p NP_013481 Gluconeogenesis 6 22 107 3e-07 
Pda1p NP_011105 Mitochondrial PDH complex 6 14 96 4.2e-06   
Aco1p NP_013407 Mitochondrial TCA cycle 10 15 143 7.6e-11   
Ndi1p NP_013586 Mitochondrial ETC 7 16 113 7.6e-08 
Sdh1p NP_012774 Mitochondrial TCA cycle and 
ETC 
7 12 105 4.8e-07   
Cyt1p NP_014708 Mitochondrial ETC 5 28 99 1.8e-06 
Hem14p NP_010930 Heme synthesis in 
mitochondria 
8 18 124 6e-09   
Cyc3p NP_009361 Heme attachment to apo-
cytochrome c 
5 18 94 5.6e-06   
Ssq1p NP_013473 Assembly of Fe/S clusters into 
proteins 
7 12 102 9.5e-07 
Sod2p NP_011872 Detoxification of ROS in 
mitochondria 
5 29 102 9.5e-07 
Prx1p NP_009489 Detoxification of ROS in 
mitochondria 
8 31 148 2.4e-11   
Atp1p NP_009453 Mitochondrial ATP synthase 10 22 164 6e-13   
Atp2p NP_012655 Mitochondrial ATP synthase 7 17 116 3.8e-08 
Pet9p NP_009523 Mitochondrial ADP/ATP 
carrier 
5 17 85 5.2e-05 
Mir1p NP_012611 Mitochondrial phosphate 
carrier 
7 26 129 1.9e-09   
YP + 1% glucose; Day 9 (ST phase) 
Tps1p NP_009684 Trehalose biosynthesis 7 18 117 3e-08   
Tps2p NP_010359 Trehalose biosynthesis 9 9 115 1.7e-05   
Ath1p NP_015351 Trehalose degradation 9 7 113 7.6e-08 
Nth1p NP_010284 Trehalose degradation 6 9 84 5.9e-05 
Nth2p NP_009555 Trehalose degradation 7 11 101 1.2e-06   
Glg2p NP_012398 Glycogen biosynthesis 7 18 120 1.5e-08 
Glc3p NP_010905 Glycogen biosynthesis 8 12 115 4.8e-08 
Gsy2p NP_013359 Glycogen biosynthesis 9 14 131 1.2e-09 
Gph1p NP_015486 Glycogen degradation 10 13 141 1.2e-10 
Gpt2p NP_012993 Biosynthesis of TAG 8 11 116 3.8e-08 
Ayr1p NP_012142 Biosynthesis of TAG 6 28 112 9.5e-08 
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Slc1p NP_010231 Biosynthesis of TAG 8 32 142 9.5e-11   
Pah1p NP_013888 Biosynthesis of TAG 6 8 86 3.5e-05 
Lpp1p NP_010791 Biosynthesis of TAG 5 19 94 5.7e-06 
Dga1p NP_014888 Biosynthesis of TAG 6 17 102 9.5e-07   
Are2p NP_014416 Biosynthesis of TAG and EE 5 7 76 0.00041 
Tgl1p NP_012782 Degradation of EE 6 15 103 7.6e-07 
Tgl3p NP_014044 Degradation of TAG 5 8 76 0.00041   
Tgl4p NP_013015 Degradation of TAG 10 14 141 1.2e-10   
Tgl5p NP_014724 Degradation of TAG 5 7 69 0.0017   
Yeh1p NP_013089 Degradation of EE 8 17 129 1.9e-09 
Fat1p NP_009597 Conversion of FFA to FA-
CoA 
7 13 108 2.4e-07 
Faa1p NP_014962 Conversion of FFA to FA-
CoA 
6 10 89 1.9e-05 
Faa2p NP_010931 Conversion of FFA to FA-
CoA 
7 12 106 3.8e-07   
Faa4p NP_013974 Conversion of FFA to FA-
CoA 
8 13 121 1.2e-08 
Fox1p NP_011310 Peroxisomal oxidation of FA-
CoA 
7 11 93 7.6e-06   
Fox2p NP_012934 Peroxisomal oxidation of FA-
CoA 
7 11 102 9.5e-07 
Fox3p NP_012106 Peroxisomal oxidation of FA-
CoA 
4 16 74 0.00064 
Adh1p NP_014555 Ethanol biosynthesis 8 27 145 4.8e-11 
Adh2p NP_014032 Ethanol oxidation 11 37 199 1.9e-16  
Pyc1p NP_011453 Gluconeogenesis 8 9 98 2.3e-06 
Pck1p NP_013023 Gluconeogenesis 9 20 146 3.8e-11 
Fbp1p NP_013481 Gluconeogenesis 6 22 107 3e-07 
Pda1p NP_011105 Mitochondrial PDH complex 7 17 109 1.9e-07   
Aco1p NP_013407 Mitochondrial TCA cycle 10 15 145 4.8e-11 
Ndi1p NP_013586 Mitochondrial ETC 6 15 98 2.7e-06 
Sdh1p NP_012774 Mitochondrial TCA cycle and 
ETC 
10 17 147 3e-11   
Cyt1p NP_014708 Mitochondrial ETC 6 26 113 7.6e-08 
Hem14p NP_010930 Heme synthesis in 
mitochondria 
11 23 169 1.9e-13 
Cyc3p NP_009361 Heme attachment to apo-
cytochrome c 
6 22 113 7.6e-08 
Ssq1p NP_013473 Assembly of Fe/S clusters into 
proteins 
10 16 145 4.8e-11   
Sod2p NP_011872 Detoxification of ROS in 
mitochondria 
5 26 99 1.7e-06   
Prx1p NP_009489 Detoxification of ROS in 
mitochondria 
8 31 148 2.4e-11   
Atp1p NP_009453 Mitochondrial ATP synthase 8 19 132 9.5e-10 
Atp2p NP_012655 Mitochondrial ATP synthase 9 20 148 2.4e-11   
Pet9p NP_009523 Mitochondrial ADP/ATP 
carrier 
6 20 102 9.5e-07 
Mir1p NP_012611 Mitochondrial phosphate 
carrier 
7 27 130 1.5e-09   
YP + 2% glucose; Day 9 (ST phase) 
Tps1p NP_009684 Trehalose biosynthesis 6 15 100 1.6e-06 
Tps2p NP_010359 Trehalose biosynthesis 8 8 107  3e-07   
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Ath1p NP_015351 Trehalose degradation 10 8 122 9.5e-09 
Nth1p NP_010284 Trehalose degradation 8 11 108 2.4e-07 
Nth2p NP_009555 Trehalose degradation 10 14 145 4.8e-11 
Glg2p NP_012398 Glycogen biosynthesis 6 17 105 4.8e-07 
Glc3p NP_010905 Glycogen biosynthesis 8 12 115 4.8e-08 
Gsy2p NP_013359 Glycogen biosynthesis 9 14 131 1.2e-09 
Gph1p NP_015486 Glycogen degradation 12 15 164 6e-13 
Gpt2p NP_012993 Biosynthesis of TAG 8 11 110 1.5e-07   
Ayr1p NP_012142 Biosynthesis of TAG 7 34 135 4.8e-10 
Slc1p NP_010231 Biosynthesis of TAG 8 32 138 2.4e-10 
Pah1p NP_013888 Biosynthesis of TAG 8 11 114 6e-08 
Lpp1p NP_010791 Biosynthesis of TAG 4 16 76 0.00041 
Dga1p NP_014888 Biosynthesis of TAG 7 19 121 1.2e-08 
Are2p NP_014416 Biosynthesis of TAG and EE 5 7 76 0.00041 
Tgl1p NP_012782 Degradation of EE 5 12 83 8.1e-05 
Tgl3p NP_014044 Degradation of TAG 5 8 76 0.00041   
Tgl4p NP_013015 Degradation of TAG 8 11 114 6e-08   
Tgl5p NP_014724 Degradation of TAG 7 10 96 3.4e-06 
Yeh1p NP_013089 Degradation of EE 6 13 94 5.7e-06 
Fat1p NP_009597 Conversion of FFA to FA-
CoA 
5 10 74 0.00057   
Faa1p NP_014962 Conversion of FFA to FA-
CoA 
8 12 120 1.5e-08   
Faa2p NP_010931 Conversion of FFA to FA-
CoA 
6 10 90 1.3e-05 
Faa4p NP_013974 Conversion of FFA to FA-
CoA 
8 13 121 1.2e-08 
Fox1p NP_011310 Peroxisomal oxidation of FA-
CoA 
9 13 125 4.8e-09   
Fox2p NP_012934 Peroxisomal oxidation of FA-
CoA 
8 12 115 4.8e-08 
Fox3p NP_012106 Peroxisomal oxidation of FA-
CoA 
6 21 108 2.4e-07   
Adh1p NP_014555 Ethanol biosynthesis 7 24 127 3e-09   
Adh2p NP_014032 Ethanol oxidation 11 37 199 1.9e-16  
Pyc1p NP_011453 Gluconeogenesis 8 9 98 2.3e-06 
Pck1p NP_013023 Gluconeogenesis 7 17 115 4.8e-08 
Fbp1p NP_013481 Gluconeogenesis 5 18 92 1.1e-05  
Pda1p NP_011105 Mitochondrial PDH complex 7 17 109 1.9e-07   
Aco1p NP_013407 Mitochondrial TCA cycle 10 15 143 7.6e-11   
Ndi1p NP_013586 Mitochondrial ETC 6 14 97 3.2e-06   
Sdh1p NP_012774 Mitochondrial TCA cycle and 
ETC 
9 15 134 6e-10   
Cyt1p NP_014708 Mitochondrial ETC 5 28 99 1.8e-06 
Hem14p NP_010930 Heme synthesis in 
mitochondria 
8 18 124 6e-09   
Cyc3p NP_009361 Heme attachment to apo-
cytochrome c 
5 19 95 5.2e-06   
Ssq1p NP_013473 Assembly of Fe/S clusters into 
proteins 
7 12 102 9.5e-07 
Sod2p NP_011872 Detoxification of ROS in 
mitochondria 
6 30 119 1.9e-08 
Prx1p NP_009489 Detoxification of ROS in 
mitochondria 
8 30 147 3e-11   
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Atp1p NP_009453 Mitochondrial ATP synthase 8 19 132 9.5e-10 
Atp2p NP_012655 Mitochondrial ATP synthase 9 20 148 2.4e-11   
Pet9p NP_009523 Mitochondrial ADP/ATP 
carrier 
5 17 85 5.2e-05 
Mir1p NP_012611 Mitochondrial phosphate 
carrier 
7 26 129 1.9e-09   
 
1
The probability based Mowse score for comparing the calculated peptide masses for each entry in the 
sequence database with the set of experimental mass spectrometry data; Mowse scores greater than 54 are 
significant (p < 0.05). 
2
The expectation value for the matching peptides, which provides the number of matches with equal or 
better Mowse scores that are expected to occur by chance alone. 
 
 
Table 3.2. Relative levels of proteins recovered in total lysates of WT cells cultured in YP medium initially 
containing 0.2%, 0.5%, 1% or 2% glucose. For making total lysates, cells were collected at day 1 (L phase), 
day 2 (D phase), day 4 (PD phase) and day 9 (ST phase). Proteins were identified and quantified using 
MALDI MS peptide mapping. Relative protein levels are presented as fold difference relative to that on 2% 
glucose. 
 
Protein  NCBI 
accession 
no. 
Function Protein level 
Glucose concentration (%)  
0.2 0.5 1 2 
Day 1 (L phase) 
Tps1p NP_009684 Trehalose biosynthesis 1.22 ± 0.31 1.42 ± 0.13 1.14 ± 0.43 1 
Tps2p NP_010359 Trehalose biosynthesis 0.92 ± 0.13 1.34 ± 0.32 1.21 ± 0.24 1 
Ath1p NP_015351 Trehalose degradation 0.80 ± 0.22 1.12 ± 0.43 1.36 ± 0.12 1 
Nth1p NP_010284 Trehalose degradation 0.37 ± 0.04 0.68 ± 0.11 0.91 ± 0.15 1 
Nth2p NP_009555 Trehalose degradation 1.14 ± 0.29 0.86 ± 0.18 0.88 ± 0.11 1 
Glg2p NP_012398 Glycogen biosynthesis 1.25 ± 0.21 1.37 ± 0.30 1.18 ± 0.24 1 
Glc3p NP_010905 Glycogen biosynthesis 0.89 ± 0.14 1.18 ± 0.27 0.93 ± 0.17 1 
Gsy2p NP_013359 Glycogen biosynthesis 1.26 ± 0.33 1.19 ± 0.46 0.88 ± 0.28 1 
Gph1p NP_015486 Glycogen degradation 0.79 ± 0.17 0.93 ± 0.28 1.28 ± 0.24 1 
Gpt2p NP_012993 Biosynthesis of TAG 0.41 ± 0.07 0.28 ± 0.09 0.87 ± 0.13 1 
Ayr1p NP_012142 Biosynthesis of TAG 0.92 ± 0.18 0.88 ± 0.29 1.19 ± 0.33 1 
Slc1p NP_010231 Biosynthesis of TAG 0.30 ± 0.08 0.22 ± 0.06 0.92 ± 0.21 1 
Pah1p NP_013888 Biosynthesis of TAG 1.08 ± 0.26 0.82 ± 0.22 1.21 ± 0.15 1 
Lpp1p NP_010791 Biosynthesis of TAG 0.44 ± 0.07 0.26 ± 0.09 0.83 ± 0.21 1 
Dga1p NP_014888 Biosynthesis of TAG 0.71 ± 0.24 0.35 ± 0.04 1.32 ± 0.41 1 
Are2p NP_014416 Biosynthesis of TAG and EE 0.26 ± 0.11 0.21 ± 0.05 0.81 ± 0.22 1 
Tgl1p NP_012782 Degradation of EE 1.31 ± 0.33 2.51 ± 0.23 1.19 ± 0.13 1 
Tgl3p NP_014044 Degradation of TAG 2.73 ± 0.15 3.46 ± 0.32 1.42 ± 0.25 1 
Tgl4p NP_013015 Degradation of TAG 1.69 ± 0.27 2.78 ± 0.41 1.29 ± 0.23 1 
Tgl5p NP_014724 Degradation of TAG 1.48 ± 0.34 1.72 ± 0.23 1.07 ± 0.41 1 
Yeh1p NP_013089 Degradation of EE 2.81 ± 0.42 3.69 ± 0.31 1.46 ± 0.33 1 
Fat1p NP_009597 Conversion of FFA to FA-CoA 0.44 ± 0.12 0.88 ± 0.20 1.14 ± 0.27 1 
Faa1p NP_014962 Conversion of FFA to FA-CoA 1.72 ± 0.33 2.49 ± 0.28 0.91 ± 0.29 1 
Faa2p NP_010931 Conversion of FFA to FA-CoA 1.43 ± 0.28 1.67 ± 0.41 1.22 ± 0.32 1 
Faa4p NP_013974 Conversion of FFA to FA-CoA 1.59 ± 0.33 2.83 ± 0.19 1.30 ± 0.41 1 
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Fox1p NP_011310 Peroxisomal oxidation of FA-CoA 1.77 ± 0.21 1.59 ± 0.32 1.17 ± 0.19 1 
Fox2p NP_012934 Peroxisomal oxidation of FA-CoA 1.19 ± 0.13 1.31 ± 0.42 0.79 ± 0.18 1 
Fox3p NP_012106 Peroxisomal oxidation of FA-CoA 1.62 ± 0.31 1.47 ± 0.19 1.31 ± 0.42 1 
Adh1p NP_014555 Ethanol biosynthesis 0.29 ± 0.08 0.37 ± 0.11 0.88 ± 0.13 1 
Adh2p NP_014032 Ethanol oxidation 5.21 ± 0.53 5.73 ± 0.39 2.28 ± 0.21 1 
Pyc1p NP_011453 Gluconeogenesis 2.39 ± 0.31 1.76 ± 0.17 1.27 ± 0.32 1 
Pck1p NP_013023 Gluconeogenesis 1.33 ± 0.15 1.47 ± 0.29 0.84 ± 0.12 1 
Fbp1p NP_013481 Gluconeogenesis 1.79 ± 0.27 1.56 ± 0.18 1.31 ± 0.37 1 
Pda1p NP_011105 Mitochondrial PDH complex 2.49 ± 0.31 1.72 ± 0.31 1.19 ± 0.25 1 
Aco1p NP_013407 Mitochondrial TCA cycle 2.73 ± 0.23 1.59 ± 0.16 1.24 ± 0.13 1 
Ndi1p NP_013586 Mitochondrial ETC 1.89 ± 0.29 1.28 ± 0.31 0.89 ± 0.16 1 
Sdh1p NP_012774 Mitochondrial TCA cycle and ETC 1.43 ± 0.13 1.22 ± 0.22 1.17 ± 0.33 1 
Cyt1p NP_014708 Mitochondrial ETC 1.58 ± 0.24 1.39 ± 0.18 1.28 ± 0.29 1 
Hem14p NP_010930 Heme synthesis in mitochondria 1.65 ± 0.19 1.43 ± 0.28 1.41 ± 0.21 1 
Cyc3p NP_009361 Heme attachment to apo-cytochrome c 0.89 ± 0.13 1.21 ± 0.24 0.91 ± 0.17 1 
Ssq1p NP_013473 Assembly of Fe/S clusters into proteins 1.33 ± 0.32 1.19 ± 0.21 1.41 ± 0.31 1 
Sod2p NP_011872 Detoxification of ROS in mitochondria 0.79 ± 0.08 0.83 ± 0.19 1.22 ± 0.24 1 
Prx1p NP_009489 Detoxification of ROS in mitochondria 1.42 ± 0.32 1.76 ± 0.23 0.81 ± 0.17 1 
Atp1p NP_009453 Mitochondrial ATP synthase 1.17 ± 0.16 1.53 ± 0.29 1.33 ± 0.32 1 
Atp2p NP_012655 Mitochondrial ATP synthase 1.34 ± 0.27 1.47 ± 0.33 0.79 ± 0.09 1 
Pet9p NP_009523 Mitochondrial ADP/ATP carrier 1.39 ± 0.12 1.45 ± 0.31 1.08 ± 0.21 1 
Mir1p NP_012611 Mitochondrial phosphate carrier 1.59 ± 0.21 1.32 ± 0.28 0.86 ± 0.16 1 
Day 2 (D phase) 
Tps1p NP_009684 Trehalose biosynthesis 1.79 ± 0.33 2.67 ± 0.29 1.28 ± 0.18 1 
Tps2p NP_010359 Trehalose biosynthesis 1.34 ± 0.22 2.82 ± 0.34 0.91 ± 0.21 1 
Ath1p NP_015351 Trehalose degradation 0.87 ± 0.13 0.76 ± 0.26 1.23 ± 0.17 1 
Nth1p NP_010284 Trehalose degradation 0.38 ± 0.08 0.81 ± 0.21 1.34 ± 0.32 1 
Nth2p NP_009555 Trehalose degradation 0.69 ± 0.13 1.23 ± 0.30   0.93 ± 0.14 1 
Glg2p NP_012398 Glycogen biosynthesis 1.71 ± 0.21 2.56 ± 0.15 1.44 ± 0.33 1 
Glc3p NP_010905 Glycogen biosynthesis 1.85 ± 0.13 2.78 ± 0.31 1.19 ± 0.19 1 
Gsy2p NP_013359 Glycogen biosynthesis 3.59 ± 0.61 4.72 ± 0.52 2.24 ± 0.21 1 
Gph1p NP_015486 Glycogen degradation 0.38 ± 0.11 0.43 ± 0.34 0.82 ± 0.17 1 
Gpt2p NP_012993 Biosynthesis of TAG 0.28 ± 0.08 0.21 ± 0.06 0.45 ± 0.07 1 
Ayr1p NP_012142 Biosynthesis of TAG 0.34 ± 0.05 0.22 ± 0.03 0.76 ± 0.18 1 
Slc1p NP_010231 Biosynthesis of TAG 0.21 ± 0.06 0.25 ± 0.09 0.85 ± 0.21 1 
Pah1p NP_013888 Biosynthesis of TAG 0.44 ± 0.09 0.29 ± 0.05 1.21 ± 0.33 1 
Lpp1p NP_010791 Biosynthesis of TAG 0.26 ± 0.03 0.22 ± 0.07 0.87 ± 0.20 1 
Dga1p NP_014888 Biosynthesis of TAG 0.47 ± 0.13 0.31 ± 0.08 0.93 ± 0.32 1 
Are2p NP_014416 Biosynthesis of TAG and EE 0.20 ± 0.05 0.24 ± 0.07 0.46 ± 0.12 1 
Tgl1p NP_012782 Degradation of EE 3.63 ± 0.51 4.59 ± 0.44 1.28 ± 0.26 1 
Tgl3p NP_014044 Degradation of TAG 4.84 ± 0.32  5.66 ± 0.58 1.17 ± 0.15 1 
Tgl4p NP_013015 Degradation of TAG 3.47 ± 0.42 4.79 ± 0.31 0.89 ± 0.11  1 
Tgl5p NP_014724 Degradation of TAG 1.67 ± 0.23  2.33 ± 0.31 1.28 ± 0.19 1 
Yeh1p NP_013089 Degradation of EE 4.78 ± 0.43 5.29 ± 0.67  1.67 ± 0.32 1 
Fat1p NP_009597 Conversion of FFA to FA-CoA 2.87 ± 0.33 3.45 ± 0.49 1.34 ± 0.21 1 
Faa1p NP_014962 Conversion of FFA to FA-CoA 3.59 ± 0.54 5.84 ± 0.66 1.74 ± 0.19 1 
Faa2p NP_010931 Conversion of FFA to FA-CoA 2.77 ± 0.34 3.83 ± 0.49 1.36 ± 0.31 1 
Faa4p NP_013974 Conversion of FFA to FA-CoA 4.39 ± 0.53  5.67 ± 0.71  1.73 ± 0.49 1 
Fox1p NP_011310 Peroxisomal oxidation of FA-CoA 3.87 ± 0.45 3.39 ± 0.53 1.19 ± 0.32 1 
Fox2p NP_012934 Peroxisomal oxidation of FA-CoA 2.78 ± 0.33 1.81 ± 0.16 1.34 ± 0.43 1 
Fox3p NP_012106 Peroxisomal oxidation of FA-CoA 3.45 ± 0.56  2.73 ± 0.44  1.44 ± 0.17  1 
Adh1p NP_014555 Ethanol biosynthesis 0.22 ± 0.04 0.29 ± 0.09 0.87 ± 0.11 1 
Adh2p NP_014032 Ethanol oxidation 5.87 ± 0.56  5.95 ± 0.33  2.31 ± 0.47 1 
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Pyc1p NP_011453 Gluconeogenesis 5.69 ± 0.49 4.37 ± 0.52 2.23 ± 0.31 1 
Pck1p NP_013023 Gluconeogenesis 4.49 ± 0.32 4.25 ± 0.56 1.36 ± 0.23 1 
Fbp1p NP_013481 Gluconeogenesis 5.69 ± 0.67 4.48 ± 0.52 2.23 ± 0.37 1 
Pda1p NP_011105 Mitochondrial PDH complex 3.34 ± 0.42 2.59 ± 0.30 1.23 ± 0.13 1 
Aco1p NP_013407 Mitochondrial TCA cycle 3.69 ± 0.39 2.78 ± 0.41 1.36 ± 0.20  1 
Ndi1p NP_013586 Mitochondrial ETC 4.49 ± 0.13  2.34 ± 0.32 1.25 ± 0.17 1 
Sdh1p NP_012774 Mitochondrial TCA cycle and ETC 2.54 ± 0.33 1.49 ± 0.21 0.87 ± 0.15 1 
Cyt1p NP_014708 Mitochondrial ETC 2.76 ± 0.39 1.39 ± 0.44 0.74 ± 0.19 1 
Hem14p NP_010930 Heme synthesis in mitochondria 2.87 ± 0.37 2.56 ± 0.43 1.33 ± 0.21 1 
Cyc3p NP_009361 Heme attachment to apo-cytochrome c 2.91 ± 0.18 1.67 ± 0.32  1.18 ± 0.21 1 
Ssq1p NP_013473 Assembly of Fe/S clusters into proteins 4.45 ± 0.80 2.67 ± 0.28 0.81 ± 0.19 1 
Sod2p NP_011872 Detoxification of ROS in mitochondria 1.76 ± 0.45 2.80 ± 0.39 1.19 ± 0.16 1 
Prx1p NP_009489 Detoxification of ROS in mitochondria 2.34 ± 0.34 2.67 ± 0.48 0.76 ± 0.15  1 
Atp1p NP_009453 Mitochondrial ATP synthase 2.59 ± 0.41 2.73 ± 0.54 1.43 ± 0.23 1 
Atp2p NP_012655 Mitochondrial ATP synthase 2.76 ± 0.53 2.59 ± 0.33 1.14 ± 0.19 1 
Pet9p NP_009523 Mitochondrial ADP/ATP carrier 2.69 ± 0.34 3.76 ± 0.45 0.87 ± 0.11 1 
Mir1p NP_012611 Mitochondrial phosphate carrier 2.83 ± 0.44 3.59 ± 0.56 1.34 ± 0.17 1 
Day 4 (PD phase) 
Tps1p NP_009684 Trehalose biosynthesis 2.78 ± 0.33 3.56 ± 0.41 1.29 ± 0.23 1 
Tps2p NP_010359 Trehalose biosynthesis 2.89 ± 0.44 3.77 ± 0.23 1.17 ± 0.19 1 
Ath1p NP_015351 Trehalose degradation 0.35 ± 0.09 0.41 ± 0.05 1.25 ± 0.11 1 
Nth1p NP_010284 Trehalose degradation 0.27 ± 0.06 0.38 ± 0.04 0.87 ± 0.09 1 
Nth2p NP_009555 Trehalose degradation 0.39 ± 0.09 0.81 ± 0.11  1.23 ± 0.12  1 
Glg2p NP_012398 Glycogen biosynthesis 2.65 ± 0.22 4.19 ± 0.15 0.78 ± 0.23 1 
Glc3p NP_010905 Glycogen biosynthesis 2.78 ± 0.31 3.65 ± 0.22 1.34 ± 0.17 1 
Gsy2p NP_013359 Glycogen biosynthesis 4.78 ± 0.61 5.64 ± 0.43 1.45 ± 0.24 1 
Gph1p NP_015486 Glycogen degradation 0.30 ± 0.10 0.41 ± 0.08 0.88 ± 0.12 1 
Gpt2p NP_012993 Biosynthesis of TAG 0.27 ± 0.06 0.22 ± 0.04 0.45 ± 0.13 1 
Ayr1p NP_012142 Biosynthesis of TAG 0.35 ± 0.08 0.41 ± 0.09  0.86 ± 0.16 1 
Slc1p NP_010231 Biosynthesis of TAG 0.21 ± 0.04  0.17 ± 0.05 0.91 ± 0.21  1 
Pah1p NP_013888 Biosynthesis of TAG 0.38 ± 0.09 0.26 ± 0.07 1.23 ± 0.13 1 
Lpp1p NP_010791 Biosynthesis of TAG 0.34 ± 0.06 0.29 ± 0.04 0.88 ± 0.17 1 
Dga1p NP_014888 Biosynthesis of TAG 0.28 ± 0.03 0.22 ± 0.09 0.91 ± 0.28 1 
Are2p NP_014416 Biosynthesis of TAG and EE 0.21 ± 0.04 0.14 ± 0.02 0.77 ± 0.31 1 
Tgl1p NP_012782 Degradation of EE 4.67 ± 0.61 5.91 ± 0.52 1.34 ± 0.26 1 
Tgl3p NP_014044 Degradation of TAG 3.77 ± 0.43 4.29 ± 0.31 1.29 ± 0.13 1 
Tgl4p NP_013015 Degradation of TAG 3.56 ± 0.21 4.77 ± 0.49 1.59 ± 0.19 1 
Tgl5p NP_014724 Degradation of TAG 4.49 ± 0.60 5.73 ± 0.53 1.12 ± 0.21 1 
Yeh1p NP_013089 Degradation of EE 2.76 ± 0.32 3.34 ± 0.41 0.83 ± 0.27 1 
Fat1p NP_009597 Conversion of FFA to FA-CoA 4.81 ± 0.56 5.76 ± 0.38 1.53 ± 0.33 1 
Faa1p NP_014962 Conversion of FFA to FA-CoA 2.72 ± 0.34 3.49 ± 0.43 1.71 ± 0.41 1 
Faa2p NP_010931 Conversion of FFA to FA-CoA 4.34 ± 0.52 5.67 ± 0.35 1.19 ± 0.23 1 
Faa4p NP_013974 Conversion of FFA to FA-CoA 3.56 ± 0.41 4.49 ± 0.22 0.84 ± 0.11 1 
Fox1p NP_011310 Peroxisomal oxidation of FA-CoA 5.59 ± 0.53 5.87 ± 0.41 1.37 ± 0.23 1 
Fox2p NP_012934 Peroxisomal oxidation of FA-CoA 5.83 ± 0.61 5.61 ± 0.22 1.71 ± 0.41 1 
Fox3p NP_012106 Peroxisomal oxidation of FA-CoA 5.19 ± 0.33 5.49 ± 0.28 1.29 ± 0.12 1 
Adh1p NP_014555 Ethanol biosynthesis 0.22 ± 0.07 0.29 ± 0.04 0.78 ± 0.17 1 
Adh2p NP_014032 Ethanol oxidation 4.78 ± 0.49 4.56 ± 0.37 2.23 ± 0.22 1 
Pyc1p NP_011453 Gluconeogenesis 4.49 ± 0.51 2.77 ± 0.24 1.34 ± 0.19 1 
Pck1p NP_013023 Gluconeogenesis 4.83 ± 0.25 2.44 ± 0.19 0.86 ± 0.22 1 
Fbp1p NP_013481 Gluconeogenesis 4.78 ± 0.61 4.81 ± 0.52 1.39 ± 0.21 1 
Pda1p NP_011105 Mitochondrial PDH complex 4.63 ± 0.57 3.72 ± 0.33 1.17 ± 0.23 1 
Aco1p NP_013407 Mitochondrial TCA cycle 3.48 ± 0.35 2.71 ± 0.22 0.76 ± 0.23 1 
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Ndi1p NP_013586 Mitochondrial ETC 4.45 ± 0.52 3.59 ± 0.18 1.18 ± 0.17 1 
Sdh1p NP_012774 Mitochondrial TCA cycle and ETC 4.88 ± 0.38 3.32 ± 0.42 0.84 ± 0.24 1 
Cyt1p NP_014708 Mitochondrial ETC 4.56 ± 0.51 3.83 ± 0.23 1.32 ± 0.19 1 
Hem14p NP_010930 Heme synthesis in mitochondria 4.28 ± 0.33  3.49 ± 0.37 0.87 ± 0.28 1 
Cyc3p NP_009361 Heme attachment to apo-cytochrome c 3.77 ± 0.44 2.85 ± 0.20 0.79 ± 0.34 1 
Ssq1p NP_013473 Assembly of Fe/S clusters into proteins 4.55 ± 0.26 3.74 ± 0.42 0.92 ± 0.33 1 
Sod2p NP_011872 Detoxification of ROS in mitochondria 2.89 ± 0.32 4.53 ± 0.56 1.42 ± 0.29 1 
Prx1p NP_009489 Detoxification of ROS in mitochondria 3.65 ± 0.41 4.79 ± 0.39 1.23 ± 0.17 1 
Atp1p NP_009453 Mitochondrial ATP synthase 3.56 ± 0.24 4.45 ± 0.50 1.38 ± 0.21 1 
Atp2p NP_012655 Mitochondrial ATP synthase 3.79 ± 0.38 4.93 ± 0.27 1.67 ± 0.34 1 
Pet9p NP_009523 Mitochondrial ADP/ATP carrier 3.88 ± 0.23 3.57 ± 0.36 0.85 ± 0.19 1 
Mir1p NP_012611 Mitochondrial phosphate carrier 3.56 ± 0.38 3.74 ± 0.41 0.92 ± 0.23 1 
Day 9 (ST phase) 
Tps1p NP_009684 Trehalose biosynthesis 5.48 ± 0.34 4.72 ± 0.23 1.87 ± 0.28  1 
Tps2p NP_010359 Trehalose biosynthesis 5.54 ± 0.21 4.41 ± 0.42 2.29 ± 0.33 1 
Ath1p NP_015351 Trehalose degradation 0.36 ± 0.06 0.86 ± 0.18 1.16 ± 0.34 1 
Nth1p NP_010284 Trehalose degradation 0.42 ± 0.08 0.79 ± 0.26 1.29 ± 0.46 1 
Nth2p NP_009555 Trehalose degradation 0.27 ± 0.05 0.42 ± 0.08 0.83 ± 0.20 1 
Glg2p NP_012398 Glycogen biosynthesis 1.67 ± 0.45 1.89 ± 0.22 1.24 ± 0.17 1 
Glc3p NP_010905 Glycogen biosynthesis 1.78 ± 0.33 1.65 ± 0.16 1.15 ± 0.22 1 
Gsy2p NP_013359 Glycogen biosynthesis 3.67 ± 0.41 2.78 ± 0.23 1.45 ± 0.11 1 
Gph1p NP_015486 Glycogen degradation 1.34 ± 0.25 2.89 ± 0.16 1.31 ± 0.24 1 
Gpt2p NP_012993 Biosynthesis of TAG 0.75 ± 0.12 0.36 ± 0.28 1.29 ± 0.37 1 
Ayr1p NP_012142 Biosynthesis of TAG 0.83 ± 0.11 0.76 ± 0.23 1.37 ± 0.29 1 
Slc1p NP_010231 Biosynthesis of TAG 0.34 ± 0.04 0.42 ± 0.09 0.85 ± 0.12 1 
Pah1p NP_013888 Biosynthesis of TAG 0.43 ± 0.06 0.35 ± 0.04 1.24 ± 0.09 1 
Lpp1p NP_010791 Biosynthesis of TAG 0.77 ± 0.16 0.42 ± 0.07 0.92 ± 0.22 1 
Dga1p NP_014888 Biosynthesis of TAG 0.89 ± 0.12 0.35 ± 0.05 1.56 ± 0.17 1 
Are2p NP_014416 Biosynthesis of TAG and EE 0.34 ± 0.07 0.46 ± 0.09 0.83 ± 0.22 1 
Tgl1p NP_012782 Degradation of EE 2.87 ± 0.18 2.95 ± 0.34 2.28 ± 0.13 1 
Tgl3p NP_014044 Degradation of TAG 1.82 ± 0.27 2.73 ± 0.42 1.57 ± 0.38 1 
Tgl4p NP_013015 Degradation of TAG 1.78 ± 0.31 1.86 ± 0.23 0.76 ± 0.12 1 
Tgl5p NP_014724 Degradation of TAG 2.87 ± 0.42 3.79 ± 0.54 1.59 ± 0.33 1 
Yeh1p NP_013089 Degradation of EE 1.43 ± 0.21 1.84 ± 0.36 1.17 ± 0.21 1 
Fat1p NP_009597 Conversion of FFA to FA-CoA 2.69 ± 0.37 3.77 ± 0.45 1.56 ± 0.30 1 
Faa1p NP_014962 Conversion of FFA to FA-CoA 1.56 ± 0.22 1.87 ± 0.34 1.29 ± 0.18 1 
Faa2p NP_010931 Conversion of FFA to FA-CoA 2.86 ± 0.41 2.73 ± 0.42 1.18 ± 0.16 1 
Faa4p NP_013974 Conversion of FFA to FA-CoA 1.39 ± 0.23 2.92 ± 0.37 0.67 ± 0.11 1 
Fox1p NP_011310 Peroxisomal oxidation of FA-CoA 4.45 ± 0.67 5.76 ± 0.73 2.23 ± 0.52 1 
Fox2p NP_012934 Peroxisomal oxidation of FA-CoA 4.69 ± 0.43 4.73 ± 0.55 1.72 ± 0.23 1 
Fox3p NP_012106 Peroxisomal oxidation of FA-CoA 4.46 ± 0.61 5.57 ± 0.38 2.34 ± 0.32 1 
Adh1p NP_014555 Ethanol biosynthesis 0.21 ± 0.06 0.29 ± 0.09 0.42 ± 0.13 1 
Adh2p NP_014032 Ethanol oxidation 4.67 ± 0.62 4.85 ± 0.54 2.48 ± 0.29 1 
Pyc1p NP_011453 Gluconeogenesis 2.68 ± 0.35 1.73 ± 0.27 0.82 ± 0.18 1 
Pck1p NP_013023 Gluconeogenesis 1.77 ± 0.23 1.59 ± 0.31 0.67 ± 0.13 1 
Fbp1p NP_013481 Gluconeogenesis 2.74 ± 0.35 1.86 ± 0.25 0.79 ± 0.26 1 
Pda1p NP_011105 Mitochondrial PDH complex 2.75 ± 0.44 2.37 ± 0.39 1.12 ± 0.19 1 
Aco1p NP_013407 Mitochondrial TCA cycle 2.63 ± 0.37 2.42 ± 0.42 0.73 ± 0.15 1 
Ndi1p NP_013586 Mitochondrial ETC 2.77 ± 0.54 2.84 ± 0.28 1.23 ± 0.26 1 
Sdh1p NP_012774 Mitochondrial TCA cycle and ETC 3.86 ± 0.61 2.73 ± 0.39 1.35 ± 0.22 1 
Cyt1p NP_014708 Mitochondrial ETC 3.65 ± 0.27 2.49 ± 0.16 1.19 ± 0.34 1 
Hem14p NP_010930 Heme synthesis in mitochondria 2.84 ± 0.34 1.59 ± 0.23 0.73 ± 0.16 1 
Cyc3p NP_009361 Heme attachment to apo-cytochrome c 3.67 ± 0.45 2.85 ± 0.42 1.35 ± 0.27 1 
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Ssq1p NP_013473 Assembly of Fe/S clusters into proteins 2.76 ± 0.37 2.43 ± 0.18 1.28 ± 0.32 1 
Sod2p NP_011872 Detoxification of ROS in mitochondria 2.89 ± 0.21 4.45 ± 0.33 1.64 ± 0.19 1 
Prx1p NP_009489 Detoxification of ROS in mitochondria 2.57 ± 0.36 4.87 ± 0.52 1.57 ± 0.13 1 
Atp1p NP_009453 Mitochondrial ATP synthase 3.76 ± 0.44 4.59 ± 0.60 1.72 ± 0.21 1 
Atp2p NP_012655 Mitochondrial ATP synthase 3.68 ± 0.51 4.74 ± 0.43 1.34 ± 0.32 1 
Pet9p NP_009523 Mitochondrial ADP/ATP carrier 2.45 ± 0.37 3.87 ± 0.49 1.29 ± 0.17 1 
Mir1p NP_012611 Mitochondrial phosphate carrier 2.87 ± 0.43 3.71 ± 0.22 1.66 ± 0.24 1 
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Figure 3.8. CR remodels trehalose and glycogen metabolism and accelerates ethanol catabolism. (A) 
Outline of metabolic pathways and interorganellar communications operating in chronologically aging 
yeast. (B-D) The dynamics of age-dependent changes in the intracellular levels of trehalose (B) and 
glycogen (C) and in the extracellular concentrations of ethanol (D) during chronological aging of WT cells. 
Cells were cultured in rich YP medium initially containing 0.2%, 0.5%, 1% or 2% glucose. Data are 
presented as mean  SEM (n = 3-5). For trehalose and glycogen levels, p < 0.001 at days 3 to 21 for cells 
grown on 0.2% or 0.5% glucose versus cells grown on 2% glucose. For ethanol levels, p < 0.001 at days 1 
to 9 for cells grown on 0.2% or 0.5% glucose versus cells grown on 2% glucose. Abbreviations: Ac-CoA, 
acetyl-CoA; AcOH, acetic acid; CL, cardiolipins; DAG, diacylglycerols; EE, ethyl esters; ER, endoplasmic 
reticulum; EtOH, ethanol; FA-CoA, CoA esters of fatty acids; FFA, free fatty acids; LB, lipid bodies; PL, 
phospholipids; TAG, triacylglycerols. 
 
glycolytic oxidation, can adequately explain the observed dynamics of age-dependent 
changes in levels of trehalose and glycogen (Figures 3.8B and 3.8C). Finally, I also found 
that CR increases the levels of mitochondrial proteins serving the formation of acetyl-
CoA and its subsequent oxidation via the tricarboxylic acid (TCA) cycle, electron 
transport and oxidative phosphorylation coupled to ATP synthesis, as well as the 
detoxification of mitochondrially formed reactive oxygen species (ROS) (Figure 3.7B). 
          Taken together, my lipidomic, proteomic and metabolomic analyses suggest the 
following scenario for the CR-promoted remodeling of carbohydrate and lipid 
metabolism that yeast undergo prior to entry into the non-proliferative ST phase (Figure 
3.7C). Chronologically aging CR yeast shift carbohydrate metabolism toward glucose 
formation via gluconeogenesis. By activating the synthesis of enzymes catalyzing the 
biosynthesis of trehalose and glycogen and by suppressing the synthesis of enzymes 
required for their degradation, CR promotes the accumulation of these two major glucose 
stores. In contrast, the deposited in LBs neutral lipids TAG and EE, the two major lipid 
stores, are rapidly hydrolyzed by CR yeast prior to entry into the non-proliferative ST 
phase. The rapid lipolysis of neutral lipids in CR yeast produces substantial amounts of 
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FFA. FFA are rapidly converted to FA-CoA that are then oxidized to acetyl-CoA via a 
peroxisome-confined pathway greatly accelerated by CR. The subsequent oxidation of 
the peroxisome-derived acetyl-CoA in mitochondria generates the bulk of ATP in CR 
yeast. This process also generates considerable quantities of mitochondrial ROS (see data 
presented further in this Chapter of the thesis). Within the mitochondrion, ROS are 
decomposed in CR-promoted antioxidant scavenger reactions catalyzed by superoxide 
dismutase Sod2p and peroxiredoxin Prx1p, both of which are induced by CR (Figure 
3.7B). In contrast to CR yeast, chronologically aging non-CR yeast generate the bulk of 
ATP via glycolytic oxidation of glycogen-derived glucose. The glycolytic oxidation of 
glucose to pyruvate in non-CR yeast is followed by its conversion to ethanol, which 
accumulates in non-CR yeast. On the contrary, CR yeast avoid ethanol accumulation by 
modulating the quantities of Adh1p and Adh2p, the two alcohol dehydrogenase isozymes 
that catalyze ethanol synthesis and degradation, respectively. The importance of this 
effect of CR on ethanol concentration for longevity is discussed further in this Chapter of 
the thesis. 
 
3.4.4. Concentration of ethanol is one of the key factors influencing 
chronological aging 
I found that the steady-state level of ethanol depends on a balance of enzymatic activities 
of the Adh1p and Adh2p isozymes of alcohol dehydrogenase (Figure 3.9A). Both 
isozymes are under the control of CR. In fact, by decreasing the level of Adh1p and by 
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Figure 3.9. Ethanol is one of the key factors regulating longevity. (A) Outline of metabolic pathways and 
interorganellar communications operating in chronologically aging yeast cells. (B-E) The dynamics of age-
dependent changes in the extracellular concentration of ethanol for WT, adh1 and adh2. Data are 
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presented as mean  SEM (n = 3-5). (F and G) Survival (F) and the mean chronological life spans (G) of 
WT, adh1 and adh2. Data are presented as mean  SEM (n = 3-5); *p < 0.05, **p < 0.005. (H and I) A 
dose-response relationship between the mean chronological life span and the degree of CR for WT, adh1 
and adh2. Data are presented as mean  SEM (n = 3-5). (B-I) Cells were cultured in YP medium initially 
containing 0.2%, 0.5%, 1% or 2% glucose. 
 
ethanol from yeast grown on 0.2% or 0.5% glucose (Figure 3.8D). To evaluate the effect 
of endogenously produced ethanol on longevity, I incubated WT, adh1 and adh2 
strains in media containing different glucose concentrations. I monitored the 
chronological life spans of these strains and assessed the dynamics of changes in ethanol 
concentration during their aging. When yeast were placed on the CR diet by incubating 
them on 0.2% or 0.5% glucose, lack of Adh1p or Adh2p did not affect ethanol 
concentration (Figures 3.9B and 3.9C) or chronological life span (Figures 3.9F and 
3.9G). Conversely, lack of Adh1p substantially decreased ethanol concentration when 
yeast were grown on 1% or 2% glucose (Figures 3.9D and 3.94E), prolonging their life 
span (Figures 3.9F and 3.9G). Furthermore, lack of Adh2p led to a considerable rise of 
ethanol concentration in non-CR yeast grown on 1% or 2% glucose (Figures 3.9D and 
3.9E), shortening their life span (Figures 3.9F and 3.9G). By extending life span of non-
CR yeast, adh1 to a great extent abolished the positive effect of CR on longevity 
(Figures 3.9H and 3.9I). Alternatively, by shortening life span of non-CR yeast, adh2 
enhanced the benefit of CR for longevity (Figures 3.9H and 3.9I). 
          My data also strongly suggest that ethanol modulates the dynamics of trehalose, 
glycogen, neutral lipids, FFA and DAG in chronologically aging yeast. In fact, by 
decreasing ethanol concentration in non-CR yeast, adh1 remodelled the metabolism of 
these key for longevity compounds in non-CR yeast by making it similar to the metabolic  
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Figure 3.10. In chronologically aging yeast, ethanol modulates the dynamics of trehalose, glycogen, neutral 
lipids, FFA and DAG. (A) Outline of metabolic pathways and interorganellar communications operating in 
chronologically aging yeast. (B, C, E-H) The dynamics of age-dependent changes in the levels of trehalose 
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(B), glycogen (C), TAG (E), EE (F), FFA (G) and DAG (H) during chronological aging of WT, adh1 and 
adh2. Data are presented as mean  SEM (n = 3-4). (D) Percent of WT, adh1 and adh2 cells that 
contain lipid bodies. Data are presented as mean  SEM (n = 4). (B-H) Cells were cultured in rich YP 
medium initially containing 2% glucose. Abbreviations: Ac-CoA, acetyl-CoA; AcOH, acetic acid; DAG, 
diacylglycerols; EE, ethyl esters; ER, endoplasmic reticulum; FA-CoA, CoA esters of fatty acids; FFA, free 
fatty acids; LB, lipid bodies; PL, phospholipids; TAG, triacylglycerols.  
 
design of CR yeast. Specifically, the adh1 mutation 1) increased the level of trehalose 
(Figure 3.10B); 2) redesigned glycogen metabolism by promoting glycogen accumulation 
in PD phase and delaying its consumption until ST phase (Figure 3.10C); 3) accelerated 
the lipolytic consumption of lipid bodies-deposited neutral lipids (Figures 3.10D-3.10F); 
4) accelerated the consumption of FFA and DAG during late PD and early ST phases 
(Figures 3.10G and 3.10H). In contrast, by elevating ethanol level in non-CR yeast, 
adh2 enhanced the negative effect of a calorie-rich diet on longevity by further 
decreasing trehalose concentration, accelerating glycogen consumption, slowing down 
neutral lipids lipolysis, and decelerating FFA and DAG consumption (Figure 3.10). 
          In sum, based on the findings presented in Chapter 3.4.4, I concluded that ethanol 
is one of the key factors regulating longevity by specifically modulating the metabolism 
of trehalose, glycogen, neutral lipids, FFA and DAG in chronologically aging yeast. 
 
3.4.5. Ethanol decelerates the consumption of neutral lipids deposited in 
lipid bodies (LBs) by slowing down fatty acid oxidation in peroxisomes 
that are associated with LBs 
I sought to define a mechanism by which ethanol modulates the dynamics of neutral 
lipids, FFA and DAG in chronologically aging yeast. Importantly, I found that the 
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observed rapid depletion of ethanol seen in CR yeast (Figure 3.8D) coincides with 1) 
elevated levels of Fox1p, Fox2p and Fox3p (Figure 3.7B), all of which are the core 
enzymes of peroxisomal fatty acid β-oxidation [237]; and 2) rapid consumption of FFA 
during PD phase (Figure 3.4F). Of note, it has been previously shown that in the yeast 
species that need peroxisomes to utilize methanol as a sole carbon source for growth, 
ethanol suppresses the synthesis of peroxisomal enzymes catalyzing methanol oxidation 
[238]. Based on these findings, I hypothesized that the accumulation of ethanol in non-
CR yeast cultures (Figure 3.8D) suppresses peroxisomal oxidation of FFA by repressing 
the synthesis of Fox1p, Fox2p and Fox3p, thereby causing the accumulation of FFA 
during PD phase (Figure 3.4F). This hypothesis was confirmed by my finding that a 
premature depletion of ethanol from non-CR cells of adh1 (Figures 3.9D and 3.9E) led 
to an early synthesis of Fox1p, Fox2p and Fox3p in PD phase (Figure 3.11B) and 
promoted FFA consumption (Figure 3.10G). In addition, I found that a postponed 
depletion of ethanol from non-CR cells of adh2 (Figures 3.9D and 3.9E) delays the 
synthesis of Fox1p, Fox2p and Fox3p (Figure 3.11B) and slows down FFA consumption 
(Figure 3.10G). 
          How exactly ethanol modulates the dynamics of neutral lipids in chronologically 
aging yeast? By substantially decreasing ethanol concentration in non-CR yeast, adh1 
accelerated not only the consumption of FFA but also the lipolysis of neutral lipids 
deposited in LBs (Figures 3.10D-3.10G). Moreover, by elevating ethanol level in non-CR 




Figure 3.11. By suppressing fatty acid oxidation in peroxisomes that are associated with lipid bodies 
(LBs), ethanol and fox1, fox2 and fox3 mutations decelerate the lipolytic consumption of neutral lipids 
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deposited in LBs. (A) Outline of metabolic pathways and interorganellar communications operating in 
chronologically aging yeast cells. (B) Western blot analysis of Fox1p, Fox2p, Fox3p and actin in aging 
WT, adh1 and adh2 cultured in YP medium initially containing 0.2%, 0.5%, 1% or 2% glucose. Protein 
recovered in total cell lysates were resolved by SDS-PAGE and detected by immunoblotting. (C) Survival 
of WT, fox1, fox2 and fox3. Data are presented as mean  SEM (n = 4). (D) Percent of WT, fox1, 
fox2 and fox3 cells that contain lipid bodies. Data are presented as mean  SEM (n = 4). (E-G) TAG (E), 
EE (F) and FFA (G) levels in aging WT, fox1, fox2 and fox3. Data are presented as mean  SEM (n = 
5-6). (H) Spectra of lipids that were extracted from purified ER and lipid bodies of WT, fox1, fox2 and 
fox3 cells. The equivalent of 200 μg of ER proteins and 20 μg of lipid body proteins was used for lipid 
extraction at each time point. Lipids were analyzed by TLC. A representative of 3 independent experiments 
is shown. (I) Transmission electron micrographs of aging fox1 cells recovered at day 7. Panels show two 
magnifications of the same micrograph. Bars, 1 μm. (J and K) Percent of cells that contain pexopodia (J) 
and/or gnarls (K). Images similar to the representative image shown in (I) were quantitated. Data are 
presented as mean  SEM (n = 3). (C-K) Cells were cultured in YP medium initially containing 0.2% 
glucose.  
 
strongly suggest that any diet or genetic manipulation that decelerates peroxisomal 
oxidation of FFA by Fox1p, Fox2p and/or Fox3p could also decelerate the lipolysis of 
neutral lipids in LBs, perhaps due to a feedback inhibition of the lipolysis by the 
concentrations of FFA or FA-CoA exceeding a critical level. This suggestion was further 
supported by my finding that lack of Fox1p, Fox2p or Fox3p abolishes the lipolysis of 
LB-deposited neutral lipids even in CR yeast (Figures 3.11D-3.11F). Importantly, I found 
that lack of Fox1p, Fox2p or Fox3p shortens the chronological life span of CR yeast 
(Figure 3.11C), implying that both the lipolysis of neutral lipids in LBs and the 
subsequent oxidation of FFA in peroxisomes are mandatory for the observed extension of 
life span by CR. 
          The proposed feedback inhibition of the lipolysis of neutral lipids by the 
concentrations of FFA or FA-CoA exceeding a critical level could be due to a recently 
described extensive physical contact existing between LBs and peroxisomes [239]. Such 
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tight contact has been shown to stimulate the lipolysis of neutral lipids within LBs, 
thereby initiating the import of the newly formed FFA into and their oxidation within 
peroxisomes [239]. The LBs-peroxisome association can lead to peroxisome invasion 
into the lipid core of LBs, thereby generating so-called pexopodia [239]. Importantly, 
pexopodia of the yeast mutants that are unable to oxidize FFA due to the absence of 
Fox1p, Fox2p or Fox3p cause the accumulation of electron-dense arrays of FFA (called 
gnarls) within LBs (Figure 3.11I; [239]). I found that, during D phase, all WT, fox1, 
fox2 and fox3 grown on 0.2% glucose accumulate pexopodia (Figure 3.11J). 
Pexopodia in WT cells disappeared during the subsequent PD phase, concomitantly with 
the complete consumption of FFA within LBs of these cells (Figures 3.11G-3.11J). In 
contrast, pexopodia in prematurely aging fox1, fox2 and fox3 continued to proliferate 
during PD phase, eventually becoming very abundant (Figure 3.11J). By the end of PD 
phase and in the beginning of ST phase, with the number of pexopodia in their cells 
reached a plateau (Figure 3.11J), fox1, fox2 and fox3 began accumulating FFA 
(Figure 3.11G). These FFA were formed due to the lipolysis of limited amounts of ER-
originated neutral lipids within LBs of the mutant strains (Figure 3.11H). I found that the 
accumulation of FFA within LBs of these fox mutants coincide with the build-up of 
gnarls (Figures 3.11I and 3.11K), which represent organized arrays of FFA [239]. Of 
note, the closer to the beginning of the peroxisomal β-oxidation pathway the reaction 
missing in a fox mutant was (Figure 3.11A), the more pexopodia and, eventually, gnarls 
accumulated within its LBs (Figures 3.11J and 3.11K). Altogether, my findings suggest 
that the build-up of gnarls within LBs of aging non-CR yeast initiates several negative 
feedback loops regulating the biosynthesis and degradation of TAG in the ER and LBs 
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(Figure 3.12). Due to the action of these negative feedback loops (Figure 3.12), aging 












Gnarls (Arrays of FFA)
Figure 3.12. Several negative feedback loops regulate the biosynthesis and degradation of triacylglycerols 
(TAG) in the ER and lipid bodies (LBs). In chronologically aging yeast placed on a calorie-rich diet, the 
accumulation of electron-dense arrays of free fatty acids (called gnarls) within LBs initiates several 
negative feedback loops that regulate the biosynthesis and degradation of TAG in the ER and LBs. Due to 
the action of these negative feedback loops, yeast placed on a calorie-rich diet accumulate FFA and DAG. 
Abbreviations: DAG, diacylglycerols; ER, endoplasmic reticulum; FA-CoA, CoA esters of fatty acids; 
FFA, free fatty acids; LB, lipid bodies; TAG, triacylglycerols. 
 
3.4.6. Peroxisomal fatty acid oxidation could regulate longevity via three 
different mechanisms 
As I found, lack of Fox1p, Fox2p or Fox3p shortens the chronological life span of CR 
yeast (Figure 3.11C) but has no effect on longevity of non-CR yeast (Figure 3.14A). 
Hence, peroxisomal oxidation of FFA is mandatory for life-span extension by CR. At 
least three aspects of FFA oxidation in peroxisomes could influence longevity of WT 
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yeast under CR. First, the formation of hydrogen peroxide in the Fox1p-dependent 
reaction of fatty acid oxidation in peroxisomes (Figure 3.13A) could generate the bulk 
quantities of this ROS molecule, which is known for its essential role in regulating 
longevity [223, 240 - 244]. Second, the formation of acetyl-CoA via FFA oxidation in 
peroxisomes followed by its delivery to mitochondria for the oxidation via the TCA cycle 
(Figure 3.13A) could be responsible for the synthesis of the bulk quantities of ATP in 
mitochondria and could affect other longevity-related mitochondrial processes. Third, by 
regulating the biosynthesis and degradation of TAG in the ER and LBs via several 
negative feedback loops, fatty acid oxidation in peroxisomes controls the levels of FFA 
and DAG (Figures 3.11 and 3.12). Importantly, a short-term exposure to exogenously 
added FFA (i.e., palmitoleic acid and oleic acid) and DAG induces necrotic cell death in 
chronologically aging yeast (Figure 3.15) [222]. Furthermore, DAG also modulates a 
signal transduction network affecting multiple longevity-related cellular targets [245, 
246]. It is conceivable therefore that the accumulation of FFA and DAG in aging yeast 
that have low rate of peroxisomal fatty acid oxidation could trigger their necrotic cell 
death and, perhaps, other processes shortening their life span. 
 
3.4.7. ROS produced in peroxisomes during fatty acid oxidation do not 
influence longevity 
Although the bulk of ROS is produced in mitochondria, they are also formed during 
peroxisomal oxidation of FFA [223, 237, 240]. The only chemical reaction in yeast 
peroxisomes that generates hydrogen peroxide, the most abundant ROS molecule in the 
cell [241], is catalyzed by Fox1p (Figure 3.13A). Importantly, the peroxisomal isoform 
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Cta1p of catalase decomposes hydrogen peroxide inside the organelle (Figure 3.13A), 
thereby protecting yeast from oxidative damage by this ROS molecule [223, 237]. Hence, 
the steady-state level of hydrogen peroxide in the peroxisome depends on a balance of 
enzymatic activities of Fox1p and Cta1p. To elucidate the importance of peroxisome-
produced ROS in the chronological aging of CR yeast, I compared the life spans of WT, 
fox1 and cta1 grown on 0.2% glucose. I reasoned that if peroxisomal ROS modulate 
longevity, the fox1 mutation would prolong life span by decreasing ROS level in the 
peroxisome, whereas the cta1 mutation would have an opposite effect on life span by 
raising the concentration of peroxisomal ROS. However, as I mentioned earlier, lack of 
ROS-generating Fox1p shortened life span (Figure 3.13C) for a reason discussed in the 
next section of this Chapter of my thesis. Furthermore, I found that lack of ROS-
decomposing Cta1p has no effect on the life span of CR yeast (Figure 3.13C). I therefore 
concluded that ROS that are made during FFA oxidation in peroxisomes of 
chronologically aging yeast do not influence their longevity. Moreover, it appeared that 
FFA oxidation in peroxisomes does not produce a considerable fraction of ROS 
generated in yeast cell. In fact, I found that lack of ROS-decomposing Cta1p has no 
effect on the intracellular concentration of ROS formed in CR yeast (Figures 3.13D and 
3.13E). Furthermore, the observed during D phase spike in the intracellular level of ROS 
in the fox1 mutant (Figures 3.13D and 3.136E), which lacks the only ROS-generating 
peroxisomal enzyme, further supports the notion that peroxisomes do not produce 
significant amounts of ROS in CR yeast. The sharp rise of ROS and its following rapid 
decline in CR cells of fox1, a pattern that was also seen in fox2 and fox3, was due to 
an important role that peroxisomal FFA oxidation plays in modulating essential processes 
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taking place in ROS-producing mitochondria (see next section of this Chapter of my 
thesis). 
 
3.4.8. Fatty acid oxidation in peroxisomes controls longevity in part by 
modulating essential processes in mitochondria 
As soon as CR cells of prematurely aging fox1, fox2 and fox3 entered ST phase, a 
rapid decline in the percentage of viable cells occurred (Figure 3.11C). I found that such 
premature aging of the three fox mutants during ST phase precedes by a sharp decrease in 
oxygen consumption by their mitochondria (Figure 3.13F) and by an abrupt decline in the 
steady-state level of mitochondrially synthesized ATP during PD phase (Figure 3.13B). I 
therefore concluded that, during PD phase, CR yeast synthesize the bulk of their ATP in 
mitochondria by oxidizing the pool of acetyl-CoA that has been generated in peroxisomes 
via Fox1p-, Fox2p- and Fox3p-dependent FFA oxidation. In contrast, the pools of acetyl-
CoA formed via oxidation of pyruvate in mitochondria or cytosol (Figure 3.13A) are not 
the major sources of NADH and FADH2 for oxidative phosphorylation that takes place in 
mitochondria of aging CR yeast. 
          My conclusion that peroxisomal FFA oxidation in CR yeast controls longevity in 
part by modulating ATP synthesis in mitochondria prompted me to examine if the 
efficiency of acetyl-CoA formation in peroxisomes influences any other essential 
processes in mitochondria. I found that lack of Fox1p, Fox2p or Fox3p: 1) in CR yeast 
entering D phase, dramatically increases the amplitude of the observed spike in the rates 
of oxygen consumption and ROS generation by mitochondria (Figures 3.13D and 3.13F); 




Figure 3.13. In CR yeast, the efficiency of fatty acid oxidation in peroxisomes modulates essential 
processes in mitochondria. (A) Outline of metabolic pathways and interorganellar communications 
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operating in chronologically aging yeast cells. (B) ATP levels in WT, fox1, fox2 and fox3 cells. Data 
are presented as mean  SEM (n = 3); *p < 0.05, p < 0.005. (C) Survival of WT, fox1 and cta1..Data 
are presented as mean  SEM (n = 4). (D) ROS levels in aging WT, fox1 and cta1. ROS were visualized 
using the fluorescent dye Dihydrorhodamine-123 (DHR). At least 800 cells were used for quantitation of 
DHR staining for each of 4 independent experiments. Data are presented as mean  SEM (n = 4). (E) 
Representative images of WT, fox1 and cta1 cells stained with DHR. ROS were visualized using 
fluorescence microscopy. (F) Rates of oxygen consumption by aging WT, fox1, fox2 and fox3 cells. 
Data are presented as mean  SEM (n = 5). (G and H) Enzymatic activities of cytochrome c oxidase (CCO; 
G) and succinate dehydrogenase (H; SDH) in mitochondria purified from aging WT, fox1, fox2 and 
fox3. Data are presented as mean  SEM (n = 3). (I) Morphology of mitochondria in WT and fox1 cells. 
Mitochondria were visualized by indirect immunofluorescence microscopy using monoclonal anti-porin 
primary antibodies and Alexa Fluor 568-conjugated goat anti-mouse IgG secondary antibodies. 
Representative images are shown. (J) Representative images of WT and fox1 and cta1 cells stained with 
rhodamine 123 (R123) for monitoring the mitochondrial membrane potential () in living cells.  was 
visualized using fluorescence microscopy. (K) Enzymatic activities of aconitase (ACO) in total cell lysates 
of aging WT and fox1. The ACO activity was measured with or without the reactivation agents Fe3+ and 
Na2S. Data are presented as mean  SEM (n = 3). (L) Western blot analysis of porin and actin in aging WT, 
fox1, fox2 and fox3. Protein recovered in total cell lysates were resolved by SDS-PAGE and detected 
by immunoblotting. (M)  values for aging WT, fox1, fox2 and fox3.  was visualized using the 
fluorescent dye R123. At least 1000 cells were used for quantitation of R123 staining for each of 3 
independent experiments. Data are presented as mean  SEM (n = 3). (B-M) Cells were cultured in YP 
medium initially containing 0.2% glucose. Abbreviations: AU, arbitrary units; BF, bright field. 
 
and ROS production by mitochondria (Figures 3.13D and 3.13F). Thus, the efficiency of 
acetyl-CoA formation via peroxisomal FFA oxidation modulates the efficiencies of 
electron flow through the mitochondrial electron transport chain (ETC) and of the ROS-
generating transfer of a single electron to oxygen. 
          It seems that the observed early spike in ROS production by mitochondria of all 
three fox mutants irreversibly damaged some key mitochondrial proteins. In fact, I found 
that lack of any of the three Fox proteins resulted in rapid inactivation of cytochrome c 





























































































































































































































































































































































































































































Day 3 (PD) Day 3 (PD)
Day 3 (PD)Day 3 (PD)
*
Figure 3.14. Lack of Fox1p, Fox2p or Fox3p shortens the chronological life span of yeast only under CR 
conditions, enhances their susceptibility to mitochondria-controlled cell death induced by exogenous 
hydrogen peroxide or acetic acid, but does not alter their susceptibility to cell death induced by 
exogenously added FFA or DAG. (A) The mean chronological life spans of WT, fox1, fox2 and fox3. 
Data are presented as mean  SEM (n = 4-5); p < 0.005. Cells were cultured in YP medium containing 
0.2%, 0.5%, 1% or 2% glucose. (B - F) Viability of WT, fox1, fox2 and fox3 cells treated with different 
concentrations of hydrogen peroxide (B), acetic acid (C), palmitoleic acid (D), oleic acid (E) or DiC8 
diacylglycerol (F). Data are presented as mean  SEM (n = 3-4); p < 0.005. Cells were cultured in YP 
medium containing 0.2% glucose. 
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the prematurely aging fox mutants entering PD phase (Figures 3.13G, 3.13H and 3.13K). 
Each of these three mitochondrial proteins is a key target for the oxidative damage by 
ROS [18, 240, 247].  
          I next used fluorescence microscopy to monitor the mitochondrial membrane 
potential () in living cells of WT and fox mutant strains, all placed on the CR diet. I 
found that lack of Fox1p, Fox2p or Fox3p: 1) in cells entering D phase, drastically 
increases , thereby leading to the hyper-polarization of the inner mitochondrial 
membrane (Figures 3.13J and 3.13M); and 2) in cells entering PD phase, results in an 
abrupt decline of  (Figures 3.13J and 3.13M), thereby rapidly abrogating the -
dependent processes in mitochondria, including the transport of solutes and the synthesis 
of ATP. 
          It should be stressed that, although the inability of each of the three fox mutants to 
form acetyl-CoA via peroxisomal FFA oxidation caused the above age-related changes in 
essential mitochondrial processes, it did not affect the abundance of mitochondria in CR 
yeast. Indeed, the levels of porin, one of the most abundant mitochondrial proteins, were 
very similar in WT, fox1, fox2 and fox3 cells (Figure 3.13L). However, the 
morphology of mitochondria in CR cells of the fox mutants was altered. Mitochondria in 
chronologically aging WT formed a tubular network (Figure 3.13I). In contrast, in each 
of the three fox mutants, this network was fragmented into individual mitochondria 
(Figure 3.13I). Thus, the efficiency with which peroxisomes supply acetyl-CoA for its  
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Figure 3.15. A short-term exposure to exogenously added FFA and DAG causes necrotic, not apoptotic, 
cell death. Fluorescence microscopy of WT yeast treated for 2 h with 0.25 mM palmitoleic acid, 0.6 mM 
oleic acid or 4.0 mM DiC8 diacylglycerol. Cells were co-stained with 1) Annexin V for visualizing the 
externalization of phosphatidylserine, a hallmark event of apoptosis; and 2) propidium iodide (PI) for 
visualizing the loss of plasma membrane integrity, a hallmark event of necrosis. Abbreviations: DIC, 
differential interference contrast.  
 
oxidation via the TCA cycle in mitochondria modulates, by a yet-to-be established 
mechanism, the balance of fission and fusion of mitochondrial tubules. Such delicate 
balance plays a pivotal role in establishing and maintaining the shape of mitochondria 
[248, 249]. Notably, a balance between the opposing processes of mitochondrial fission 
and fusion modulates the ability of yeast to survive a short-term exposure to hydrogen 
peroxide or acetic acid, each of which induces a mitochondria-controlled, caspase-
dependent pathway of apoptosis [250 - 252]. In fact, mitochondrial fragmentation due to 
excessive mitochondrial fission plays a casual role in this form of programmed cell death 
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[252 - 254]. Importantly, the observed fragmentation of the mitochondrial network in 
cells of each of the three prematurely aging fox mutants coincided with their increased 
susceptibility to mitochondria-controlled, hydrogen peroxide- and acetic acid-induced 
apoptosis (Figures 3.14B and 3.14C). 
 
3.4.9. Free fatty acids (FFA) and diacylglycerol (DAG) regulate longevity 
by two different mechanisms that operate at two different stages of the 
aging process 
As I found, a short-term exposure to exogenously added FFA (i.e., palmitoleic acid and 
oleic acid) and DAG induces necrotic cell death in chronologically aging yeast (Figure 
3.15) [222]. To test the validity of my hypothesis (see section 3.4.8 of this Chapter) that 
the accumulation of FFA and DAG in yeast shortens their chronological life span by 
triggering cell death (apoptotic and/or necrotic), I first compared the susceptibility of 
WT, fox1, fox2 and fox3 to a short-term exposure to exogenous FFA and DAG. 
Under CR conditions, each of the three fox mutations caused the build-up of both these 
lipids in LBs as soon as cells entered ST phase (Figures 3.11G and 3.11H). The observed 
during ST phase rapid accumulation of FFA and DAG in LBs of the fox mutants 
coincided with a prompt decline in the percentage of their viable cells during this phase 
(Figure 3.11C). Importantly, despite the observed build-up of FFA and DAG in fox cells 
beginning of ST phase, none of the fox mutations had an effect on the susceptibility of 
yeast to necrotic cell death induced in response to their short-term exposure to exogenous 
FFA or DAG (Figures 3.14D-3.14F). In contrast, as I found (see section 3.4.8 of this 
Chapter), all three fox mutations increased the susceptibility of yeast to mitochondria-
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controlled, hydrogen peroxide- and acetic acid-induced apoptosis (Figures 3.14B and 
3.14C). Importantly, unlike CR cells of each of the three fox mutants that reached ST 
phase, CR cells of these mutants during PD phase did not accumulate FFA or DAG 
(Figures 3.11G and 3.11H) and were viable (Figure 3.11C), and did not differ from WT 
cells in their susceptibility to cell death induced by exogenous FFA or DAG (Figures 
3.14D-3.146F, left panels). Altogether, these findings suggest that the observed during 
ST phase rapid build-up of FFA and DAG in LBs of the fox mutants causes their 
premature aging by promoting mitochondria-controlled apoptotic cell death, but not by 
activating FFA- and DAG-induced necrotic cell death pathway. 
          As a further test of the validity of my hypothesis (see section 3.4.8 of this Chapter) 
on the essential negative role of FFA and DAG in regulating longevity by promoting cell 
death, I then measured the chronological life spans of mutants impaired in the 
biosynthesis or degradation of TAG (Figure 3.16). Importantly, most of the enzymes 
involved in these metabolic pathways are redundant and all of these redundant enzymes 
are not essential proteins (Figure 3.16) [212, 255]. I reasoned that, in the absence of any 
of them, cells would still be able to produce FFA and DAG. However, lack of any of 
them would change the concentration of each of these two lipid species (Figure 3.16). I 
expected therefore that, if my hypothesis is correct, any mutation that reduces the 
concentration of a critical lipid (i.e., FFA and/or DAG) by eliminating a redundant 
enzyme would extend the life span of CR yeast. Conversely, any mutation that increases 
the concentration of a critical lipid by eliminating a redundant enzyme would shorten the 
life span of CR yeast. Concomitantly with measuring the life spans of the mutants lacking 
individual redundant enzymes of the metabolic pathways depicted in Figure 3.16, I 
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Figure 3.16. Any mutation that reduces the level of DAG by eliminating a redundant enzyme involved in 
the biosynthesis or degradation of triacylglycerols (TAG) extends the life span of CR yeast. (A and D) 
Outline of metabolic pathways for the biosynthesis (A) and degradation (D) of TAG. (B, C and E) Survival 
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of WT strain and single-gene-deletion mutant strains, each lacking a redundant enzyme involved in the 
biosynthesis (B and C) or degradation (E) of TAG. Data are presented as mean  SEM (n = 3). Some of the 
mutations increase () the concentrations of diacylglycerol (DAG), free fatty acids (FFA) or TAG, 
whereas the other mutations decrease () them. Cells were cultured in YP medium initially containing 
0.2% glucose. 
 
susceptibility to FFA- and DAG-induced cell death.  
          I found that any mutation that reduces the level of DAG by eliminating a redundant 
enzyme extends the life span of CR yeast, regardless of its effect on the level of FFA 
(Figure 3.16). In fact, the ability of mutations eliminating individual redundant enzymes 
of DAG biosynthesis or TAG degradation to extend life span coincided with their ability 
to decrease DAG concentration but did not correlate with the specific changes in the 
concentration of FAA they caused (Figures 3.16B and 3.16E). Moreover, any mutation 
that increases the level of DAG by eliminating a redundant enzyme of TAG biosynthesis 
from DAG shortens the life span of CR yeast (Figure 3.16C). Noteworthy, the effect of 
all of these life-span shortening mutations on the level of FFA was very similar to that of 
the life-span extending mutations eliminating individual redundant enzymes of DAG 
biosynthesis (compare Figures 3.16B and 3.16C). It should be stressed that, although any 
mutation that eliminates a redundant enzyme involved in the biosynthesis or degradation 
of TAG extended or shortened life span by increasing or decreasing cell viability during 
ST phase (Figure 3.16), it altered the concentrations of FFA and DAG only during the 
preceding D and PD phases (Figure 3.17). Indeed, akin to WT cells, cells of the mutant 
strains carrying any of these mutations entirely consumed both FFA and DAG prior to 
entry into ST phase (Figure 3.17). I therefore concluded that the viability of yeast during 
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Figure 3.17. Any mutation that eliminates a redundant enzyme involved in the biosynthesis or degradation 
of triacylglycerols (TAG) alters the concentrations of FFA and DAG during growth phases preceding the 
non-proliferative ST phase. The dynamics of age-dependent changes in the levels of diacylglycerol (DAG) 
(A, D and G), free fatty acids (FFA) (B, E and H) and TAG (C, F and I) during chronological aging of WT 
strain and single-gene-deletion mutant strains, each lacking a redundant enzyme involved in the 
biosynthesis (A - F) or degradation (G - I) of TAG. Data are presented as mean  SEM (n = 3). Cells were 
cultured in rich YP medium containing 0.2% glucose. 
 
to maintain during D and PD phase in a diet- and genotype-dependent fashion. On the 
contrary, my findings imply that the concentration of FFA during D and PD phase does 
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not influence the viability of CR yeast during ST phase. Furthermore, the observed lack 
of correlation between the life spans of mutant strains missing individual redundant 
enzymes of DAG biosynthesis or TAG degradation and the levels of TAG maintained 
during D, PD and ST phases in their cells (Figures 3.16 and 3.17) implies that TAG 
species do not regulate longevity.  
          I then examined how the lpp1, lro1 and tgl4 mutations, each having a different 
effect on the intracellular levels of FFA and DAG in CR yeast during D and PD phases 
by eliminating a different redundant enzyme involved in the biosynthesis or degradation 
of TAG, influences the susceptibility of CR yeast to 1) mitochondria-controlled apoptotic 
cell death caused by their short-term exposure to exogenous hydrogen peroxide or acetic 
acid; and 2) necrotic cell death caused by their short-term exposure to exogenous FFA or 
DAG. The results of this kind of analysis are outlined below. 
          The lpp1 mutation: 1) increases the chronological life span (Figure 3.16B) of CR 
yeast; 2) reduces the intracellular concentration of DAG during D and PD phases (Figure 
3.17A): 3) increases the intracellular concentration of FFA during D and PD phases 
(Figure 3.17B); and 4) does not prevent the complete consumption of the intracellular 
pools of DAG and FFA prior to entry into ST phase (Figures 3.17A and 3.17B). I found 
that the lpp1 mutation: 1) does not alter the susceptibility of CR yeast to mitochondria-
controlled apoptotic cell death caused by their short-term exposure to exogenous 
hydrogen peroxide or acetic acid (Figures 3.18A and 3.18B); but 2) increases the 
resistance of CR yeast to necrotic cell death caused by a short-term exposure to 


































































































































































































































































































































































































Figure 3.18. The single-gene-deletion mutations that alter DAG concentration prior to entry into ST phase 
have no effect on the mitochondrial pathway of programmed cell death, but alter the susceptibility of CR 
yeast to the programmed necrotic death. Viability of WT, lpp1, lro1 and tgl4 cells treated with 
different concentrations of hydrogen peroxide (A), acetic acid (B), palmitoleic acid (C), oleic acid (D) or 
DiC8 diacylglycerol (E). Data are presented as mean  SEM (n = 3). *p < 0.05, p < 0.005. Cells were 
cultured in YP medium containing 0.2% glucose. 
 
          The lro1 mutation: 1) shortens the chronological life span (Figure 3.16C) of CR 
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yeast; 2) increases the intracellular concentration of DAG during D and PD phases 
(Figure 3.17D): 3) increases the intracellular concentration of FFA during D and PD 
phases (Figure 3.17E); and 4) does not prevent the complete consumption of the 
intracellular pools of DAG and FFA prior to entry into ST phase (Figures 3.17D and 
3.17E). I found that the lro1 mutation: 1) does not alter the susceptibility of CR yeast to 
mitochondria-controlled apoptotic cell death caused by their short-term exposure to 
exogenous hydrogen peroxide or acetic acid (Figures 3.18A and 3.18B); but 2) reduces 
the resistance of CR yeast to necrotic cell death caused by a short-term exposure to 
exogenous FFA or DAG (Figures 3.18C, 3.18D and 3.18E). 
          The tgl4 mutation: 1) increases the chronological life span (Figure 3.16E) of CR 
yeast; 2) reduces the intracellular concentration of DAG during D and PD phases (Figure 
3.17G): 3) reduces the intracellular concentration of FFA during D and PD phases 
(Figure 3.17H); and 4) does not prevent the complete consumption of the intracellular 
pools of DAG and FFA prior to entry into ST phase (Figures 3.17G and 3.17H). I found 
that the tgl4 mutation: 1) does not alter the susceptibility of CR yeast to mitochondria-
controlled apoptotic cell death caused by their short-term exposure to exogenous 
hydrogen peroxide or acetic acid (Figures 3.18A and 3.18B); but 2) increases the 
resistance of CR yeast to necrotic cell death caused by a short-term exposure to 
exogenous FFA or DAG (Figures 3.18C, 3.18D and 3.18E).  
          Altogether, my findings imply that FFA and DAG regulate longevity by two 
different mechanisms that operate at two different stages of the aging process. One 
mechanism involves sensing the concentration of DAG maintained by cells (in a diet- and 
genotype-dependent fashion) during D and PD growth phases. DAG concentration during 
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D and PD phases programs cell viability during ST growth phase by modulating the FFA- 
and DAG-induced necrotic cell death pathway, but not by influencing the mitochondria-
controlled apoptotic pathway of cell death. Another mechanism involves sensing the 
concentrations of FFA and DAG during ST phase. Any diet or genetic manipulation that 
causes the build-up of these two lipids during ST phase shortens the chronological life 
span of yeast in part by promoting rapid mitochondria-controlled apoptotic cell death, but 
not by activating FFA- and DAG-induced necrotic cell death pathway. 
 
3.5. Discussion 
Using a combination of functional genetic, cell biological, electron and fluorescence 
microscopical, proteomic, lipidomic, and metabolomic analyses, I established the 
molecular mechanism underlying the ability of CR to extend longevity of chronologically 
aging yeast by specifically remodelling lipid metabolism in the ER, LBs and 
peroxisomes. In this mechanism, LBs in yeast cells function as a hub in a regulatory 
network that modulates neutral lipids synthesis in the ER and fatty acid oxidation in 
peroxisomes. Ethanol accumulated in yeast placed on a calorie-rich diet represses the 
synthesis of Fox1p, Fox2p and Fox3p, thereby suppressing peroxisomal oxidation of FFA 
that originate from TAG synthesized in the ER and deposited within LBs. The resulting 
build-up of arrays of FFA (called gnarls) within LBs of non-CR yeast initiates several 
negative feedback loops regulating the metabolism of TAG. Due to the action of these 
negative feedback loops, chronologically aging non-CR yeast not only amass TAG in 
LBs but also accumulate FFA and DAG in the ER. FFA and DAG regulate longevity by 
two different mechanisms that operate at two different stages of the aging process. One 
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mechanism involves sensing the concentration of DAG maintained by cells (in a diet- and 
genotype-dependent fashion) during D and PD growth phases. DAG concentration during 
D and PD phases programs cell viability during the non-proliferative ST growth phase by 
modulating the FFA- and DAG-induced necrotic cell death pathway, but not by 
influencing the mitochondria-controlled apoptotic pathway of cell death. Another 
mechanism involves sensing the concentrations of FFA and DAG during ST phase. Any 
diet or genetic manipulation that causes the build-up of these two lipids during ST phase 
shortens the chronological life span of yeast in part by promoting rapid mitochondria-
controlled apoptotic cell death, but not by activating FFA- and DAG-induced necrotic 
cell death pathway. 
          The proposed above mechanism can satisfactorily explain my data on the observed 
effects of various dietary and genetic interventions that I examined on age-related lipid 
dynamics and longevity. My explanations of these effects for each intervention I used are 
outlined below within the framework of the proposed here mechanism. 
          Chronologically aging WT cells placed on a calorie-rich diet generate the bulk of 
ATP via glycolytic oxidation of glycogen- and trehalose-derived glucose (Figure 3.19A). 
These cells accumulate ethanol, a product of glucose fermentation (Figure 3.19A). By 
repressing the synthesis of Fox1p, Fox2p and Fox3p, ethanol suppresses peroxisomal 
oxidation of FFA that originate from TAG synthesized in the ER and deposited within 
LBs. The low efficiency of peroxisomal oxidation of FFA causes the build-up of gnarls 
(the arrays of FFA) within LBs (Figure 3.19A). This, in turn, initiates several negative 
feedback loops that regulate the metabolism of TAG and ultimately result in the 







































































Figure 3.19. Outline of metabolic pathways and interorganellar communications operating in 
chronologically aging cells of WT and adh mutant strains grown under CR or non-CR conditions. The 
longevity-defining features of the diet- or mutation-driven metabolic design for each strain and growth 
condition are discussed in details in the Discussion section of this Chapter. 
 
cells under non-CR conditions amasses only in the non-proliferative ST growth phase, it 
does not activate the age-related necrotic cell death pathway and, thus, does not play a 
role in shortening the chronological life span of these cells (Figure 3.19A). The reduced 
life span of WT cells placed on a calorie-rich diet is due to their rapid apoptotic death 
controlled by mitochondria and initiated upon their entry into ST phase. The primary 
reason for such activation of an age-related form of mitochondria-controlled apoptosis 
lies in the low levels of enzymes functioning in the formation of FA-CoA and in their 
uptake and subsequent oxidation by peroxisomes seen in non-CR WT cells. The 









































































Figure 3.20. Outline of metabolic pathways and interorganellar communications operating in 
chronologically aging cells of fox1 and other mutant strains grown under CR conditions. The longevity-
defining features of the mutation-driven metabolic design for each mutant strain and growth condition are 
discussed in details in the Discussion section of this Chapter. 
 
during ST phase greatly impairs their ability to generate significant quantities of ATP by 
oxidizing peroxisome-derived acetyl-CoA in mitochondria. The resulting decline in 
oxidation-reduction processes within mitochondria 1) reduces the flow of electron pairs 
through the mitochondrial ETC, thereby intensifying the transfer of single electrons on 
molecular oxygen and the resulting production of excessive ROS, which accelerate aging 
by causing oxidative molecular damage; 2) decreases the electrochemical gradient across 
the inner mitochondrial membrane (); and 3) causes mitochondrial fragmentation by 
promoting fission of the mitochondrial tubular network (Figure 3.19A). The 
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Figure 3.21. Outline of metabolic pathways and interorganellar communications operating in 
chronologically aging cells of dga1 and other mutant strains grown under CR conditions. The longevity-
defining features of the mutation-driven metabolic design for each mutant strain and growth condition are 
discussed in details in the Discussion section of this Chapter. 
 
entry into ST phase and initiates the life-shortening process of age-related death, which is 
driven by the release of pro-apoptotic factors from fragmented mitochondria (Figure 
3.19A). Of note, the low levels of trehalose in chronologically aging WT cells placed on 
a calorie-rich diet is another factor that could contribute to shortening their life span, as 
compared to WT cells grown under CR conditions (Figure 3.19A). Although trehalose 
has been long considered only as a reserve carbohydrate [256], it seems that the major 
function of this non-reducing disaccharide in yeast consists in enabling the survival of 
cells exposed to elevated temperature or ROS [257 - 259]. In fact, trehalose in yeast cells 
prevents aggregation of proteins denatured during and immediately after their exposure to 
these stresses [260]. I therefore propose that the reduced levels of trehalose seen in non-
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CR cells of WT strain during PD phase are unable to protect from aggregation those 
proteins that have been denatured due to their exposure to ROS accumulated during this 
growth phase (Figure 3.19A). Lack of such protective effect of trehalose in WT cells 
grown under non-CR conditions, due to the low concentrations of this non-reducing 
disaccharide (as compared to CR cells of WT strain), could contribute to the reduced (as 
compared WT cells grown under CR conditions) survival of non-CR cells during the 
following ST phase.  
          Within the framework of the proposed here mechanism, WT cells grown under CR 
conditions have extended chronological life span (as compared to that of WT cells placed 
on a calorie-rich diet) due to the following features of their diet-driven metabolic design 
(Figure 3.19B): 1) the very low level of ethanol, which therefore is unable to repress the 
synthesis of Fox1p, Fox2p and Fox3p and to suppress peroxisomal oxidation of FFA that 
originate from TAG synthesized in the ER and deposited within LBs; 2) lack of gnarls, 
due to the rapid oxidation of FFA in peroxisomes, and the resulting inability to initiate 
several negative feedback loops that regulate the metabolism of TAG and would 
ultimately result in the accumulation of TAG in LBs as well as FFA and DAG in the ER; 
3) the very low level of DAG in PD phase and the complete consumption of this lipid in 
ST phase (it should be stressed that, if DAG amasses in PD phase, it can initiate age-
related necrotic cell death; see below); 4) the highly efficient ability to oxidize FFA to 
acetyl-CoA via a peroxisome-confined pathway during ST phase, which not only allows 
cells to generate the bulk of ATP by oxidizing peroxisome-derived acetyl-CoA in 
mitochondria but also activates oxidation-reduction processes in mitochondria, maintains 
high , and prevents the fragmentation of the mitochondrial tubular network - thereby 
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protecting cells from age-related form of apoptotic death controlled by mitochondria; and 
5) the elevated level trehalose, which contributes to the life span extension seen in CR 
cells of WT strain by  protecting from aggregation those proteins that have been 
denatured due to their exposure to mitochondrially produced ROS.       
          Within the framework of the proposed here mechanism, adh2 cells under CR 
conditions have shortened chronological life span (as compared to that of calorie-limited 
WT cells) due to the following features of their adh2 mutation-driven metabolic design 
(Figure 3.19A): 1) the elevated level of ethanol, which therefore is able to repress the 
synthesis of Fox1p, Fox2p and Fox3p and to suppress peroxisomal oxidation of FFA that 
originate from TAG synthesized in the ER and deposited within LBs; 2) the build-up of 
gnarls within LBs, due to suppressed oxidation of FFA in peroxisomes, and the resulting 
initiation of several negative feedback loops that regulate the metabolism of TAG and 
ultimately result in the accumulation of TAG in LBs as well as FFA and DAG in the ER; 
3) the reduced efficiency of oxidizing FFA to acetyl-CoA via a peroxisome-confined 
pathway during ST phase, which not only impairs ATP synthesis in mitochondria but also 
leads to a decline in oxidation-reduction processes within mitochondria, enhances 
mitochondrial ROS production, decreases  and causes fragmentation of the 
mitochondrial tubular network - thereby promoting the age-related form of apoptotic cell 
death controlled by mitochondria and shortening life span. 
          Within the framework of the proposed here mechanism, adh1 cells under CR 
conditions have increased chronological life span (as compared to that of calorie-limited 
WT cells) due to the following features of their adh1 mutation-driven metabolic design 
(Figure 3.19B): 1) the greatly reduced level of ethanol, which therefore is unable to 
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repress the synthesis of Fox1p, Fox2p and Fox3p and to suppress peroxisomal oxidation 
of FFA that originate from TAG synthesized in the ER and deposited within LBs; 2) lack 
of gnarls, due to the accelerated oxidation of FFA in peroxisomes, and the resulting 
inability to initiate several negative feedback loops that regulate the metabolism of TAG 
and would ultimately result in the accumulation of TAG in LBs as well as FFA and DAG 
in the ER; 3) the very low level of DAG in PD phase and the complete consumption of 
this lipid in ST phase (it should be stressed that, if DAG amasses in PD phase, it can 
initiate age-related necrotic cell death; see below); 4) the enhanced ability to oxidize FFA 
to acetyl-CoA via a peroxisome-confined pathway during ST phase, which not only 
allows cells to generate the bulk of ATP by oxidizing peroxisome-derived acetyl-CoA in 
mitochondria but also activates oxidation-reduction processes in mitochondria, maintains 
high , and prevents the fragmentation of the mitochondrial tubular network - thereby 
protecting cells from age-related form of apoptotic death controlled by mitochondria; and 
5) the greatly elevated level trehalose, which contributes to the life span extension seen in 
CR cells of adh1 strain by  protecting from aggregation those proteins that have been 
denatured due to their exposure to mitochondrially produced ROS. 
          Within the framework of the proposed here mechanism, fox1 , fox2 and fox3 
cells grown under CR conditions have shortened chronological life span (as compared to 
that of calorie-limited WT cells) due to the following features of their fox mutation-
driven metabolic design (Figure 3.20A): 1) the complete inability to oxidize FFA that 
originate from TAG synthesized in the ER and deposited within LBs; 2) the build-up of 
gnarls within LBs, due to impaired oxidation of FFA in peroxisomes, and the resulting 
initiation of several negative feedback loops that regulate the metabolism of TAG and 
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ultimately result in the accumulation of TAG in LBs as well as FFA and DAG in the ER 
(it should be stressed that, although fox1 , fox2 and fox3 cells grown under CR 
conditions amass DAG, they do so only in ST phase; therefore, the shortened life spans 
of these cells is not due to accelerated age-related necrotic cell death, which can be 
initiated by DAG only if it accumulates in PD phase - see below); and 3) the inability to 
oxidize FFA to acetyl-CoA via a peroxisome-confined pathway during ST phase not only 
impairs ATP synthesis in mitochondria but also leads to a decline in oxidation-reduction 
processes within mitochondria, enhances mitochondrial ROS production, decreases  
and causes fragmentation of the mitochondrial tubular network - thereby promoting the 
age-related form of apoptotic cell death controlled by mitochondria and shortening life 
span. 
          Within the framework of the proposed here mechanism, gpt2, sct1, ayr1, 
slc1, lpp1 and dpp1 cells grown under CR conditions have increased chronological 
life span (as compared to that of calorie-limited WT cells) due to the reduced level of 
DAG in D and PD phases (Figures 3.17A and 3.20B). As I found, DAG concentration 
during D and PD phases programs cell viability during ST growth phase by modulating 
the FFA- and DAG-induced necrotic cell death pathway, but not by influencing the 
mitochondria-controlled apoptotic pathway of cell death. Thus, the reduced (as compared 
to calorie-limited WT cells) level of DAG in D and PD phases extends the chronological 
life spans of gpt2, sct1, ayr1, slc1, lpp1 and dpp1 cells grown under CR by 
delaying their age-related, FFA- and DAG-induced necrotic cell death during ST phase 
(Figure 3.20B). 
          Within the framework of the proposed here mechanism, dga1, are1, are2 and 
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lro1 cells grown under CR conditions have reduced chronological life span (as 
compared to that of calorie-limited WT cells) due to the elevated level of DAG in D and 
PD phases (Figures 3.17D and 3.21A). As I found, DAG concentration during D and PD 
phases programs cell viability during ST growth phase by modulating the FFA- and 
DAG-induced necrotic cell death pathway, but not by influencing the mitochondria-
controlled apoptotic pathway of cell death. Thus, the elevated (as compared to calorie-
limited WT cells) level of DAG in D and PD phases shortens the chronological life spans 
of dga1, are1, are2 and lro1 cells grown under CR conditions by accelerating their 
age-related, FFA- and DAG-induced necrotic cell death during ST phase (Figure 3.21A). 
          Within the framework of the proposed here mechanism, tgl1, tgl2, tgl3, tgl4 
and tgl5 cells grown under CR conditions have increased chronological life span (as 
compared to that of calorie-limited WT cells) due to the reduced level of DAG in D and 
PD phases (Figures 3.17G and 3.21B). As I found, DAG concentration during D and PD 
phases programs cell viability during ST growth phase by modulating the FFA- and 
DAG-induced necrotic cell death pathway, but not by influencing the mitochondria-
controlled apoptotic pathway of cell death. Thus, the reduced (as compared to calorie-
limited WT cells) level of DAG in D and PD phases extends the chronological life spans 
of tgl1, tgl2, tgl3, tgl4 and tgl5 cells grown under CR conditions by delaying their 
age-related, FFA- and DAG-induced necrotic cell death during ST phase (Figure 3.20B). 
 
3.6. Conclusions 
My functional genetic, cell biological, electron and fluorescence microscopical, 
proteomic, lipidomic, and metabolomic analyses resulted in defining the molecular 
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mechanism underlying the ability of CR to extend longevity of chronologically aging 
yeast by specifically remodelling lipid metabolism in the ER, LBs and peroxisomes. I 
expect that this knowledge will be instrumental for designing high-throughput screening 
of novel anti-aging drugs that can extend longevity by targeting different aspects of this 
mechanism.   
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4. A mechanism underlying the ability of a novel anti-aging drug to extend yeast 
life span by targeting the longevity-defining aspects of lipid metabolism confined 
to the ER, LBs and peroxisomes   
 
4.1. Abstract 
As described in Chapter 3 of this thesis, I established the molecular mechanism 
underlying the ability of caloric restriction (CR) to extend longevity of chronologically 
aging yeast by specifically remodelling lipid metabolism in the endoplasmic reticulum 
(ER), lipid bodies (LBs) and peroxisomes. This knowledge has been instrumental for 
choosing the single-gene-deletion mutant pex5 as a short-lived mutant strain for high-
throughput screen of novel anti-aging drugs that can extend longevity by targeting such 
mechanism under CR conditions. In experiments described in this Chapter, I first 
elucidated how the pex5 mutation affects different aspects of the mechanism linking 
longevity and lipid metabolism in the ER, LBs and peroxisomes. I found that in yeast 
placed on a CR diet this mutation leads to: 1) increase in free fatty acids (FFA), 
diacylglycerols (DAG), triacylglycerols (TAG) and ergosteryl esters (EE) and their build-
up in the ER and LBs; 2) excessive accumulation of the ER membranes and ER-
originated LBs; and 3) enhanced susceptibility to necrotic cell death caused to a short-
term exposure to exogenously added FFA and DAG. Using the short-lived pex5 mutant 
strain, Alexander Goldberg in Dr. Titorenko’s laboratory conducted a high-throughput 
screen of novel anti-aging compounds that can extend the chronological life span (CLS) 
of yeast by targeting these longevity-defining aspects of lipid metabolism under CR 
conditions. One of the life-extending compounds identified in such screen was lithocholic 
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acid (LCA), a bile acid. Studies in Dr. Titorenko’s laboratory revealed that LCA greatly 
extends the CLS of wild-type (WT) strain of yeast placed on a CR diet. By elucidating 
how LCA influences the metabolism of lipids as well as age-related forms of necrotic and 
apoptotic death in chronologically aging yeast and how it alters yeast proteome, in 
experiments described in this Chapter I established the molecular mechanism underlying 
the ability of LCA to extend yeast CLS by targeting these longevity-defining aspects of 
lipid metabolism confined to the ER, LBs and peroxisomes. In such mechanism, under 
CR conditions LCA accelerates the biosynthesis of TAG from FFA and DAG in the ER 
as well as decelerates the FFA- and DAG-generating lipolysis of TAG in LBs. The 
resulting reduction of the ER- and LB-confined levels of FFA and DAG during diauxic 
(D), post-diauxic (PD) and stationary (ST) growth phases affects both mechanisms (see 
Chapter 3 of this thesis) by which these two lipid species regulate longevity. First, by 
lowering the intracellular concentration of DAG during D and PD phases, LCA 
attenuates the FFA- and DAG-induced necrotic cell death pathway – thereby impairing 
the age-related form of necrotic cell death and ultimately extending longevity of 
chronologically aging yeast placed on a CR diet. Second, by reducing the intracellular 
concentrations of FFA and DAG during ST phase, LCA attenuates the mitochondria-
controlled apoptotic cell death pathway – thereby impairing the age-related form of 
apoptotic cell death and ultimately extending longevity of chronologically aging yeast 
under CR conditions.  
 
4.2. Introduction 
          As I described in Chapter 1 of this thesis, certain pharmacological interventions 
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can extend life span across phyla and, in some cases, improve overall health by 
beneficially influencing age-related pathologies (see Figure 4.1). Noteworthy, two anti-
aging compounds known prior to my study have been shown to alter lipid levels in 
mammals and fruit flies under non-DR conditions. Specifically, resveratrol treatment 
reduces the levels of the neutral lipids TAG and increases FFA levels in mouse 
adipocytes [116]. Furthermore, feeding rapamycin to fruit flies results in elevated TAG 
levels [38].  
          Although it remains to be seen if such effects of resveratrol and rapamycin on lipid 
levels play a casual role in their anti-aging action under non-DR conditions, it should be 
stressed that lipid metabolism has been shown to be involved in longevity regulation in 
yeast [18, 153], worms [46, 63, 182, 190], fruit flies [183, 190] and mice [140, 141, 185, 
187, 188, 190] (see Chapters 1 and 3 for a detailed discussion of this topic). In Chapter 3 
of this thesis, I proposed a mechanism linking yeast longevity and lipid dynamics in the 
ER, LBs and peroxisomes. In this mechanism, a CR diet extends yeast CLS by activating 
FFA oxidation in peroxisomes [18, 153]. It is conceivable that the identification of small 
molecules targeting this mechanism could yield novel anti-aging compounds. Such 
compounds can be used as research tools for defining the roles for different longevity 
pathways in modulating lipid metabolism and in integrating lipid dynamics with other 
longevity-related processes. Furthermore, the availability of such compounds would 
enable a quest for housekeeping longevity assurance pathways that do not overlap (or 
only partially overlap) with the adaptable TOR and cAMP/PKA pathways (see Chapter 1 
of this thesis for a detailed discussion of this topic). Moreover, such compounds would 
have a potential to be used as pharmaceutical agents for increasing life span and 
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promoting healthy aging by delaying the onset of age-related diseases caused by various 
defects in lipid metabolism and signaling, regardless of an organism’s dietary regimen.            
          A performed by Alexander Goldberg in Dr. Titorenko’s laboratory high-throughput 
screen of novel anti-aging compounds that can extend yeast longevity under CR 
conditions by altering lipid metabolism identified LCA as one of these compounds. In 
studies described in this Chapter, I established the molecular mechanism underlying the 
ability of LCA to extend yeast CLS by targeting the essential longevity-defining aspects 
of lipid metabolism confined to the ER, LBs and peroxisomes. 
 
4.3. Materials and Methods 
Strains and media  
The wild-type strain Saccharomyces cerevisiae BY4742 (MAT his31 leu20 lys20 
ura30) and mutant strains pex5 (MAT his31 leu20 lys20 ura30 
pex5::kanMX4), tor1 (MAT his31 leu20 lys20 ura30 tor1::kanMX4), ras2 
(MAT his31 leu20 lys20 ura30 ras2::kanMX4) and rim15 (MAT his31 
leu20 lys20 ura30 rim15::kanMX4) were used in this study. Media components 
were as
 
follows: 1) YEPD (0.2% Glucose), 1% yeast extract, 2% peptone, 0.2% glucose; 
2) YEPD (0.5% Glucose), 1% yeast extract, 2% peptone, 0.5% glucose; 3) YEPD (1% 
Glucose), 1% yeast extract, 2% peptone, 1% glucose; and 4) YEPD (2% Glucose), 1% 
yeast extract, 2% peptone, 2% glucose.  
 
A plating assay for the analysis of chronological life span 
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Cells were grown in YEPD medium initially containing 0.2%, 0.5%, 1% or 2% glucose 
as carbon source at 30
o
C with rotational shaking at 200 rpm in Erlenmeyer flasks at a 
flask volume/medium volume ratio of 5:1. A sample of cells was removed from each 
culture at various time points. A fraction of the cell sample was diluted in order to 
determine the total number of cells per ml of culture using a hemacytometer. 10 l of 
serial dilutions (1:10 to 1:10
3
) of cells were applied to the hemacytometer, where each 
large square is calibrated to hold 0.1 l. The number of cells in 4 large squares was then 
counted and an average was taken in order to ensure greater accuracy. The concentration 
of cells was calculated as follows: number of cells per large square x dilution factor × 10 
× 1,000 = total number of cells per ml of culture. A second fraction of the cell sample 




) of cells were plated onto YEPD (2% 
Glucose) plates in triplicate in order to count the number of viable cells per ml of each 
culture. 100 l of diluted culture was plated onto each plate. After a 48-h incubation at 
30
o
C, the number of colonies per plate was counted. The number of colony forming units 
(CFU) equals to the number of viable cells in a sample. Therefore, the number of viable 
cells was calculated as follows: number of colonies × dilution factor × 10 = number of 
viable cells per ml. For each culture assayed, % viability of the cells was calculated as 
follows: number of viable cells per ml / total number of cells per ml × 100%. The % 
viability of cells in mid-logarithmic phase was set at 100% viability for that particular 
culture.  
 
Visualization of intracellular lipid bodies (LBs) 
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Wild-type and mutant cells grown in YEPD medium initially containing 0.2%, 0.5%, 1% 
or 2% glucose as carbon source were tested microscopically for the presence of 
intracellular LBs by incubation with BODIPY 493/503. Cells were also probed with a 
fluorescent counterstain CW in order to visualize all cells in the population. BODIPY 
493/503 was stored in the dark at –20oC as 100 l aliquots of a 1 mM solution in ethanol. 
CW was stored in the dark at –20oC as the 5 mM stock solution in anhydrous DMSO. 
          The concurrent staining of cells with BODIPY 493/503 and CW was carried out as 
follows. The required amounts of the 100 l BODIPY 493/503 aliquots (1 mM) and of 
the 5 mM stock solution of CW were taken out of the freezer and warmed to room 
temperature. The solutions of DHR and CW were then centrifuged at 21,000 × g for 5 
min in order to clear them of any aggregates of fluorophores. For cell cultures with a titre 
of ~ 10
7
 cells/ml, 100 l was taken out of the culture to be treated. If the cell titre was 
lower, proportionally larger volumes were used. The samples were then centrifuged at 
21,000 × g for 1 min, and pelleted cells were resuspended in 100 l of TNT buffer (25 
mM Tris/HCl (pH 7.5), 150 mM NaCl and 0.2 % Triton X-100). After a 10-min 
incubation at room temperature, the samples were centrifuged at 21,000 × g for 1 min. 
Pellets were then resuspended in 100 l of TN buffer (25 mM Tris/HCl (pH 7.5), 150 
mM NaCl), and the samples were subjected to centrifugation at 21,000 × g for 1 min. 
Pelleted cells were finally resuspended in 100 l of TN buffer. Each 100 l aliquot of 
cells was then supplemented with 1 μl of the 1 mM BODIPY 493/503 and 1 l of the 5 
mM CW solutions. After a 15-min incubation in the dark at room temperature, the 
samples were centrifuged at 21,000 × g for 5 min. Pellets were resuspended in 100 l of 
TN buffer. The samples were centrifuged again at 21,000 × g for 5 min, and pellets were 
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resuspended in 100 l of TN buffer. 10 l of the BODIPY 493/503- and CW-treated cell 
suspension was then added to a microscope slide and covered with a coverslip. The slides 
were then sealed using nail polish. Once the slides were prepared, they were visualized 
under the Zeiss Axioplan fluorescence microscope mounted with a SPOT Insight 2 
megapixel color mosaic digital camera.  Several pictures of the cells on each slide were 
taken, with two pictures taken of each frame. One of the two pictures was of the cells 
seen through a fluorescein filter in order to detect cells dyed with BODIPY 493/503. The 
second picture was of the cells seen through a DAPI filter in order to visualize CW, and 
therefore all the cells present in the frame. For evaluating the percentage of BODIPY 
493/503-positive cells, the UTHSCSA Image Tool (Version 3.0) software was used to 
calculate both the total number of cells and the number of stained cells. 
 
Electron microscopy and morphometric analysis 
Cells were fixed in 1.5% KMnO4 for 20 min at room temperature, dehydrated by 
successive incubations in increasing concentrations of ethanol, and embedded in 
Poly/Bed 812 epoxy resin (Polysciences). Ultrathin sections were cut using an Ultra-Cut 
E Microtome (Reichert-Jung). Silver/gold thin sections from the embedded blocks were 
examined in a JEOL JEM-2000FX transmission electron microscope. For morphometric 
analysis of random electron microscopic sections of cells, digitized images were analyzed 
using the UTHSCSA Image Tool (Version 3.0) software. In each of 2 independent 
experiments, the percentage of cells that contain pexopodia and/or accumulate gnarled 
LBs was calculated by analyzing at least 300 cells that were collected at each time point. 
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The values of the percentage of cells containing pexopodia and/or accumulating gnarled 
LBs were plotted as a function of the number of days cells were cultured. 
 
Preparation of total cell lysates 
An aliquot containing 1 × 10
9 
cells was centrifuged for 7 min at 3,000 rpm at room 
temperature. Pelleted cells were washed twice with distilled water and further centrifuged 
for 3 min at 16,000 × g at room temperature. The recovered cell pellet was then 
resuspended in 500 μl of 4% CHAPS in 25 mM Tris/HCl buffer (pH 8.5) and centrifuged 
for 15 sec at 16,000 × g at room temperature. The cells were then washed again, first by 
resuspending them in 500 μl of 4% CHAPS in 25 mM Tris/HCl buffer (pH 8.5) and then 
by centrifuging for 15 sec at 16,000 × g at room temperature. The pellet of washed cells 
was then resuspended in 1 ml of ice-cold 4% CHAPS in 25 mM Tris/HCl buffer (pH 8.5), 
divided into 5 equal aliquots of 200 μl each and placed in Eppendorf tubes kept on ice. 
Each 200 μl aliquot was supplemented with ~100 μl of glass beads and vortexed three 
times for 1 minute. Apart from the vortexing steps, the samples were kept on ice at all 
times. Glass beads and cell debris were then pelleted by 5 min centrifugation at 16,000 × 
g at 4
o
C.  The resulting supernatant of the glass bead lysate was immediately transferred 
into a pre-chilled Eppendorf tube and stored at -20
o
C for further analysis. 
 
Purification of the ER 
Reagents and solutions 
1. TSD reduction buffer: 0.1 M Tris/Sulfate (pH 9.4), 10 mM DTT 
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2. HEPES lysis buffer: 20 mM HEPES/KOH, pH 6.8, 50 mM KCl, 200 mM sorbitol, 2 
mM EDTA, 1 mM DTT 
3. Spheroplast medium A (pH 7.5): 0.67% yeast nitrogen base (w/o) amino acids, 2 % 
(w/v) glucose, 1 M sorbitol, 20 mM Tris/HCl (pH 7.5) 
4. Spheroplast medium B: 0.67% yeast nitrogen base (w/o) amino acids, 2 % (w/v) 
glucose, 1 M sorbitol 
5. 1.2 M sucrose/ HEPES, 36% (w/w): 7.2 g sucrose + 12.8 ml HEPES lysis buffer 
6. 1.5 M sucrose/ HEPES, 43% (w/w): 8.6 g sucrose + 11.4 ml HEPES lysis buffer 
7. MES buffer 1 (MES breaking buffer): 10 mM MES/Tris (pH 6.9), 12 % (w/w) Ficoll 
400, 0.2 mM EDTA 
8. MES buffer 2: 10 mM MES/Tris (pH 6.9), 8 % (w/w) Ficoll 400, 0.2 mM EDTA 
9. MES buffer 3: 10 mM MES/Tris (pH 6.9), 0.6 M sorbitol, 8 % (w/w) Ficoll 400, 0.2 
mM EDTA 
10. MES buffer 4: 10 mM MES/Tris (pH 6.9), 0.25 M sorbitol, 0.2 mM EDTA 
11. KPi buffer (pH 7.4): 20 mM KH2PO4/KOH (pH 7.4), 1.2 M sorbitol 
 
Procedure 
Wild-type and mutant cells were grown in YEPD medium initially containing 0.2%, 
0.5%, 1% or 2% glucose as carbon source. Cultures were harvested at mid-exponential 
and diauxic phases, checked for contamination by bright-field microscopy and used to 
measure cell density at OD600. The non-contaminated wild-type and mutant cells were 
pelleted at 4,000 × g for 5 min at room temperature. Cells were then resuspended at 10 
OD600 units/ml in TSD reduction buffer, incubated for 10 min at room temperature and 
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centrifuged for 5 min at 4,000 × g at room temperature. Pelleted cells were then 
resuspended at 20 OD600 units/ml in Spheroplast medium A and supplemented with 
Zymolyase 100T at a concentration of 7.5 μg per OD600 units of cells. 10 μl of each cell 
suspension was then removed, diluted in 990 μl of H2O and used to measure the OD600. 
The remaining cell suspensions were incubated at 30°C for 30 min and the efficiency of 
cell wall removal was monitored by measuring the OD600. Cell wall digestion was 
allowed to proceed until the OD600 measurement of the diluted cell suspension became 
5% of the original value, with the total digestion time not exceeding 1 hour. Spheroplasts 
were then harvested by centrifugation at 1,500 × g for 5 min at room temperature, 
followed by resuspending at 1 to 5 OD600 units/ml in Spheroplast medium B by gentle 
swirling of the tube or gentle stirring with a glass rod. Spheroplasts were then harvested 
by centrifugation at 1,500 × g for 5 min at 4°C and then resuspended at a concentration of 
1,000 OD600 units/ml of ice-cold HEPES lysis buffer with freshly-added DTT. 
Spheroplasts were then homogenized using 20 strokes and resulting lysates were 
centrifuged at 1, 000 × g for 10 min at 4°C. The supernatants (S1000) were subjected to 
another round of centrifugation at 1, 000 × g for 10 min at 4°C, and resulting 
supernatants were further centrifuged at 27,000 × g for 10 min at 4°C. The pelleted 
membranes (P27,000) were resuspended in 1.0 ml of HEPES lysis buffer (5,000 OD600 
equivalents per ml) using a trimmed 1-ml pipette tip and carefully layered on top of a 
sucrose gradient prepared in advance (2.1 ml of 1.5 M sucrose/HEPES solution was 
deposited to the bottom of a Beckman Ultra-Clear centrifuge tube for the Beckman MLS-
50 rotor, and then overlaid with 2.1 ml of 1.2 M sucrose/HEPES solution). The gradient 
tubes were then placed in the pre-chilled swinging bucket Beckman MLS-50 rotor and 
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centrifuged at 100,000 × g (36,000 rpm) for 1 hr at 4°C using the slow acceleration and 
deceleration setting to minimize disruption of gradients. 18 gradient fractions of 227 μl 
each were then collected starting from the top of the sucrose gradient and stored at -20°C 
for further analyses.  
 
Purification of LBs 
Reagents and solutions 
1. TSD reduction buffer: 0.1 M Tris/Sulfate (pH 9.4), 10 mM DTT 
2. HEPES lysis buffer: 20 mM HEPES/KOH, pH 6.8, 50 mM KCl, 200 mM sorbitol, 2 
mM EDTA, 1 mM DTT 
3. Spheroplast medium A (pH 7.5): 0.67% yeast nitrogen base (w/o) amino acids, 2 % 
(w/v) glucose, 1 M sorbitol, 20 mM Tris/HCl (pH 7.5) 
4. Spheroplast medium B: 0.67% yeast nitrogen base (w/o) amino acids, 2 % (w/v) 
glucose, 1 M sorbitol 
5. 1.2 M sucrose/ HEPES, 36% (w/w): 7.2 g sucrose + 12.8 ml HEPES lysis buffer 
6. 1.5 M sucrose/ HEPES, 43% (w/w): 8.6 g sucrose + 11.4 ml HEPES lysis buffer 
7. MES buffer 1 (MES breaking buffer): 10 mM MES/Tris (pH 6.9), 12 % (w/w) Ficoll 
400, 0.2 mM EDTA 
8. MES buffer 2: 10 mM MES/Tris (pH 6.9), 8 % (w/w) Ficoll 400, 0.2 mM EDTA 
9. MES buffer 3: 10 mM MES/Tris (pH 6.9), 0.6 M sorbitol, 8 % (w/w) Ficoll 400, 0.2 
mM EDTA 
10. MES buffer 4: 10 mM MES/Tris (pH 6.9), 0.25 M sorbitol, 0.2 mM EDTA 
11. KPi buffer (pH 7.4): 20 mM KH2PO4/KOH (pH 7.4), 1.2 M sorbitol 
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Procedure 
Wild-type and mutant cells were grown in YEPD medium initially containing 0.2%, 
0.5%, 1% or 2% glucose as carbon source. Cultures were harvested at mid-exponential 
and diauxic phases, checked for contamination by bright-field microscopy and used to 
measure cell density at OD600. The non-contaminated wild-type and mutant cells were 
pelleted at 4,000 × g for 5 min at room temperature. The cells were then washed once 
with distilled water and resuspended in the TSD reduction buffer at 10 x OD600 units/ml. 
Following a 10-min incubation at room temperature, the cells were pelleted by 
centrifugation at 4,000 × g for 5min at room temperature and then washed once in 
Spheroplasts medium A. The cells were then resuspended in Spheroplasts medium A at 
20 × OD600 units/ml, supplemented with Zymolyase 100T at a concentration of 2.5 μg per 
OD600 units of cells, and incubated at 30°C for 45 min on a shaker set at 75 rpm. 
Spheroplasts were then pelleted by 5min centrifugation at 1,500 × g at room temperature, 
resuspended in the ice-cold Spheroplasts medium B at 5 × OD600 units/ml using pipettes 
with cut tips, and centrifuged for 5 min at 1,500 × g at 4
o
C. Spheroplasts were then 
washed twice by resuspending the pellets in ice-cold KPi buffer at a concentration of 5 
OD600 units/ml followed by centrifugation for 5 min at 1,500 × g at 4
o
C. After the second 
wash and centrifugation step, clean spheroplasts were resuspended in ice-cold MES 
Buffer 1 at a concentration of 1,000 OD600 units/ml using pipettes with non-cut tips. 
Spheroplasts were then lysed in a homogenizer using 20 strokes at 4°C. Lysates were 
centrifuged for 5 min at 5,000 × g at 4°C and the resulting supernatants (S5,000) were 
transferred to pre-chilled centrifuge tubes kept on ice. LBs were then purified by 
subjecting the spheroplast lysates to a series of flotation gradient centrifugations using a 
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MLS 50 swinging bucket rotor (Beckman). The first flotation gradient was prepared by 
placing 2.5 ml of the S5,000 fraction to the bottom of a centrifuge tube (Ultra-Clear 
Beckman tubes for MLS 50 rotor) and overlaying it with 2.5 ml of ice-cold MES Buffer 
1. Following 1 hour centrifugation at 100,000 × g (36,000 rpm) at 4°C,  the floating layer 
from the top portions of the gradients was collected with a cut tip and transferred to the 
bottom of a new centrifuge tube, which was then supplemented with MES buffer 2 to a 
total volume of 2.5 ml and gently mixed by pipetting. Resulting suspension was overlaid 
with 2.5 ml of ice-cold MES buffer 2 and then centrifuged for 1 hr at 100,000 × g (36,000 
rpm) at 4°C. The floating layer from the top portions of the gradients was again collected 
with a cut tip and transferred to the bottom of a new centrifuge tube, which was then 
supplemented with MES buffer 3 to a total volume of 2.5 ml and gently mixed by 
pipetting. Resulting suspension was overlaid with 2.5 ml of ice-cold MES buffer 4 and 
then centrifuged for 1 hr at 100,000 × g (36,000 rpm) at 4°C. The floating layer from the 
top portions of the gradients was collected with a cut tip and purified lipid bodies were 
stored -20°C for further analyses.  
 
Protein precipitation, SDS-PAGE and silver staining of gels 
Protein concentration was determined using the RC DC protein assay kit (Bio-Rad) 
according to the manufacturer's instructions. Proteins were precipitated by adding 
trichloroacetic acid (TCA) to the final concentration of 10%, incubated on ice for 30 min, 
pelleted by centrifugation, and then washed with ice-cold 80% acetone. Dried protein 
pellets were then resuspended in the SDS-PAGE sample buffer and the pH was adjusted 
to neutral using 2 M Tris/HCl (pH 8.8). The samples were boiled for 5 min at 63°C, 
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centrifuged for 30 sec at 16,000 x g, loaded onto a 7.5%, 10%, 12.5% or 16% gel and 
resolved by SDS-PAGE. Following an overnight incubation of the gels in 50% methanol, 
proteins were visualized by silver staining using the mass spectrometry-compatible silver 
staining kit (Bio-Rad Silver Staining Plus) according to the manufacturer’s instructions. 
The Bio-Rad unstained molecular marker and a 0.1 mg/ml solution of BSA in the SDS-
PAGE sample buffer were also subjected to SDS-PAGE. The proteins were then 
visualized by silver staining. 
 
Analysis of proteins by mass spectrometry 
Proteins were resolved by SDS-PAGE and visualized by silver staining [226]. Protein 
bands were excised from the gel, reduced, alkylated and in-gel digested with trypsin 
[226]. The proteins were identified by matrix-assisted laser desorption/ionization mass 
spectrometric (MALDI MS) peptide mapping [227], using a Micromass M@LDI time-of-
flight (TOF) mass spectrometer (Waters). Database searching using peptide masses was 
performed with the Mascot web-based search engine. For evaluating relative levels of 
individual proteins recovered in total cell lysates or purified mitochondria, a selected 
protein band was excised from the silver-stained gel and placed into an Eppendorf tube. 
A band of BSA containing 2 μg of this protein, which was also excised from the silver-
stained gel, was added to each of the protein bands to be analyzed. Protein bands were 
reduced, alkylated and in-gel digested with trypsin [226]. The desalted peptide mixture 
was added to the surface of a MALDI target plate and allowed to air dry. The sample spot 
was then overlaid with MALDI matrix solution containing the Angiotensin I peptide 
standard (1:1 ratio). The presence of Angiotensin I in the sample carrying the analyzed 
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mixture of peptides provided an additional estimate of the mass measurement accuracy 
after calibration, giving an opportunity to calculate the value of peptide mass tolerance 
for each individual mass spectrum. After the desalted peptide mixture was analyzed by 
MALDI-TOF, the monoisotopic masses of recovered BSA peptides and the intensities of 
their monoisotopic peaks were grouped separately from the masses and intensities of 
peptides originated from the protein of interest. These data provided an additional 
estimate of the mass measurement accuracy and were used for the quantitation of relative 
levels of the same protein recovered in different samples. For evaluating relative levels of 
the protein of interest found in the samples to be compared, a ratio “the intensity of the 
monoisotopic peak of a peptide originated from the protein of interest/the intensity of the 
monoisotopic peak of a BSA peptide with the monoisotopic mass closest to the mass of 
the peptide of interest” was calculated for each peptide originated from the protein of 
interest. Based on these data, the average value for relative levels of the protein of 
interest found in the two compared samples was calculated. The method for evaluating 
relative levels of the protein of interest recovered in different samples was validated by 
calculating relative levels of several standard proteins in the samples supplemented with 
different quantities of each of these proteins. 
 
Analysis of lipids by mass spectrometry 
1 × 10
10
 cells were harvested by centrifugation and washed three times with cold water. 
The lipids were extracted by resuspending the cells in 3.8 ml of chloroform - methanol - 
water (1:2:0.8) and by vortexing the cell suspension with glass beads two times for 1 min. 
1 ml of chloroform was then added, and the extract was incubated for 5 min with 
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occasional mixing. 1 ml of water was then added, and the extract was incubated for 5 min 
with occasional mixing. The extract was centrifuged and the entire supernatant was 
collected. The pellet was resuspended in 1.6 ml of chloroform, and the lipids were 
extracted by vortexing the suspension with glass beads two times for 1 min. The extract 
was then centrifuged and the entire supernatant was collected. The pooled supernatants 
were centrifuged and the organic phase was collected. The lipid extract was dried under 
nitrogen. The lipid film was dissolved in 400 μl of chloroform - methanol (1:1) 
containing either 3 mM ammonium hydroxide for positive-ion analyses
 
or no additive for 
negative-ion measurements. Mass spectrometric analyses were performed with a 
Micromass Q-TOF 2 mass spectrometer equipped with a nano-electrospray
 
source 
operating at a flow rate of 1 μl/min. The instrument was used in the single-stage mass 
spectrometry mode for positive- or negative-ion analyses as described in Chapter 2 of this 
thesis. For quantification of individual lipid molecular species, the commercially 
available lipids (Avanti Polar Lipids, Larodan AB and Sigma) with non-natural fatty acid 
compositions were used as internal standards that do not occur in a significant
 
amount in 
the sample to be analyzed. Lipid quantification was performed as described in Chapter 2 
of this thesis. 
 
Miscellaneous procedures 
Protocols for lipid extraction, separation by TLC, visualization by 5% phosphomolybdic 
acid in ethanol, and quantitation by densitometric analysis of TLC plates have been 
described elsewhere [232]. Preparation of cellular extracts and microanalytic biochemical 
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assays for measuring ATP, glucose, trehalose and glycogen concentrations was 
performed as previously described [233]. 
 
4.4. Results 
4.4.1. A rationale for choosing a short-lived mutant strain to conduct a 
high-throughput screen of novel anti-aging compounds that can extend 
longevity by altering lipid metabolism in chronologically aging yeast 
My pilot experiments on elucidating the metabolism of lipids in various yeast mutants 
were aimed at finding a short-lived mutant strain most suitable for conducting a high-
throughput screen of novel anti-aging compounds that can extend longevity by altering 
lipid metabolism under CR conditions. Based on my findings, I proposed to use pex5 as 
such mutant strain. Because pex5 lacks a cytosolic shuttling receptor for peroxisomal 
import of Fox1p and Fox2p, these two enzymes of the β-oxidation of FFA reside in the 











Figure 4.1. By spatially separating Fox1p and Fox2p from Fox3p within a cell, the pex5 mutation impairs 
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oxidation of free fatty acids (FFA) in the peroxisome. Outline of subcellular localization of the Fox1p, 
Fox2p and Fox3p enzymes of FFA oxidation in β-oxidation in WT and pex5 cells. 
 
import of Fox3p, the third enzyme of the FFA β-oxidation pathway, sorts it to the 
peroxisome in pex5 cells [261]. By spatially separating Fox1p and Fox2p from Fox3p 
within a cell, the pex5 mutation impairs FFA oxidation (Figure 4.1). In chronologically 
aging yeast grown under CR conditions on 0.2% or 0.5% glucose, peroxisomal FFA 
oxidation regulates longevity by 1) efficiently generating acetyl-CoA to synthesize the 
bulk of ATP in mitochondria; and 2) acting as a rheostat that modulates the age-related 
dynamics of FFA and DAG, two regulatory lipids that, as I found (see Chapter 3 of this 
thesis), promote longevity-shortening necrotic cell death. Unlike CR yeast, 
chronologically aging non-CR yeast grown on 1% or 2% glucose are unable to generate 
significant quantities of ATP by oxidizing peroxisome-derived acetyl-CoA in 
mitochondria and, instead, produce the bulk of ATP via glycolytic oxidation of glycogen- 
and trehalose-derived glucose (see Chapters 1 and 3 of this thesis for a detailed 
discussion of this topic). As Alexander Goldberg in Dr. Titorenko’s laboratory found, 
consistent with the essential role of peroxisomal FFA oxidation as a longevity assurance 
process only under CR conditions, the pex5 mutation substantially shortens the CLS of 
CR yeast but causes a significantly lower reduction of longevity in non-CR yeast, 
especially in yeast grown on 2% glucose [18].  
 
4.4.2. The pex5-dependent remodelling of lipid metabolism makes the 
short-lived pex5 mutant most suitable for conducting a high-
throughput screen of anti-aging compounds that extend longevity by 
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altering the metabolism of lipids  
As described in Chapter 3 of this thesis, I found that in chronologically aging CR yeast 
peroxisomal FFA oxidation modulates, perhaps via several negative feedback loops, the 
following three processes: 1) the ER-confined biosynthesis of TAG from FFA and DAG; 
2) the subsequent deposition of TAG, the major neutral lipid reserves, in LBs; and 3) the 
consequent lipolysis of deposited TAG and the resulting formation of FFA and DAG. As 
I found, by impairing the ability of peroxisomal FFA oxidation to act as a rheostat that 
regulates cellular aging by modulating the age-related dynamics of FFA, DAG and TAG 
in the ER and LBs, the pex5 mutation causes the accumulation of the closely apposed 
ER membranes and ER-originated LBs in CR yeast (Figure 4.2). Of note, these 
morphological features of pex5 yeast under CR conditions were similar to those 
observed in a mouse model for the peroxisome biogenesis disorder Zellweger syndrome 
with hepatocyte-specific elimination of the PEX5 gene [262]. 
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Figure 4.2. The pex5 mutation alters cell morphology by causing the accumulation of the closely apposed 
ER membranes and ER-originated lipid bodies in CR yeast. Transmission electron micrographs of WT and 
pex5 yeast grown on 0.2% glucose for 2 days. Abbreviations: D, diauxic growth phase; M, mitochondrion; 
N, nucleus. 
 
          Furthermore, I found that the pex5 mutation also increases the concentrations of 
FFA, DAG and TAG in CR yeast (Figure 4.3), promoting their build-up in the ER and 
LBs (Figure 4.4). In addition, CR yeast carrying the pex5 mutation accumulate the ER-






















































































Figure 4.3. The pex5 mutation increases the concentrations of free fatty acids (FFA), diacylglycerols 
(DAG) and triacylglycerols (TAG) in CR yeast. Levels of FFA (A), DAG (B) and TAG (C) in WT and 
pex5 yeast grown on 0.2% glucose and taken for analyses at the indicated time-points are shown. FFA and 
TAG were measured by quantitative mass spectrometry. The levels of DAG were quantitated by 
densitometric analysis of TLC plates. Data are presented as means ± SEM (n = 3-8; ***p < 0.001; **p < 
0.01; *p < 0.05). 
 
          Moreover, I found that, following a short-term exposure to exogenous FFA 
(palmitoleic acid or oleic acid) or DAG, WT cells grown under CR conditions die (Figure 
4.5A). The vast majority of these WT cells displayed propidium iodide (PI) positive 
staining characteristic of the loss of plasma membrane integrity, a hallmark event of 
necrotic cell death (Figures 4.5B and 4.5C). In contrast, only a minor portion of these WT 
cells displayed Annexin V positive staining used to visualize the externalization of 
phosphatidylserine, a hallmark event of apoptotic cell death (Figures 4.5B and 4.5C). 
Thus, a brief exposure of WT cells grown under CR conditions to exogenous FFA or 
DAG causes their necrotic, not apoptotic, death. Importantly, I found that the pex5 
mutation enhances the susceptibility of CR yeast to necrotic death caused by a short-term 
exposure to exogenous FFA or DAG (Figures 4.5A and 4.5C), perhaps due to the 
increased concentrations of endogenous FFA and DAG seen in pex5 cells under CR 




Figure 4.4. Spectra of lipids extracted from purified endoplasmic reticulum (ER) and lipid bodies (LBs) 
and analyzed by TLC for WT and pex5Δ (Δ5) yeast grown on 0.2% glucose and taken for analyses at the 
indicated time-points. Abbreviations: D, diauxic growth phase; EE, ethyl esters; ERG, ergosterol; L, 
logarithmic growth phase; M, mitochondrion; N, nucleus; PD, post-diauxic growth phase; ST, stationary 





Figure 4.5. The pex5Δ mutation enhances the susceptibility of CR yeast to necrotic death caused by a 
short-term exposure to exogenous lipids. (A) Viability of WT and pex5Δ cells treated for 2 h with 
palmitoleic acid, oleic acid or DiC8 diacylglycerol. (B) Fluorescence microscopy of WT yeast treated for 2 
h with 0.25 mM palmitoleic acid, 0.6 mM oleic acid or 4.0 mM DiC8 diacylglycerol. Cells were co-stained 
with 1) Annexin V for visualizing the externalization of phosphatidylserine, a hallmark event of apoptosis; 
and 2) propidium iodide (PI) for visualizing the loss of plasma membrane integrity, a hallmark event of 
necrosis. (C) Percent of WT and pex5Δ cells that following their treatment with palmitoleic acid, oleic acid 
or DiC8 diacylglycerol displayed Annexin V negative and PI positive (Annexin V- and PI+) staining 
characteristic of necrotic cell death. Data in A and C are presented as means ± SEM (n = 3-5; ***p < 0.001; 
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**p < 0.01; *p < 0.05). Prior to their exposure to exogenous lipids, CR yeast were grown for 2 days on 
0.2% glucose. Abbreviations: DIC, differential interference contrast.  
 
          Altogether, my findings imply that, by impairing peroxisomal FFA oxidation and 
affecting lipid metabolism in the ER and LBs, the pex5 mutation affects the longevity-
defined aspects of the mechanism linking longevity and lipid metabolism confined to the 
ER, LBs and peroxisomes. Noteworthy, Tatiana Boukh-viner and Alexander Goldberg in 
Dr. Titorenko’s laboratory found that this mutation also alters the levels of numerous pro- 
and anti-aging proteins and impacts many longevity-related processes, thereby shortening 
the CLS of yeast when calorie supply is limited. Therefore, a decision was made to use 
the short-lived pex5 strain to carry out a chemical genetic screen for anti-aging 
compounds that target lipid metabolism to extend CLS in yeast placed on a CR diet. 
 
4.4.3. A mechanism underlying the ability of a novel anti-aging compound 
to extend yeast life span by targeting the longevity-defining aspects of 
lipid metabolism confined to the ER, LBs and peroxisomes   
Using the short-lived pex5 mutant strain, Alexander Goldberg in Dr. Titorenko’s 
laboratory conducted a high-throughput screen of novel anti-aging compounds that can 
extend the CLS of yeast by targeting the longevity-defining aspects of lipid metabolism 
under CR conditions. One of the life-extending compounds identified in such screen was 
lithocholic acid (LCA), a bile acid. Studies in Dr. Titorenko’s laboratory revealed that 
LCA greatly extends the CLS of WT strain of yeast placed on a CR diet.  
          To establish the molecular mechanism underlying the ability of LCA to extend 
yeast CLS by targeting the longevity-defining aspects of lipid metabolism confined to the 
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ER, LBs and peroxisomes, I first used the mass spectrometry (MS)-based identification 
and quantitation of proteins recovered in total cell lysates to elucidate how this bile acid 
influences the age-related dynamics of changes in the proteome of chronologically aging 
yeast under CR conditions. I found that the exposure of chronologically aging CR yeast 
to LCA elevated during PD and ST phases the levels of proteins that function in the 
following metabolic pathways and stress-response processes: 1) glycogen degradation; 2) 
glycolysis; 3) acetyl-CoA synthesis in the cytosol; 4) pyruvate oxidation, the 
tricarboxylic cycle (TCA) and ATP synthesis in mitochondria; 5) biosynthesis of TAG 
from FFA and DAG in the ER; 6) stress response in the cytosol; 7) reactive oxygen 
species (ROS) scavenging in the cytosol; and 8) stress response in mitochondria (Figure 
4.6). My MS-based proteomic analysis also revealed that the exposure of chronologically 
aging CR yeast to LCA reduced during PD and ST phases the levels of proteins that 
function in the following metabolic pathways and mitochondria biogenesis processes: 1) 
glyoxylate cycle in the cytosol; 2) glyoxylate cycle in mitochondria; 3) lipolysis of TAG 
to FFA and DAG in LBs; 4) mitochondrial division (Figure 4.6). Many of these proteins 
have been implicated in longevity regulation (see Chapter 1 for a detailed discussion of 
this topic) - including proteins involved in lipid metabolism (whose essential role in 
longevity regulation I revealed in experiments described in Chapter 3). Thus, during PD 
and ST growth phases LCA alters the levels of numerous pro- and anti-aging proteins and 
impacts lipid metabolism along with several other longevity-related processes, thereby 
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Figure 4.6. LCA alters the age-related dynamics of changes in the proteome of chronologically aging yeast 
under CR conditions. Relative levels (fold difference relative to that in yeast not exposed to LCA) of 
proteins recovered in total lysates of yeast cells grown under CR conditions on 0.2% glucose in the 
presence of LCA. 
 
          I then used MS-assisted quantitative lipidomics and thin layer chromatography 
(TLC)-based lipid quantitation to assess how LCA influences the dynamics of age-
dependent changes in levels of TAG, EE, FFA and DAG during chronological aging of 
CR yeast. I found that during PD phase LCA elevates the levels of TAG and EE (Figure 
4.7) and greatly reduces the levels of FFA and DAG (Figure 4.8). I therefore concluded 
that during PD phase, LCA accelerates the ER-confined biosynthesis of TAG from FFA  
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WT – LCA (1% DMSO only) 
WT + 50 μM LCA (in 1% DMSO)
YEP + 0.2% glucose:
















































































Figure 4.7. LCA alters the dynamics of age-dependent changes in levels of neutral lipids during 
chronological aging of yeast grown under CR conditions on 0.2% glucose with or without LCA. During PD 
phase, LCA elevates the levels of TAG and EE. During ST phase, LCA greatly decelerates the age-related 
decline in the levels of both these neutral lipids.    
 
and DAG as well as of EE from FFA and ergosterol (ERG).  My MS- and TLC-based 
lipidomic analysis also revealed that during ST phase LCA greatly decelerates the age-
related decline in the levels of neutral lipids (TAG and EE; Figure 4.7) as well as of FFA 
and DAG (Figure 4.8). I therefore concluded that during ST phase, LCA decelerates the 
LB-confined lipolysis of TAG and EE – thereby slowing down both the consumption of 
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Figure 4.8. LCA alters the dynamics of age-dependent changes in levels of FFA and DAG during 
chronological aging of yeast grown under CR conditions on 0.2% glucose with or without LCA. During PD 
phase, LCA greatly reduces the levels of FFA and DAG. During ST phase, LCA greatly decelerates the 
age-related decline in the levels of these two lipid species.    
 
          As I described in Chapter 3, my studies revealed that FFA and DAG regulate 
longevity by two different mechanisms that operate at two different stages of the aging 
process. One mechanism involves sensing the concentration of DAG maintained by cells 
(in a diet- and genotype-dependent fashion) during D and PD growth phases. DAG 
concentration during D and PD phases programs cell viability during ST growth phase by 
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Figure 4.9. LCA reduces the susceptibility of CR yeast recovered from the beginning of PD growth phase 
(at day 3) to necrotic death caused by a short-term exposure to exog nous oleic acid. WT cells grown under 
CR conditions on 0.2% glucose and recovered from the beginning of PD growth phase (at day 3) were 
treated for 2 h with 0.25 mM or 0.5 mM oleic acid. Data on cell viability are presented as means ± SEM (n 
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Figure 4.10. LCA reduces the susceptibility of CR yeast recovered from the beginning of ST phase (at day 
7) to necrotic death caused by a short-term exposure to exogenous oleic acid. WT cells grown under CR 
conditions on 0.2% glucose and recovered from the beginning of ST phase (at day 7) were treated for 2 h 
with 0.25 mM or 0.5 mM oleic acid. Data on cell viability are presented as means ± SEM (n = 3-4; *p < 
0.01). 
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influencing the mitochondria-controlled apoptotic pathway of cell death. Another 
mechanism that I revealed involves sensing the concentrations of FFA and DAG during 
ST phase. Any diet or genetic manipulation that causes the build-up of these two lipids 
during ST phase shortens the chronological life span of yeast in part by promoting rapid 
mitochondria-controlled apoptotic cell death, but not by activating FFA- and DAG-
induced necrotic cell death pathway. Because LCA alters the dynamics of age-dependent 
changes in levels of FFA and DAG during chronological aging of yeast grown under CR 
conditions (see data in Figures 4.7 and 4.8 and their discussion above), I next elucidated 
how this life-extending bile acid influences the susceptibility of CR yeast to necrotic and 
apoptotic forms of cell death. 
          I found that LCA reduces the susceptibility of CR yeast recovered from the 
beginning of PD phase (at day 3), beginning of ST phase (at day 7) and early ST phase 
(at day 10) to necrotic cell death caused by a short-term exposure to: 1) exogenous oleic 
acid (Figures 4.9 - 4.12); 2) exogenous palmitoleic acid (Figures 4.13 - 4.16); or 3) 





 staining (Figures 4.12 and 4.16) due to compromised integrity 
of the plasma membrane, a hallmark event of necrosis (see Chapters 1 and 3 for a 
detailed discussion of this characteristic event of necrotic cell death). Furthermore, I also 
found that LCA reduces the susceptibility of CR yeast recovered from the beginning of 
PD phase (at day 3), beginning of ST phase (at day 7) and early ST phase (at day 10) to 
mitochondria-controlled apoptotic cell death caused by a short-term exposure to: 1) 
exogenous hydrogen peroxide (Figures 4.20 - 4.24); or 2) exogenous acetic acid (Figures 
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Figure 4.11. LCA reduces the susceptibility of CR yeast recovered from early ST phase (at day 10) to 
necrotic death caused by a short-term exposure to exogenous oleic acid. WT cells grown under CR 
conditions on 0.2% glucose and recovered from early ST phase (at day 10) were treated for 2 h with 0.5 
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Figure 4.12. LCA reduces the susceptibility of CR yeast to necrotic death caused by a short-term exposure 
to exogenous oleic acid. WT cells grown under CR conditions on 0.2% glucose and recovered from the 
beginning of PD phase (at day 3), beginning of ST phase (at day 7) or early ST phase (at day 10) were 
treated for 2 h with 0.5 mM oleic acid. Data on the percentage of cells displaying propidium iodide 
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Figure 4.13. LCA reduces the susceptibility of CR yeast recovered from the beginning of PD growth phase 
(at day 3) to necrotic death caused by a short-term exposure to exogenous palmitoleic acid. WT cells grown 
under CR conditions on 0.2% glucose and recovered from the beginning of PD growth phase (at day 3) 
were treated for 2 h with 0.1 mM or 0.2 mM palmitoleic acid. Data on cell viability are presented as means 
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Figure 4.14. LCA reduces the susceptibility of CR yeast recovered from the beginning of ST phase (at day 
7) to necrotic death caused by a short-term exposure to exogenous palmitoleic acid. WT cells grown under 
CR conditions on 0.2% glucose and recovered from the beginning of ST phase (at day 7) were treated for 2 
h with 0.1 mM or 0.2 mM palmitoleic acid. Data on cell viability are presented as means ± SEM (n = 3-4; 
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Figure 4.15. LCA reduces the susceptibility of CR yeast recovered from early ST phase (at day 10) to 
necrotic death caused by a short-term exposure to exogenous palmitoleic acid. WT cells grown under CR 
conditions on 0.2% glucose and recovered from early ST phase (at day 10) were treated for 2 h with 0.1 
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Figure 4.16. LCA reduces the susceptibility of CR yeast to necrotic death caused by a short-term exposure 
to exogenous palmitoleic acid. WT cells grown under CR conditions on 0.2% glucose and recovered from 
the beginning of PD phase (at day 3), beginning of ST phase (at day 7) or early ST phase (at day 10) were 
treated for 2 h with 0.2 mM palmitoleic acid. Data on the percentage of cells displaying propidium iodide 
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Figure 4.17. LCA reduces the susceptibility of CR yeast recovered from the beginning of PD growth phase 
(at day 3) to necrotic death caused by a short-term exposure to exogenous DAG. WT cells grown under CR 
conditions on 0.2% glucose and recovered from the beginning of PD growth phase (at day 3) were treated 
for 2 h with 2.0 mM or 4.0 mM DiC8 DAG. Data on cell viability are presented as means ± SEM (n = 3-4; 
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Figure 4.18. LCA reduces the susceptibility of CR yeast recovered from the beginning of ST phase (at day 
7) to necrotic death caused by a short-term exposure to exogenous DAG. WT cells grown under CR 
conditions on 0.2% glucose and recovered from the beginning of ST phase (at day 7) were treated for 2 h 
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Figure 4.19. LCA reduces the susceptibility of CR yeast recovered from early ST phase (at day 10) to 
necrotic death caused by a short-term exposure to exogenous DAG. WT cells grown under CR conditions 
on 0.2% glucose and recovered from early ST phase (at day 10) were treated for 2 h with 2.0 mM or 4.0 
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Figure 4.20. LCA reduces the susceptibility of CR yeast recovered from the beginning of PD growth phase 
(at day 3) to apoptotic death caused by a short-term exposure to exogenous hydrogen peroxide. WT cells 
grown under CR conditions on 0.2% glucose and recovered from the beginning of PD growth phase (at day 
3) were treated for 2 h with various concentrations of hydrogen peroxide. Data on cell viability are 
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Figure 4.21. LCA reduces the susceptibility of CR yeast recovered from the beginning of ST phase (at day 
7) to apoptotic death caused by a short-term exposure to exogenous hydrogen peroxide. WT cells grown 
under CR conditions on 0.2% glucose and recovered from the beginning of ST phase (at day 7) were 
treated for 2 h with various concentrations of hydrogen peroxide. Data on cell viability are presented as 
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Figure 4.22. LCA reduces the susceptibility of CR yeast recovered from early ST phase (at day 10) to 
apoptotic death caused by a short-term exposure to exogenous hydrogen peroxide. WT cells grown under 
CR conditions on 0.2% glucose and recovered from early ST phase (at day 10) were treated for 2 h with 
various concentrations of hydrogen peroxide. Data on cell viability are presented as means ± SEM (n = 4-6; 
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Figure 4.23. LCA reduces the susceptibility of CR yea t to apoptotic death caused by a short-term 
exposure to exogenous hydrogen peroxide. WT cells grown under CR conditions on 0.2% glucose and 
recovered from the beginning of PD phase (at day 3), beginning of ST phase (at day 7) or early ST phase 
(at day 10) were treated for 2 h with 5.0 mM or 10.0 mM hydrogen peroxide. Data on the percentage of 
cells exhibiting fragmented nuclei, a hallmark event of apoptotic death, are presented as means ± SEM (n = 
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Figure 4.24. LCA reduces the susceptibility of CR yeast to apoptotic death caused by a short-term 
exposure to exogenous hydrogen peroxide. WT cells grown under CR conditions on 0.2% glucose and 
recovered from the beginning of PD phase (at day 3), beginning of ST phase (at day 7) or early ST phase 
(at day 10) were treated for 2 h with 5.0 mM or 10.0 mM hydrogen peroxide. Data on the percentage of 
cells exhibiting phosphatidylserine (PS) translocation from the inner to the outer leaflet of the plasma 
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Figure 4.25. LCA reduces the susceptibility of CR yeast recovered from the beginning of PD growth phase 
(at day 3) to apoptotic death caused by a short-term exposure to exogenous acetic acid. WT cells grown 
under CR conditions on 0.2% glucose and recovered from the beginning of PD growth phase (at day 3) 
were treated for 2 h with various concentrations of acetic acid. Data on cell viability are presented as means 
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Figure 4.26. LCA reduces the susceptibility of CR yeast recovered from the beginning of ST phase (at day 
7) to apoptotic death caused by a short-term exposure to exogenous acetic acid. WT cells grown under CR 
conditions on 0.2% glucose and recovered from the beginning of ST phase (at day 7) were treated for 2 h 
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Figure 4.27. LCA reduces the susceptibility of CR yeast recovered from early ST phase (at day 10) to 
apoptotic death caused by a short-term exposure to exogenous acetic acid. WT cells grown under CR 
conditions on 0.2% glucose and recovered from early ST phase (at day 10) were treated for 2 h with various 
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Figure 4.28. LCA reduces the susceptibility of CR yeast to apoptotic death caused by a short-term 
exposure to exogenous acetic acid. WT cells grown under CR conditions on 0.2% glucose and recovered 
from the beginning of PD phase (at day 3), beginning of ST phase (at day 7) or early ST phase (at day 10) 
were treated for 2 h with 80 mM or 200 mM acetic acid. Data on the percentage of cells exhibiting 
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Figure 4.29. LCA reduces the susceptibility of CR yea t to apoptotic death caused by a short-term 
exposure to exogenous acetic acid. WT cells grown under CR conditions on 0.2% glucose and recovered 
from the beginning of PD phase (at day 3), beginning of ST phase (at day 7) or early ST phase (at day 10) 
were treated for 2 h with 80 mM or 200 mM acetic acid. Data on the percentage of cells exhibiting 
phosphatidylserine (PS) translocation from the inner to the outer leaflet of the plasma membrane, a 
hallmark event of apoptotic death, are presented as means ± SEM (n = 4; *p < 0.01). 
 
fragmentation (Figures 4.23 and 4.28) and phosphatidylserine (PS) translocation from the 
inner to the outer leaflet of the plasma membrane (Figures 4.24 and 4.29), the two 
hallmark events of apoptosis (see Chapters 1 and 3 for a detailed discussion of these 
characteristic events of apoptotic cell death).      
  
4.5. Discussion 
Altogether, my findings described in Chapter 4 of this thesis revealed the molecular 
mechanism underlying the ability of LCA to extend yeast CLS by targeting the longevity-
defining aspects of lipid metabolism confined to the ER, LBs and peroxisomes (Figure 
4.30C). In such mechanism, under CR conditions LCA accelerates the biosynthesis of 




































































































Very long-lived: CR (WT) + LCA
C
Figure 4.30. Outline of metabolic pathways and interorganellar communications operating in 
chronologically aging cells of WT strain grown under CR or non-CR conditions with or without LCA. The 
longevity-defining features of the diet- or LCA-driven metabolic design for each type of growth conditions 
are discussed in details in the Discussion section of this Chapter. 
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lipolysis of TAG in LBs. The resulting reduction of the ER- and LB-confined levels of 
FFA and DAG during PD and ST growth phases affects both mechanisms (Figure 4.30B; 
see Chapter 3 for a detailed discussion of this topic) by which these two lipid species 
regulate longevity. First, by lowering the intracellular concentration of DAG during D 
and PD phases, LCA attenuates the FFA- and DAG-induced necrotic cell death pathway 
– thereby impairing the age-related form of necrotic cell death and ultimately extending 
longevity of chronologically aging yeast placed on a CR diet (Figure 4.30C). Second, by 
reducing the intracellular concentrations of FFA and DAG during ST phase, LCA 
attenuates the mitochondria-controlled apoptotic cell death pathway – thereby impairing 
the age-related form of apoptotic cell death and ultimately further extending longevity of 
chronologically aging yeast under CR conditions (Figure 4.30C). 
          My findings described and discussed in Chapters 3 and 4 of this thesis imply that 
there are two different ways of delaying chronological aging of yeast by targeting the 
longevity-defining aspects of lipid metabolism confined to the ER, LBs and peroxisomes. 
One way is by placing yeast on a CR diet in the absence of LCA, thereby making them 
“lean” by accelerating both the lipolysis of neutral lipids in LBs and the oxidation of FFA 
in peroxisomes (compare Figures 4.30A and Figure 4.30B). The resulting reduction of 
FFA and DAG levels during PD and ST phases slows down both the necrotic and 
apoptotic forms of cell death, thereby extending longevity of chronologically aging CR 
yeast - as compared to longevity of non-CR yeast (compare Figures 4.30A and Figure 
4.30B). The other way is by placing yeast on a CR diet in the presence of LCA, thereby 
making them “fat” by: 1) accelerating the synthesis of TAG from FFA and DAG; and 2) 
decelerating the FFA- and DAG-producing lipolysis of TAG in LBs (compare Figures 
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4.30B and Figure 4.30C). The resulting further reduction of FFA and DAG levels during 
PD and ST phases (as compared to CR yeast grown without LCA) causes additional 
attenuation of the necrotic and apoptotic forms of cell death, thereby further extending 
longevity of chronologically aging CR yeast exposed to LCA - as compared to longevity 
of CR yeast not exposed to this bile acid (compare Figures 4.30B and Figure 4.30C).      
  
4.6. Conclusions 
By elucidating how a novel anti-aging compound LCA influences the metabolism of 
lipids as well as age-related forms of necrotic and apoptotic death in chronologically 
aging yeast and how it alters yeast proteome, I established the molecular mechanism 
underlying the ability of LCA to extend yeast CLS by targeting these longevity-defining 
aspects of lipid metabolism confined to the ER, LBs and peroxisomes. 
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5. A mechanism underlying the ability of a novel anti-aging drug to extend yeast 
life span by altering the composition of mitochondrial membrane lipids   
 
5.1. Abstract 
As described in Chapters 3 and 4 of this thesis, I established the molecular mechanisms 
underlying the ability of caloric restriction (CR) and lithocholic acid (LCA) to extend 
yeast chronological life span by targeting the longevity-defining aspects of lipid 
metabolism confined to the endoplasmic reticulum (ER), lipid bodies (LBs) and 
peroxisomes. Recent studies by other graduate students in Dr. Titorenko’s laboratory 
have revealed that in chronologically aging yeast LCA has a pleiotropic effect on the 
mitochondrial protein machines involved in mitochondrial respiration, maintenance of the 
electrochemical potential across the inner mitochondrial membrane, reactive oxygen 
species (ROS) production in mitochondria, mitochondrial fusion and mitochondria-
controlled apoptosis. These findings prompted me to elucidate how LCA influences the 
composition of mitochondrial membrane lipids and their metabolism in yeast. Cardiolipin 
(CL) is a mitochondria-specific dimeric glycerophospholipid, which is synthesized and 
almost exclusively localized in the mitochondrial inner membrane [193, 195, 196, 198 - 
200]. Phosphatidylethanolamine (PE) is a glycerophospholipid, which is almost 
exclusively synthesized in the mitochondrial inner membrane – from which it is then 
distributed to various other cellular membranes [198, 200]. In experiments described in 
this Chapter, I first elucidated how mutations eliminating nucleus-encoded mitochondrial 
proteins involved in the synthesis of CL and PE within the mitochondrial inner 
membrane influence the life-extending efficacy of LCA in chronologically aging yeast 
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grown under CR conditions. I found that the synthesis of both these membrane lipids in 
mitochondria plays a pivotal role in the ability of LCA to extend yeast longevity under 
CR conditions. To establish the molecular mechanism underlying the essential role of CL 
and PE dynamics in longevity-extending effect of LCA, I then used mass spectrometry 
(MS)-based lipidomics to elucidate how LCA influences the composition and quantities 
of membrane lipids in mitochondria that were purified from wild-type (WT) strain and 
from various long- and short-lived mutant strains impaired in different aspects of CL and 
PE metabolism. By correlating the effects of LCA on the age-related dynamics of 
changes in the repertoire of membrane lipids in mitochondria of these strains to the 
effects of this bile acid on their chronological life span (CLS), I concluded that under CR 
conditions LCA extends yeast longevity by remodeling the composition of mitochondrial 
membrane lipids and thereby modulating longevity-defining processes confined to and/or 
governed by mitochondria. My findings imply that LCA extends the CLS of WT yeast 
by: 1) increasing the level of phosphatidylserine (PS; a precursor for the synthesis of PE 
in mitochondria) in the mitochondrial membrane, thereby enhancing its positive effect on 
longevity-defining processes in this membrane; 2) decreasing the level of PE in the 
mitochondrial membrane, thereby weakening its negative effect on longevity-defining 
processes in this membrane; and 3) proportionally decreasing the levels of PE and CL in 
the mitochondrial membrane, thereby increasing PS/CL and PS/PE ratios but maintaining 
PE/CL ratio of mitochondrial membrane lipids and causing some longevity-extending 
changes in this membrane. My analysis of the biological implications of these specific 
changes in mitochondrial membrane lipids revealed that, by altering the levels of PS, CL 
and PE, LCA: 1) changes the curvature of the inner mitochondrial membrane; and 2) 
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enhances the positive effect of PS and weakens the negative effect of PE on membrane 
proteins whose activity depends on these two lipid species - thereby enhancing the ability 
of the inner mitochondrial membrane to form cristae and activating protein machines 
involved in mitochondrial respiration, the maintenance of mitochondrial membrane 
potential and ROS production in mitochondria. 
 
5.2. Introduction 
CL is a unique class of membrane lipids whose various molecular species can be found 
only in mitochondria – mostly in the mitochondrial inner membrane, but also (up to 20% 
of the total CL pool) in the mitochondrial outer membrane [195, 198 - 200]. Because of 
the ability to interact with a number of functionally distinct proteins in the mitochondrial 
inner membrane and to serve as a precursor for the synthesis of the potent signaling 
molecule phosphatidic acid (PA), CL has been shown to govern a number of vital 
processes taking place in and/or orchestrated from this membrane, including 1) the 
assembly and functional state of all five complexes of the mitochondrial respiratory chain 
and their organization into supercomplexes; 2) the retention in the mitochondrial inner 
membrane of cytochrome c, a heme-containing mobile component of the mitochondrial 
respiratory chain also known for its essential role in mitochondria-controlled apoptosis; 
3) the functional state of the adenine nucleotide translocator in the mitochondrial 
membrane; 4) the maintenance of the electrochemical gradient across the mitochondrial 
inner membrane;  5) the fluidity and stability of the inner membrane of mitochondria; 6) 
the susceptibility of mitochondrial membrane proteins and lipids to an ROS-inflicted 
oxidative damage; 7) the import of various proteins into mitochondria; 8) the fusion of 
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individual mitochondria into a tubular network; and 9) the fission (division) of 
mitochondria leading to fragmentation of this tubular mitochondrial network [194 - 203]. 
Due to the essential role of CL in a plethora of basic biological processes, certain changes 
in its content and/or species composition have been have been shown to cause 
pathological states characteristic of various disorders. Among these disorders are: 1) a 
Barth Syndrome spectrum of X-linked recessive disorders, which includes cardioskeletal 
myopathy, neutropenia and abnormal growth [193, 195, 198]; 2) Tangier disease [195, 
198]; 3) diabetic cardiomyopathy [195, 198]; 4) dilated cardiomyopathy with ataxia [195, 
198]; and 5) non-alcoholic fatty liver disease [195, 198].  
          Importantly, reduced levels of CL and the resulting accumulation of dysfunctional 
mitochondria are characteristic of the early stages of aging in rodents and humans [194, 
195, 198]. Moreover, I found that a longevity-extending CR diet reduces the level of CL 
in the mitochondrial membrane of chronologically aging yeast [18]. It is conceivable 
therefore that CL plays a pivotal role in regulating various mitochondria-governed 
processes whose dysfunction underlies aging and age-related pathologies. However, the 
molecular basis of such essential role for CL in modulating longevity-defining processes 
confined to and/or governed by mitochondria remains elusive. In studies described in this 
Chapter, I used a combination of functional genetic, cell biological, electron and 
fluorescence microscopical, and lipidomic experimental approaches to decipher the 
molecular mechanism underlying the ability of LCA to extend longevity of 
chronologically aging yeast by altering the concentrations of CL and other mitochondrial 
membrane lipids and by modifying the spectra of their various molecular species.   
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5.3. Materials and Methods 
Strains and media  
The wild-type strain Saccharomyces cerevisiae BY4742 (MAT his31 leu20 lys20 
ura30) and mutant strains ups1 (MAT his31 leu20 lys20 ura30 
ups1::kanMX4), taz1 (MAT his31 leu20 lys20 ura30 taz1::kanMX4), gep1 
(MAT his31 leu20 lys20 ura30 gep1::kanMX4), psd1 (MAT his31 leu20 
lys20 ura30 psd1::kanMX4) and crd1 (MAT his31 leu20 lys20 ura30 
crd1::kanMX4) were used in this study. Yeast were grown in YEPD medium initially 
containing 0.2% glucose as carbon source at 30
o
C with rotational shaking at 200 rpm in 
Erlenmeyer flasks at a flask volume/medium volume ratio of 5:1. 
 
A plating assay for the analysis of chronological life span 
A sample of cells was removed from each culture at various time points. A fraction of the 
cell sample was diluted in order to determine the total number of cells per ml of culture 
using a hemacytometer. 10 l of serial dilutions (1:10 to 1:103) of cells were applied to 
the hemacytometer, where each large square is calibrated to hold 0.1 l. The number of 
cells in 4 large squares was then counted and an average was taken in order to ensure 
greater accuracy. The concentration of cells was calculated as follows: number of cells 
per large square x dilution factor × 10 × 1,000 = total number of cells per ml of culture. A 




) of cells 
were plated onto YEPD (2% Glucose) plates in triplicate in order to count the number of 
viable cells per ml of each culture. 100 l of diluted culture was plated onto each plate. 
After a 48-h incubation at 30
o
C, the number of colonies per plate was counted. The 
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number of colony forming units (CFU) equals to the number of viable cells in a sample. 
Therefore, the number of viable cells was calculated as follows: number of colonies × 
dilution factor × 10 = number of viable cells per ml. For each culture assayed, % viability 
of the cells was calculated as follows: number of viable cells per ml / total number of 
cells per ml × 100%. The % viability of cells in mid-logarithmic phase was set at 100% 
viability for that particular culture.  
 
Electron microscopy and morphometric analysis 
Cells were fixed in 1.5% KMnO4 for 20 min at room temperature, dehydrated by 
successive incubations in increasing concentrations of ethanol, and embedded in 
Poly/Bed 812 epoxy resin (Polysciences). Ultrathin sections were cut using an Ultra-Cut 
E Microtome (Reichert-Jung). Silver/gold thin sections from the embedded blocks were 
examined in a JEOL JEM-2000FX transmission electron microscope. For morphometric 
analysis of random electron microscopic sections of cells, digitized images were analyzed 
using the UTHSCSA Image Tool (Version 3.0) software. In each of 2 independent 
experiments, the percentage of cells that contain pexopodia and/or accumulate gnarled 
LBs was calculated by analyzing at least 300 cells that were collected at each time point. 
The values of the percentage of cells containing pexopodia and/or accumulating gnarled 
LBs were plotted as a function of the number of days cells were cultured. 
 
Analysis of lipids by mass spectrometry 
1 × 10
10
 cells were harvested by centrifugation and washed three times with cold water. 
The lipids were extracted by resuspending the cells in 3.8 ml of chloroform - methanol - 
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water (1:2:0.8) and by vortexing the cell suspension with glass beads two times for 1 min. 
1 ml of chloroform was then added, and the extract was incubated for 5 min with 
occasional mixing. 1 ml of water was then added, and the extract was incubated for 5 min 
with occasional mixing. The extract was centrifuged and the entire supernatant was 
collected. The pellet was resuspended in 1.6 ml of chloroform, and the lipids were 
extracted by vortexing the suspension with glass beads two times for 1 min. The extract 
was then centrifuged and the entire supernatant was collected. The pooled supernatants 
were centrifuged and the organic phase was collected. The lipid extract was dried under 
nitrogen. The lipid film was dissolved in 400 μl of chloroform - methanol (1:1) 
containing either 3 mM ammonium hydroxide for positive-ion analyses
 
or no additive for 
negative-ion measurements. Mass spectrometric analyses were performed with a 
Micromass Q-TOF 2 mass spectrometer equipped with a nano-electrospray
 
source 
operating at a flow rate of 1 μl/min. The instrument was used in the single-stage mass 
spectrometry mode for positive- or negative-ion analyses as described in Chapter 2 of this 
thesis. For quantification of individual lipid molecular species, the commercially 
available lipids (Avanti Polar Lipids, Larodan AB and Sigma) with non-natural fatty acid 
compositions were used as internal standards that do not occur in a significant
 
amount in 
the sample to be analyzed. Lipid quantification was performed as described in Chapter 2 
of this thesis. 
 
5.4. Results 
5.4.1. The synthesis of CL and PE within the mitochondrial inner 
membrane defines the life-extending efficacy of LCA in chronologically 
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aging yeast under CR conditions 
As a first step towards probing a role of CL and other mitochondrial membrane lipids in the longevity-
extending ability of LCA, I tested if LCA can increase the CLS of various single-gene-deletion mutants 
lacking nuclear genes that encode different mitochondrial proteins involved in the synthesis of CL and PE 
within the mitochondrial inner membrane. The individual steps of the partially overlapping biosynthetic 
pathways for CL and PE in yeast mitochondria, as well as mitochondrial proteins catalyzing or regulating 




















Figure 5.1. Outline of the biosynthesis of cardiolipin (CL), phosphatidylglycerol (PG), 
phosphatidylethanolamine (PE) and phosphatidylserine (PS) from phosphatidic acid (PA) in the 
mitochondrial inner membrane. PA is delivered top the mitochondrial inner membrane from the 
mitochondria-associated membrane (MAM) domain of the endoplasmic reticulum (ER), where it is 
synthesized. PA is then converted to cytidine diphosphodiacylglycerol (CDP-DAG), which serves as a 
precursor for synthesis of both CL and PE in the mitochondrial inner membrane. It has been proposed that 
both CL and PE modulate the ability of prohibitins Phb1p and Phb2p - two evolutionarily conserved 
proteins that form large complexes with each other in the mitochondrial inner membrane - to maintain the 
organization and functional integrity of this membrane [197, 200, 204 - 207]. Other abbreviations: PG-P, 
phosphatidylglycerol phosphate; MLCL, monolysocardiolipin.    
 
          I found that mutations eliminating the Crd1p, Taz1p, Psd1p, Ups1p or Gep1p 
mitochondrial proteins involved in the synthesis of CL and PE within the mitochondrial 
inner membrane differentially alter the ability of LCA to extend the CLS of yeast grown 
under CR conditions on 0.2% glucose. Specifically, LCA is unable to extend the CLS of 
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the ups1 mutant (Figure 5.2) lacking a protein that regulates the biosynthesis of PG, CL 
and PE (Figure 5.1). Furthermore, LCA is unable to extend the CLS of the taz1 mutant 
(Figure 5.3) - which lacks an enzyme catalyzing the conversion of MLCL to CL (Figure 
5.1). Moreover, the gep1 mutation - which eliminates a protein regulating the 
biosynthesis of CL and PE (Figure 5.1) - enhances the ability of LCA to extend the CLS 
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Figure 5.2. LCA is unable to extend the CLS of the ups1 mutant lacking a protein that regulates the 
biosynthesis of PG, CL and PE. 
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Figure 5.3. LCA is unable to extend the CLS of the taz1 mutant, which lacks an enzyme catalyzing the 
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Figure 5.4. The gep1 mutation - which eliminates a protein regulating the biosynthesis of CL and PE - 
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Figure 5.5. The psd1 mutation – which eliminates an enzyme catalyzing the biosynthesis of PE - 
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Figure 5.6. The crd1 mutation – which eliminates an enzyme catalyzing the biosynthesis of CL - 
enhances the ability of LCA to extend the CLS of yeast grown under CR conditions. 
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eliminates an enzyme catalyzing the biosynthesis of PE (Figure 5.1) - enhances the ability 
of LCA to extend longevity of chronologically aging yeast grown under CR conditions 
(Figure 5.5). Finally, the crd1 mutation – which eliminates an enzyme catalyzing the 
biosynthesis of CL (Figure 5.1) - enhances the ability of LCA to extend the CLS of yeast 
grown under CR conditions (Figure 5.6). 
          Altogether, these data imply that the rates of synthesis of CL and PE from their 
precursors PG and PS (respectively), as well as the rate of remodeling of acyl chains of 
CL by the sequential action of a phospholipase A (converting CL to MLCL) and a 
transacylation reaction catalyzed by Taz1p (Figure 5.1), within the mitochondrial inner 
membrane define the longevity-extending efficacy of LCA. I therefore hypothesized that 
one of the mechanisms underlying the ability of LCA to extend yeast longevity consists 
in the LCA-driven remodeling of the mitochondrial membrane by altering the 
concentrations of CL, PE, PG, PS and/or MLCL and, perhaps, by changing the relative 
abundance of certain molecular species of these membrane lipids. In my hypothesis, such 
LCA-driven remodeling of the composition of mitochondrial membrane lipids extends 
the CLS of CR yeast by modulating longevity-defining processes confined to and/or 
governed by mitochondria. 
 
5.4.2. LCA alters the concentrations of membrane lipids and their 
relative abundance in mitochondria of WT cells 
In my hypothesis, LCA remodels the mitochondrial membrane by altering the 
concentrations of CL, PE, PG, PS and/or MLCL and, perhaps, by changing their relative 
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Figure 5.7. Effect of LCA on the age- elated dynamics of changes in the total levels of CL, PE, PS and 
MLCL in the membranes of mitochondria purified from WT cells. Yeast were grown in YEPD medium 
initially containing 0.2% glucose as carbon source,  without LCA or with this bile acid (used in the 
concentration of 50 μM), and collected for the purification of mitochondria at days 0, 1 or 2. Mitochondrial 
membrane lipids were identified and quantitated by MS as described in Materials and Methods. *p < 0.05.  
 
how LCA influences the age-related dynamics of changes in the levels of CL, PE, PS and 
MLCL in the membrane of mitochondria purified from WT cells (Of note, because CDP-
DAG, PG-P and PG do not accumulate in significant amounts in mitochondrial 
membranes under normal conditions [198, 200], these important intermediates for the 
synthesis of CL, PE, PS and MLCL within the mitochondrial inner membrane (Figure 
5.1) were not detectable even by MS in mitochondria purified from WT cells; I was able 
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Figure 5.8. Effect of LCA on the age-related dynamics of changes in PE/CL, PS/CL and PS/PE ratios in 
the membranes of mitochondria purified from WT cells. Yeast were grown in YEPD medium initially 
containing 0.2% glucose as carbon source,  without LCA or with this bile acid (used in the concentration of 
50 μM), and collected for the purification of mitochondria at days 0, 1 or 2. Mitochondrial membrane lipids 
were identified and quantitated by MS as described in Materials and Methods. *p < 0.05.  
 
which lacks an enzyme catalyzing the synthesis of CL from PG and CDP-DAG). I found 
that LCA reduces the total levels of CL, PE and MLCL but significantly elevates the total 
level of PE (Figure 5.7). The observed effect of LCA on the quantities of CL, PE and PS 
enables to maintain PE/CL ratio in the mitochondrial membrane (Figure 5.8). On the 
other hand, by elevating the total level of PS, LCA greatly increases PS/CL and PS/PE 
ratios in the membrane of WT mitochondria (Figure 5.8). Taken together, my findings 
suggest that LCA inhibits the Crd1p- and Psd1p-driven reactions of the biosynthesis of 
CL and PE (respectively) in the mitochondrial inner membrane - thereby reducing the 

























Figure 5.9. Based on my findings, I propose that LCA inhibits the Crd1p- and Psd1p-driven reactions of 
the biosynthesis of CL and PE (respectively) in the mitochondrial inner membrane - thereby reducing the 
quantities of these two lipid classes and increasing the quantity of PS, a precursor of PE. 
 
5.4.3. The LCA-driven remodeling of the mitochondrial membrane by 
altering the concentrations and relative abundancies of CL, PE and PS 
is essential for the longevity-extending ability of LCA and defines its 
efficacy 
In my hypothesis, the observed LCA-driven remodeling of the mitochondrial membrane 
by altering the concentrations and relative abundancies of CL, PE and PS is essential for 
the longevity-extending ability of LCA and defines its efficacy. To test the validity of 
such hypothesis, I used MS-based lipidomics for the identification and quantitation of 
various species of CL, PE and PS extracted from purified mitochondria of ups1, taz1, 
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psd1 or gep1 mutant cells grown in medium without LCA or with LCA (used in the 
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Figure 5.10. LCA cannot extend the life span of the ups1 mutant which has greatly elevated (as compared 
to WT strain) PE/CL ratio, in spite of the ability of LCA to reduce this ratio in the mitochondrial 
membranes of ups1. Yeast were grown in YEPD medium initially containing 0.2% glucose as carbon 
source,  without LCA or with this bile acid (used in the concentration of 50 μM), and collected for the 
purification of mitochondria at day 2. Mitochondrial membrane lipids were identified and quantitated by 
MS as described in Materials and Methods. *p < 0.05. 
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Figure 5.11. LCA cannot extend the life span of the taz1 mutant which has greatly elevated (as compared 
to WT strain) PE/CL ratio, in spite of the ability of LA to reduce this ratio in the mitochondrial membranes 
of taz1. Yeast were grown in YEPD medium initially containing 0.2% glucose as carbon source,  without 
LCA or with this bile acid (used in the concentration of 50 μM), and collected for the purification of 
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mitochondria at day 2. Mitochondrial membrane lipids were identified and quantitated by MS as described 
in Materials and Methods. *p < 0.05. 
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Figure 5.12. The ability of LCA to extend life span is enhanced in the psd1 mutant strain which maintains 
PE/CL ratio at the same level as WT strain and has greatly elevated (as compared to WT strain) PS/CL and 
PS/PE ratios, both of which are further increased by LCA. Yeast were grown in YEPD medium initially 
containing 0.2% glucose as carbon source,  without LCA or with this bile acid (used in the concentration of 
50 μM), and collected for the purification of mitochondria at day 2. Mitochondrial membrane lipids were 
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Figure 5.13. The ability of LCA to extend life span is enhanced in the gep1 mutant strain which 
maintains PE/CL ratio at the same level as WT strain and has greatly elevated (as compared to WT strain) 
PS/CL and PS/PE ratios, both of which are further increased by LCA. Yeast were grown in YEPD medium 
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initially containing 0.2% glucose as carbon source,  without LCA or with this bile acid (used in the 
concentration of 50 μM), and collected for the purification of mitochondria at day 2. Mitochondrial 
membrane lipids were identified and quantitated by MS as described in Materials and Methods. *p < 0.05. 
assisted lipidomic analysis leads to the following conclusions. First, LCA cannot extend 
the life span of the ups1 mutant which has greatly elevated (as compared to WT strain) 
PE/CL ratio, in spite of the ability of LCA to reduce this ratio in the mitochondrial 
membranes of ups1 (Figure 5.10). Second, LCA cannot extend the life span of the taz1 
mutant which has greatly elevated (as compared to WT strain) PE/CL ratio, in spite of the 
ability of LA to reduce this ratio in the mitochondrial membranes of taz1 (Figure 5.11). 
Third, the ability of LCA to extend life span is enhanced in the psd1 mutant strain 
which maintains PE/CL ratio at the same level as WT strain and has greatly elevated (as 
compared to WT strain) PS/CL and PS/PE ratios, both of which are further increased by 
LCA (Figure 5.12). Finally, the ability of LCA to extend life span is enhanced in the 
gep1 mutant strain which maintains PE/CL ratio at the same level as WT strain and has 
greatly elevated (as compared to WT strain) PS/CL and PS/PE ratios, both of which are 
further increased by LCA (Figure 5.13).  
          Altogether, my findings imply that under CR conditions LCA extends longevity of 
chronologically aging yeast by: 1) increasing the level of phosphatidylserine (PS; a 
precursor for the synthesis of PE in mitochondria) in the mitochondrial membrane, 
thereby enhancing its positive effect on longevity-defining processes in this membrane; 
2) decreasing the level of PE in the mitochondrial membrane, thereby weakening its 
negative effect on longevity-defining processes in this membrane; and 3) proportionally 
decreasing the levels of PE and CL in the mitochondrial membrane, thereby increasing 
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PS/CL and PS/PE ratios but maintaining PE/CL ratio of mitochondrial membrane lipids 
and causing some longevity-extending changes in this membrane. 
 
5.4.4. The known ability of prohibitins to preserve the organization and 
functional integrity of the mitochondrial inner membrane by sensing the 
relative abundancies of PE and CL is not essential for the longevity-
extending ability of LCA 
It has been proposed that in yeast both PE and CL modulate the ability of prohibitins 
Phb1p and Phb2p - two evolutionarily conserved proteins that form large complexes with 
each other in the mitochondrial inner membrane - to maintain the organization and 
functional integrity of this membrane [197, 200, 204 - 207]. I therefore hypothesized that, 
by maintaining PE/CL ratio, LCA supports this essential function of prohibitins – which 
they are believed [200, 205 - 207] to perform by sensing the relative levels of PE and CL 
enriched in the mitochondrial inner membrane domains delimited by the Phb1p-Phb2p 
supercomplexes. However, my functional genetic analysis did not validate such 
hypothesis. Indeed, I found that the phb1 mutation does not reduce the longevity-
extending efficacy of LCA under CR conditions (Figure 5.14). 
 
5.4.5. By altering the concentrations and relative abundancies of different 
molecular species of PS, CL and PE, LCA causes profound changes in 
mitochondrial size, number, morphology and longevity-related function  
I then put forward a hypothesized that, by altering the levels of PS, CL and PE, LCA 
may: 1) change the curvature of the inner mitochondrial membrane; and/or 2) enhance 
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the positive effect of PS and weaken the negative effect of PE on membrane proteins 
whose activity depends on these two lipids. I thought that, by causing such remodeling of 
lipids in the mitochondrial membrane, LCA may activate protein machines involved in  
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Figure 5.14. The phb1 mutation does not reduce the longevity-extending efficacy of LCA under CR 
conditions. Yeast were grown in YEPD medium initially containing 0.2% glucose as carbon source, 
without LCA or with this bile acid (used in the concentration of 50 μM). 
 
mitochondrial respiration, the maintenance of mitochondrial membrane potential and 
ROS production in mitochondria as well as may enhance the ability of the inner 
mitochondrial membrane to form cristae. All these processes have recently been shown 
by Dr. Titorenko’s laboratory to define longevity of chronologically aging yeast 
(Michelle T. Burstein et al., manuscript in preparation). But how exactly PS, CL and PE 
can influence the curvature of the inner mitochondrial membrane, thereby altering its 
ability to form cristae, contact sites or remain flat - as well as, perhaps, specifically 
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modulating the longevity-defining morphology and functional state of mitochondria? My 
analysis of the effect of LCA on the levels of various molecular forms of PS, CL and PE 
– that differ from each other by the extent of saturation of the hydrophobic tails and their  
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Figure 5.15. LCA increases the level of the inverted cone-shaped species of PS enriched in saturated fatty 
acids, and thus is expected to enhance cristae formation by promoting positive curvature of the inner 
mitochondrial membrane. 
 
length – implies that: 1) LCA increases the level of the inverted cone-shaped species of 
PS enriched in saturated fatty acids, and thus is expected to enhance cristae formation by 
promoting positive curvature of the inner mitochondrial membrane (Figure 5.15); 2) LCA 
decreases the level of the cone-shaped species of CL enriched in unsaturated fatty acids, 
and thus is expected to decrease the number of contact sites by reducing negative 
curvature of the inner mitochondrial membrane; perhaps by causing such effect, LCA 
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may shift the equilibrium of membrane curvature towards the enhancement of cristae 
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Figure 5.16. LCA decreases the level of the cone-shaped species of CL enriched in unsaturated fatty acids, 
and thus is expected to decrease the number of contact sites by reducing negative curvature of the inner 
mitochondrial membrane; perhaps by causing such effect, LCA may shift the equilibrium of membrane 
curvature towards the enhancement of cristae formation by promoting positive curvature of the inner 
mitochondrial membrane. 
 
5.16); and 3) LCA decreases the level of the cone-shaped species of PE enriched in 
unsaturated fatty acids, and thus is expected to decrease the number of contact sites by 
reducing negative curvature of the inner mitochondrial membrane (Figure 5.17).  
          Based on these findings, I hypothesized that, by enhancing the ability of the inner 
mitochondrial membrane to form cristae, LA alters the dynamics of mitochondrial 
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respiration, electrochemical membrane potential maintenance, ROS production - 
ultimately increasing life span. In support of my hypothesis, I found that LCA causes  
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Figure 5.17. LCA decreases the level of the cone-shaped species of PE enriched in unsaturated fatty acids, 
and thus is expected to decrease the number of contact sites by reducing negative curvature of the inner 
mitochondrial membrane.  
 
profound changes in the size and number of mitochondria as well as in the length and 
morphology of mitochondrial cristae in WT cells (Figures 5.18 and 5.19) and in gep1, 
psd1 and crd1 cells (Figures 5.20, 5.21 and 5.22, respectively) - in which LCA is even 
more potent anti-aging compound (see Figures 5.4, 5.5 and 5.6). As a further validation 
of my hypothesis, I revealed that LCA not only changes mitochondrial morphology, but 
also alters the age-related dynamics of several longevity-defining processes confined to 
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mitochondria, including respiration (Figure 5.23), electrochemical potential across the 
mitochondrial inner membrane (Figure 5.24) and ROS generation (Figure 5.25).    
 
 
Figure 5.18. LCA causes profound changes in the size and number of mitochondria as well as in the length 
and morphology of mitochondrial cristae in WT cells. Yeast were grown in YEPD medium initially 
containing 0.2% glucose as carbon source, without LCA or with this bile acid (used in the concentration of 
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Figure 5.19. LCA greatly reduces the number of mitochondria, increasing their size and expanding their 
inner membrane in WT cells. Yeast were grown in YEPD medium initially containing 0.2% glucose as 
carbon source, without LCA or with this bile acid (used in the concentration of 50 μM), collected at day 5, 





Figure 5.20. LCA alters the length and morphology of mitochondrial cristae in gep1 cells, in which LCA 
is even more potent anti-aging compound than it is in WT cells. Yeast were grown in YEPD medium 
initially containing 0.2% glucose as carbon source, without LCA or with this bile acid (used in the 
concentration of 50 μM), collected at day 5, and processed for electron microscopy as described in 
Materials and Methods. 
 
5.5. Discussion 
Altogether, my findings described in Chapter 5 of this thesis provide evidence that LCA 
extends longevity of chronologically aging yeast in part by altering the composition of 
mitochondrial membrane lipids. Indeed, LCA causes the remodeling of the mitochondrial 
membrane by proportionally reducing the quantities of PE and CL and simultaneously 
increasing the quantity of PS, a precursor of PE. I hypothesize that such LCA-driven  
 
Figure 5.21. LCA alters the length and morphology of mitochondrial cristae in psd1 cells, in which LCA 
is even more potent anti-aging compound than it is in WT cells. Yeast were grown in YEPD medium 
initially containing 0.2% glucose as carbon source, without LCA or with this bile acid (used in the 
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concentration of 50 μM), collected at day 5, and processed for electron microscopy as described in 
Materials and Methods. 
 
specific remodeling of the repertoire of mitochondrial membrane lipids is due to an 
inhibiting effect of LCA on the Crd1p- and Psd1p-driven reactions of the biosynthesis of 
CL and PE (respectively) in the mitochondrial inner membrane. LCA not only alters the 
total levels of PS, PE and CL in the mitochondrial membrane, but also has a specific 
effect in the relative abundance of their various molecular forms that differ from each 
other by the extent of saturation of the hydrophobic tails and their length. In fact, LCA: 1) 
elevates the concentration of the inverted cone-shaped species of PS enriched in saturated 
fatty acids, thereby enhancing cristae formation by promoting positive curvature of the  
 
Figure 5.22. LCA alters the shape and number of mitochondria as well as the length and morphology of 
mitochondrial cristae in crd1 cells, in which LCA is even more potent anti-aging compound than it is in 
WT cells. Yeast were grown in YEPD medium initially containing 0.2% glucose as carbon source, without 
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LCA or with this bile acid (used in the concentration of 50 μM), collected at day 5, and processed for 
electron microscopy as described in Materials and Methods. 
 
inner mitochondrial membrane; and 2) reduces the concentrations of the cone-shaped 
species of CL and PE enriched in unsaturated fatty acids, thereby shifting the equilibrium 
of membrane curvature towards the enhancement of cristae formation by promoting 
positive curvature of the inner mitochondrial membrane. Such LCA-driven remodeling of 
differently shaped molecular forms of PS, CL and PE reduces the number of 
mitochondria and increases their size. I hypothesized that the observed effect of LCA on 
the abundance of mitochondria is caused by the ability of this bile acid to shift a balance 
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Figure 5.23. LCA alters the age-dependent dynamics of cellular respiration by modulating mitochondrial 
oxygen consumption in WT cells. Yeast were grown in YEPD medium initially containing 0.2% glucose as 
carbon source, without LCA or with this bile acid (used in the concentration of 50 μM). Oxygen 
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consumption in aliquots of cells taken at different time-points was measured as described in Materials and 
Methods. 
 
thereby preventing the fragmentation of mitochondria and the resulting efflux of 
cytochrome c and several other pro-apoptotic proteins from the mitochondrial 
intermembrane space. Ultimately, such effect of LCA on mitochondrial morphology 
results in the observed delay of the age-related form of mitochondria-controlled apoptosis 
and longevity extension (see Chapter 4 for a detailed discussion of this topic). Another 
outcome of the observed LCA-driven remodeling of differently shaped molecular forms 
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Figure 5.24. LCA alters the age-dependent dynamics of the electrochemical potential across the inner 
mitochondrial membrane () in WT cells. Yeast were grown in YEPD medium initially containing 0.2% 
glucose as carbon source, without LCA or with this bile acid (used in the concentration of 50 μM).  in 
aliquots of cells taken at different time-points was monitored using fluorescence microscopy followed by 
quantitative analysis as described in Materials and Methods. 
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which is manifested in a great increase of the length of mitochondrial cristae and in a 
change of their morphology. It is conceivable that such LCA-driven enhancement of the 
ability of the mitochondrial inner membrane to form cristae is responsible for the 
observed ability of LCA to alter the age-related dynamics of several longevity-defining 
processes confined to mitochondria, including respiration, electrochemical potential 
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Figure 5.25. LCA alters the age-dependent dynamics of ROS generation in mitochondria of WT cells. 
Yeast were grown in YEPD medium initially containing 0.2% glucose as carbon source, without LCA or 
with this bile acid (used in the concentration of 50 μM). ROS in aliquots of cells taken at different time-
points was monitored using fluorescence microscopy followed by quantitative analysis as described in 




By elucidating how a novel anti-aging compound LCA changes the composition of 
mitochondrial membrane lipids and how genetic interventions affecting its ability to  
cause such changes influence its longevity-extending efficacy, I established the molecular 
mechanism underlying the ability of LCA to extend yeast CLS under CR conditions by 
altering the repertoire of membrane lipids in mitochondria. 
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6. Conclusions and suggestions for future work 
6.1. General conclusions 
6.1.1. A method that I developed for quantitative assessment of the 
lipidomes of yeast and cultured human cells using survey-scan 
electrospray ionization mass spectrometry (ESI/MS) 
Altogether, my findings reported in Chapter 2 imply that I was able to solve the inherent 
limitations of the currently used methods for lipidomic analysis (including the limitations 
characteristic of the ESI/MS-MS-based analysis) by developing a survey-scan method for 
quantitative assessment of the the entire complement of lipids in yeast cells and cultured 
human cells using ESI/MS.  
          Using this method of MS-based lipidomic analysis I demonstrated that: 1) yeast has 
a relatively simple lipidome with 7 major lipid classes, namely PA, PE, PS, PI, CL, PC 
and TAG; 2) the majority of individual molecular forms within each of these different 
lipid classes have chain length of 16 or 18 carbon atoms; and 3) the fatty acyl moieties of 
all of lipid species composing yeast lipidome are either mono-unsaturated or saturated, 
perhaps due to the presence of a single acyl desaturase enzyme in yeast [212 - 215].  
          It should be stressed that the method that I developed is highly sensitive. In fact, it 
is: 1) sensitive to the low µM range (0.6 to 2 µM depending on lipid class) for all lipid 
species tested; and 2) linear to the hundreds of µM range, with the concentration linearity 
spreading over 2 to 3 orders of magnitude. Moreover, the method that I developed 
enables very accurate quantitation of different lipid species within a wide range of lipid 
concentrations.  
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          Importantly, if compared to the currently used ESI/MS-MS-based method of 
lipidomic analysis [213 - 220], my method has the following important advantages: 1) 
unlike the ESI/MS-MS-based method, it can be carried out within a very limited period 
of time; 2) unlike the ESI/MS-MS-based method, it does not require to maintain stable 
spray conditions at the ESI source for long periods of time; 3) unlike the ESI/MS-MS-
based method, it does not have a bias towards certain lipid species, thereby being 
sufficiently sensitive to unexpected changes in lipid spectra of analyzed cells; 4) it is 
more sensitive than the ESI/MS-MS-based method and, thus, does not require abundant 
quantities of cells for lipid extraction and analysis; and 5) it has lower than the ESI/MS-
MS-based method limits of detection and quantitation for all yeast lipid species.  
          In sum, my findings reported in Chapter 2 support the notion that the survey-scan 
ESI/MS method of lipidomic analysis that I developed enables within a very limited 
period of time and using a very low number of cells to resolve, unequivocally identify 
and accurately quantitate all molecular forms of lipid species composing yeast lipidome 
and the majority of molecular forms of lipid species composing the lipidome of cultured 
human microglial cells.   
 
6.1.2. A mechanism underlying the ability of CR to extend longevity of 
chronologically aging yeast by specifically remodelling lipid metabolism 
in the ER, LBs and peroxisomes 
The results of my functional genetic, cell biological, electron and fluorescence 
microscopical, proteomic, lipidomic, and metabolomic analyses described in Chapter 3 
revealed the molecular mechanism underlying the ability of CR to extend longevity of 
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chronologically aging yeast by specifically remodelling lipid metabolism in the ER, LBs 
and peroxisomes.  
          In this mechanism, LBs in yeast cells function as a hub in a regulatory network that 
modulates neutral lipids synthesis in the ER and fatty acid oxidation in peroxisomes. 
Ethanol accumulated in yeast placed on a calorie-rich diet represses the synthesis of 
Fox1p, Fox2p and Fox3p, thereby suppressing peroxisomal oxidation of FFA that 
originate from TAG synthesized in the ER and deposited within LBs. The resulting build-
up of arrays of FFA (called gnarls) within LBs of non-CR yeast initiates several negative 
feedback loops regulating the metabolism of TAG. Due to the action of these negative 
feedback loops, chronologically aging non-CR yeast not only amass TAG in LBs but also 
accumulate FFA and DAG in the ER. FFA and DAG regulate longevity by two different 
mechanisms that operate at two different stages of the aging process. One mechanism 
involves sensing the concentration of DAG maintained by cells (in a diet- and genotype-
dependent fashion) during D and PD growth phases. DAG concentration during D and 
PD phases programs cell viability during the non-proliferative ST growth phase by 
modulating the FFA- and DAG-induced necrotic cell death pathway, but not by 
influencing the mitochondria-controlled apoptotic pathway of cell death. Another 
mechanism involves sensing the concentrations of FFA and DAG during ST phase. Any 
diet or genetic manipulation that causes the build-up of these two lipids during ST phase 
shortens the chronological life span of yeast in part by promoting rapid mitochondria-
controlled apoptotic cell death, but not by activating FFA- and DAG-induced necrotic 
cell death pathway. 
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6.1.3. A mechanism underlying the ability of a novel anti-aging compound 
to extend yeast life span by targeting the longevity-defining aspects of 
lipid metabolism confined to the ER, LBs and peroxisomes 
My findings described in Chapter 4 revealed the molecular mechanism underlying the 
ability of LCA, a novel anti-aging compound, to extend yeast chronological life span by 
targeting the longevity-defining aspects of lipid metabolism confined to the ER, LBs and 
peroxisomes. In such mechanism, under CR conditions LCA accelerates the biosynthesis 
of TAG from FFA and DAG in the ER as well as decelerates the FFA- and DAG-
generating lipolysis of TAG in LBs. The resulting reduction of the ER- and LB-confined 
levels of FFA and DAG during PD and ST growth phases affects both mechanisms by 
which these two lipid species regulate longevity. First, by lowering the intracellular 
concentration of DAG during D and PD phases, LCA attenuates the FFA- and DAG-
induced necrotic cell death pathway – thereby impairing the age-related form of necrotic 
cell death and ultimately extending longevity of chronologically aging yeast placed on a 
CR diet. Second, by reducing the intracellular concentrations of FFA and DAG during ST 
phase, LCA attenuates the mitochondria-controlled apoptotic cell death pathway – 
thereby impairing the age-related form of apoptotic cell death and ultimately further 
extending longevity of chronologically aging yeast under CR conditions. 
          My findings described and discussed in Chapters 3 and 4 of this thesis imply that 
there are two different ways of delaying chronological aging of yeast by targeting the 
longevity-defining aspects of lipid metabolism confined to the ER, LBs and peroxisomes. 
One way is by placing yeast on a CR diet in the absence of LCA, thereby making them 
“lean” by accelerating both the lipolysis of neutral lipids in LBs and the oxidation of FFA 
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in peroxisomes. The resulting reduction of FFA and DAG levels during PD and ST 
phases slows down both the necrotic and apoptotic forms of cell death, thereby extending 
longevity of chronologically aging CR yeast - as compared to longevity of non-CR yeast. 
The other way is by placing yeast on a CR diet in the presence of LCA, thereby making 
them “fat” by: 1) accelerating the synthesis of TAG from FFA and DAG; and 2) 
decelerating the FFA- and DAG-producing lipolysis of TAG in LBs. The resulting 
further reduction of FFA and DAG levels during PD and ST phases (as compared to CR 
yeast grown without LCA) causes additional attenuation of the necrotic and apoptotic 
forms of cell death, thereby further extending longevity of chronologically aging CR 
yeast exposed to LCA - as compared to longevity of CR yeast not exposed to this bile 
acid.      
 
6.1.4. A mechanism underlying the ability of a novel anti-aging compound 
to extend yeast life span by altering the composition of mitochondrial 
membrane lipids   
By elucidating how a novel anti-aging compound LCA changes the composition of 
mitochondrial membrane lipids and how genetic interventions affecting its ability to 
cause such changes influence its longevity-extending efficacy, I established the molecular 
mechanism underlying the ability of LCA to extend yeast life span under CR conditions 
by altering the repertoire of membrane lipids in mitochondria. In this mechanism, which 
is described in Chapter 5, LCA causes the remodeling of the mitochondrial membrane by 
proportionally reducing the quantities of PE and CL and simultaneously increasing the 
quantity of PS, a precursor of PE. It is plausible that such LCA-driven specific 
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remodeling of the repertoire of mitochondrial membrane lipids is due to an inhibiting 
effect of LCA on the Crd1p- and Psd1p-driven reactions of the biosynthesis of CL and 
PE (respectively) in the mitochondrial inner membrane. LCA not only alters the total 
levels of PS, PE and CL in the mitochondrial membrane, but also has a specific effect in 
the relative abundance of their various molecular forms that differ from each other by the 
extent of saturation of the hydrophobic tails and their length. In fact, LCA: 1) elevates the 
concentration of the inverted cone-shaped species of PS enriched in saturated fatty acids, 
thereby enhancing cristae formation by promoting positive curvature of the inner 
mitochondrial membrane; and 2) reduces the concentrations of the cone-shaped species 
of CL and PE enriched in unsaturated fatty acids, thereby shifting the equilibrium of 
membrane curvature towards the enhancement of cristae formation by promoting positive 
curvature of the inner mitochondrial membrane. Such LCA-driven remodeling of 
differently shaped molecular forms of PS, CL and PE reduces the number of 
mitochondria and increases their size. It seems likely that the observed effect of LCA on 
the abundance of mitochondria is caused by the ability of this bile acid to shift a balance 
between the opposing processes of mitochondrial fission and fusion towards fusion, 
thereby preventing the fragmentation of mitochondria and the resulting efflux of 
cytochrome c and several other pro-apoptotic proteins from the mitochondrial 
intermembrane space. Ultimately, such effect of LCA on mitochondrial morphology 
results in the delay of the age-related form of mitochondria-controlled apoptosis and 
longevity extension. Another outcome of the observed LCA-driven remodeling of 
differently shaped molecular forms of PS, CL and PE consists in significant expansion of 
the mitochondrial inner membrane, which is manifested in a great increase of the length 
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of mitochondrial cristae and in a change of their morphology. It is conceivable that such 
LCA-driven enhancement of the ability of the mitochondrial inner membrane to form 
cristae is responsible for the observed ability of LCA to alter the age-related dynamics of 
several longevity-defining processes confined to mitochondria, including respiration, 
electrochemical potential across the mitochondrial inner membrane and ROS generation. 
  
6.2. Suggestions for future work 
In the established by me mechanism underlying the essential role of lipid metabolism in 
modulating programmed by calorie availability chronological aging in yeast, LBs in yeast 
cells function as a hub in a regulatory network that modulates neutral lipids synthesis in 
the ER and fatty acid oxidation in peroxisomes. Ethanol accumulated in yeast placed on a 
calorie-rich diet represses the synthesis of Fox1p, Fox2p and Fox3p, thereby suppressing 
peroxisomal oxidation of FFA that originate from TAG synthesized in the ER and 
deposited within LBs. The resulting build-up of arrays of free fatty acids (gnarls) within 
LBs of non-CR yeast initiates several negative feedback loops regulating the metabolism 
of TAG. Due to the action of these negative feedback loops, chronologically aging non-
CR yeast not only amass TAG in LBs but also accumulate FFA and DAG in the ER. FFA 
and DAG regulate longevity by two different mechanisms that operate at two different 
stages of the aging process. One mechanism involves sensing the concentration of DAG 
maintained by cells (in a diet- and genotype-dependent fashion) during D and PD growth 
phases. DAG concentration during D and PD phases programs cell viability during ST 
growth phase by modulating the FFA- and DAG-induced necrotic cell death pathway, but 
not by influencing the mitochondria-controlled apoptotic pathway of cell death. Another 
 233 
mechanism involves sensing the concentrations of FFA and DAG during ST phase. Any 
diet or genetic manipulation that causes the build-up of these two lipids during ST phase 
shortens the chronological life span of yeast in part by promoting rapid mitochondria-
controlled apoptotic cell death, but not by activating FFA- and DAG-induced necrotic 
cell death pathway.  
          The two most outstanding questions for the future research aimed at providing 
further insight into a cascade of molecular events underlying the above mechanism are: 
1) what upstream regulators govern the observed under CR conditions longevity-
extending remodeling of lipid and carbohydrate metabolism, stress response pathways, 
oxidation-reduction processes in mitochondria, mitochondrial biogenesis, and 
mitochondria-controlled apoptotic cell death? and 2) what are the downstream sensors of 
FFA and DAG that govern the age-related forms of apoptotic and necrotic cell death 
pathways by sensing the CR-triggered changes in the intracellular concentrations of these 
two lipid species? My analysis of the observed global changes in the proteomes of yeast 
placed on a CR diet has revealed a limited set of transcriptional regulators that, according 
to my database search, have been shown to regulate transcription of their encoding genes. 
These global transcriptional regulators include Rtg2p, Sfp1p, Yap1p, Msn2p and Msn4p. 
I propose that, by sensing calorie availability, these transcriptional regulators modulate 
expression of several global clusters of genes encoding proteins identified in my 
proteomic analysis as the ones whose levels are significantly altered in yeast placed on a 
CR diet. To test the validity of my hypothesis, one could evaluate how mutations 
eliminating Rtg2p, Sfp1p, Yap1p, Msn2p or Msn4p influence the life-extending efficacy 
of CR as well as the cellular and mitochondrial proteomes of chronologically aging CR 
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and non-CR yeast, their cellular and organellar (i.e., the ER and LBs) lipidomes, their 
susceptibility to apoptotic and necrotic death caused by a short-term exposure to 
exogenously added pro-apoptotic and pro-necrotic stimuli, the chronology of the events 
characteristic of their apoptotic and/or necrotic death during ST growth phase, and the 
age-related dynamics of changes in the abundance and morphology of the ER, LBs and 
mitochondria in their chronologically aging cells. 
          To answer the second of the above two most outstanding questions consisting in 
establishing the identity of the downstream sensors of FFA and DAG that govern the age-
related forms of apoptotic and necrotic cell death pathways by sensing the CR-triggered 
changes in the intracellular concentrations of these two lipid species, one could assess 
how mutations eliminating the well-known protein regulators of these death pathways 
(including Yca1p, Ndi1p, Rny1p, Bir1p, Nma11p, Aif1p, Nuc1p and Dnm1p) influence 
the life-extending efficacy of CR as well as the susceptibility of chronologically aging 
CR and non-CR yeast to apoptotic and necrotic death caused by a short-term exposure to 
exogenously added pro-apoptotic and pro-necrotic stimuli, and the chronology of the 
events characteristic of their apoptotic and/or necrotic death during ST growth phase. 
          In the future, one could use a similar to the above experimental strategy to define 
1) the upstream regulators of the longevity-extending remodeling of lipid and 
carbohydrate metabolism, stress response pathways, oxidation-reduction processes in 
mitochondria, mitochondrial biogenesis, and mitochondria-controlled apoptotic cell death 
that I observed in chronologically aging CR yeast exposed to LCA; and 2) the 
downstream sensors of FFA and DAG that ultimately execute an anti-aging program 
triggered in response to exposure of chronologically aging CR yeast to LCA.  
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          In the established by me mitochondria-centered mechanism underlying the anti-
aging effect of LCA, this bile acid extends yeast longevity under CR conditions by 
remodeling the composition of mitochondrial membrane lipids and thereby affecting 
longevity-defining processes confined to and/or governed by mitochondria. In this 
mechanism, LCA extends yeast longevity by: 1) increasing the level of PS, a precursor 
for the synthesis of PE in the mitochondrial membrane, thereby enhancing its positive 
effect on longevity-defining processes in this membrane; 2) decreasing the level of PE in 
the mitochondrial membrane, thereby weakening its negative effect on longevity-defining 
processes in this membrane; and 3) proportionally decreasing the levels of PE and CL in 
the mitochondrial membrane, thereby increasing PS/CL and PS/PE ratios but maintaining 
PE/CL ratio of mitochondrial membrane lipids and causing some longevity-extending 
changes in this membrane. By altering the levels of PS, CL and PE in the mitochondrial 
membrane, LCA: 1) changes the curvature of the inner mitochondrial membrane; and 2) 
enhances the positive effect of PS and weakens the negative effect of PE on membrane 
proteins whose activity depends on these two lipid species - thereby enhancing the ability 
of the inner mitochondrial membrane to form cristae and activating protein machines 
involved in mitochondrial respiration, the maintenance of mitochondrial membrane 
potential and ROS production in mitochondria. To provide further insight into a cascade 
of molecular events underlying this mitochondria-centered mechanism, one could 
consider performing the following set of experiments: 1) to examine how LCA influences 
the stoichiometry, composition and functional state of respiratory supercomplexes 
(“respirasomes”) in the inner mitochondrial membrane; and 2) to test my hypothesis 
 236 
(which has been indirectly supported by some of the recent findings in Dr. Titorenko’s 
laboratory) that LCA prevents the fragmentation of the mitochondrial network during late 
ST phase and thereby inhibits an age-related, mitochondria-controlled form of apoptosis 
by activating the Fzo1p and Ugo1p protein components of the mitochondrial outer 
membrane fusion machine.    
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